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Investigation Of Rna-Protein Interactions In Prc2 Function
Abstract
Chromatin regulation contributes to control of gene expression and what identity a cell will adopt. In the
last decade the role that RNA plays in chromatin regulation has become increasingly clear. RNA mediates
protein recruitment and eviction from chromatin, forms nuclear condensates with proteins and DNA, and
contributes to proper chromatin organization. Yet our knowledge of the mechanisms that govern RNA
activity on chromatin lags significantly and limits our ability to understand nuclear function. To effectively
answer some of the questions of RNA function in the nucleus we need a comprehensive atlas of RNAprotein interactions, which would enable generation of protein mutants defective in RNA-binding. The goal
of my thesis was to develop an unbiased method to profile RNA-binding proteins in the nucleus and apply
it to Polycomb repressive complex 2 (PRC2). PRC2 is an epigenetic regulatory complex that deposits
mono, di- and tri- methyl lysine onto histone H3 (H3K27me3) and maintains gene silencing during
development. PRC2 shows extensive contacts with RNA but their function remains unclear. In the first
chapter, we present a novel method, dubbed RBR-ID, for the identification of RNA-protein interactions,
which usees UV-crosslinking of photosensitive nucleotide analogs to proteins followed by high resolution
mass spectrometry (LC- MS/MS). We identified over 800 RNA-binding proteins, of which 427 were novel
and enriched for chromatin-related functions. In the second chapter we adapted RBR-ID to study PRC2,
identifying RNA-binding-regions (RBRs) on every subunit of the complex. An RBR identified on EED fell
near the regulatory center of PRC2, and we showed that RNA-mediated inhibition of PRC2 can be reversed
by stimulatory peptides that bind in the regulatory center, reflecting the antagonistic relationship between
RNA and PRC2. In the final chapter we present a testing method we developed for the SARS-CoV-2 virus.
Our method, COV-ID, uses reverse transcription and loop-mediated isothermal amplification (RT-LAMP)
from patient saliva paired with high-throughput sequencing. Using this method we can detect as little as
5-10 SARS-CoV-2 virions/μL, and we successfully replicate classification of saliva samples (10/10) from
clinical COVID-19 patients. We show that COV-ID can be multiplexed to detect influenza as well as SARSCoV-2. Finally we demonstrate thatCOV-ID can process saliva samples collected on filter paper with
sensitivity as low as 50 virions/μL.
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ABSTRACT
INVESTIGATION OF RNA-PROTEIN INTERACTIONS IN PRC2 FUNCTION
Robert R. Warneford-Thomson
Roberto Bonasio
Chromatin regulation contributes to control of gene expression and what identity a cell will adopt. In
the last decade the role that RNA plays in chromatin regulation has become increasingly clear. RNA
mediates protein recruitment and eviction from chromatin, forms nuclear condensates with proteins
and DNA, and contributes to proper chromatin organization. Yet our knowledge of the mechanisms
that govern RNA activity on chromatin lags significantly and limits our ability to understand nuclear
function. To effectively answer some of the questions of RNA function in the nucleus we need a
comprehensive atlas of RNA-protein interactions, which would enable generation of protein mutants
defective in RNA-binding. The goal of my thesis was to develop an unbiased method to profile
RNA-binding proteins in the nucleus and apply it to Polycomb repressive complex 2 (PRC2). PRC2
is an epigenetic regulatory complex that deposits mono, di- and tri- methyl lysine onto histone H3
(H3K27me3) and maintains gene silencing during development. PRC2 shows extensive contacts
with RNA but their function remains unclear. In the first chapter, we present a novel method,
dubbed RBR-ID, for the identification of RNA-protein interactions, which usees UV-crosslinking
of photosensitive nucleotide analogs to proteins followed by high resolution mass spectrometry (LCMS/MS). We identified over 800 RNA-binding proteins, of which 427 were novel and enriched for
chromatin-related functions. In the second chapter we adapted RBR-ID to study PRC2, identifying
RNA-binding-regions (RBRs) on every subunit of the complex. An RBR identified on EED fell
near the regulatory center of PRC2, and we showed that RNA-mediated inhibition of PRC2 can
be reversed by stimulatory peptides that bind in the regulatory center, reflecting the antagonistic
relationship between RNA and PRC2. In the final chapter we present a testing method we developed
for the SARS-CoV-2 virus. Our method, COV-ID, uses reverse transcription and loop-mediated
isothermal amplification (RT-LAMP) from patient saliva paired with high-throughput sequencing.
Using this method we can detect as little as 5-10 SARS-CoV-2 virions/µL, and we successfully
replicate classification of saliva samples (10/10) from clinical COVID-19 patients. We show that
COV-ID can be multiplexed to detect influenza as well as SARS-CoV-2. Finally we demonstrate that
COV-ID can process saliva samples collected on filter paper with sensitivity as low as 50 virions/µL.
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1. INTRODUCTION
1.1
1.1.1

RNA-protein interactions and chromatin
Introduction to chromatin

Chromatin describes the complement of DNA, RNA, and associated proteins that are packaged
inside the nucleus of the cell. The ordered packaging of DNA with protein components dictates the
arrangement of genetic material in the nucleus and dynamically changes to allow RNA transcription.
These complexes therefore serve both a structural and functional purpose. Chromatin is remodeled
and chemically modified by other proteins to change the pattern of gene expression, and changes
in chromatin state allow a single genome to sustain the many cell types and developmental stages
required for multicellular life.
The basic unit of chromatin structure is the nucleosome, an octamer of histone proteins
around which 147 bp of DNA is wrapped. The four core histone proteins (H3, H4, H2A, H2B)
that make up the nucleosome can be chemically modified or substituted with different histone
variants in ways that frequently correlate with different nuclear processes such as gene transcription
or silencing. Based on these connections, a ‘histone code’ hypothesis emerged that proposed
that combinations of histone modifications convey information that can be read by other proteins
to carry out their activities [1].

An example of this is the tri-methylation of histone H3 at

lysine 27 (H3K27me3) found in transcriptionally silent heterochromatin. In mammals Polycomb
repressive complex (PRC2) can deposit H3K27me3, and can also recognize its catalytic output
in a manner that allosterically stimulates the complex (Figure 1.1). This read-write activity is
required for maintenance of H3K27me3 domains across cell divisions, qualifying the mark as a
true epigenetic modification [2]. However, in the time since the ’histone code’ hypothesis was
first proposed, subsequent research has found no evidence that distinct combinations of histone
modifications directly cause different chromatin states [3, 4]. Additionally, the majority of histone
modifications that associate with different types of transcriptional activity, such as H4K16ac found
in transcriptionally active chromatin, do not persist across cell divisions or display any type of
memory [2]. Therefore the ’histone code’ has limited use in describing epigenetic inheritance, but
instead can serve as a means to understand dynamic chromatin regulation.
1

1.1.2

Chromatin and transcription regulation

Many changes on chromatin relate to transcriptional regulation, and affect gene expression in
ways that define cell type and developmental state. Much of the effort in chromatin biology has
been directed towards uncovering the relationship between chromatin structure and transcription,
which operates at several scales. In the most narrow context, chemical modifications on DNA
and histones can act to both inhibit (DNA methylation, H3K9me3, H3K27me3) or stimulate
transcription (H3K4me3, H3K27ac). Moving up to the gene scale, cis-regulatory DNA sequences
can form loops with gene promoters to activate transcription. At the scale of chromosomes,
megabase (108 nucleotide) regions of DNA are folded with architectural proteins into spatially
constricted topologically associated domains (TADs) [5] and active or inactive compartments [6].
These mechanisms are but some of the examples of the multiple levels of chromatin structure, and
indicate the scope of the challenge in understanding transcriptional regulation.
Transcription itself involves the synthesis of RNA from a DNA template via a tightlyregulated process involving conserved molecular machinery. Transcribed RNA is further spliced
and processed by additional chromatin-associated protein complexes, such as the CPSF complex
that cleaves elongating mRNA and facilitates addition of a poly(A) tail [7]. While RNA involved
in protein translation (mRNA, rRNA, and tRNA) is ultimately exported from the nucleus, there
are several types of RNA that are retained and carry out their functions inside the nucleus.
These nuclear-retained RNAs include long non-coding RNA (lncRNAs) and small nucleolar RNAs
(snoRNAs) among others. The expansive role of RNA in regulating chromatin structure is beginning
to become clear, such as mediating interactions between proteins and chromatin, regulating the
activity of chromatin-modifying enzymes, or facilitating changes in chromatin architecture. In
certain contexts RNA can also interact with proteins and/or DNA to form liquid-liquid phase
separated nuclear bodies, which have been associated with processes such as transcription [8]
and nuclear pore formation [9]. These observations have gradually updated the view that RNA
is primarily an information carrier in eukaryotic cells to include its own contributions in nuclear
function.

2

1.1.3

Nuclear bodies

Nuclear bodies form by liquid-liquid phase separation among DNA, RNA and proteins that share
mutual affinity, resulting in chemically distinct sub-compartments [10]. These nuclear bodies,
also known as nuclear condensates, display liquid-like properties and are immiscible with the
surrounding nucleoplasm. There are several examples of nuclear condensates including Cajal
bodies, histone locus bodies and nucleoli—these function in splicing assembly [11], histone
mRNA processing [12], and rRNA processing [13], respectively. The mechanisms surrounding
the nucleation and behavior of nuclear condensates are currently an area of major interest, and
there is an ongoing debate over the role such condensates play in regulating chromatin organization
and transcription [14, 15].

While the function of and mechanisms involving nuclear bodies

remain controversial, they all seem to involve a nucleation step when a combination of RNA,
DNA, and proteins reach a critical concentration and segregate into a biomolecule-rich phase.
The concentration at which condensates form is affected by the affinity between the constituent
biomolecules, which can be regulated by biochemical modifications of proteins and RNA [10]. This
indicates that RNA-protein interactions are a key part of understanding the role of liquid condensates
in chromatin biology.

1.1.4

Approaches to study RNA-protein interactions

RNA-protein interactions are emerging as increasingly relevant players in chromatin regulation.
Classically, RNA-binding proteins (RBPs) were thought to bind to specific RNA targets via a
conserved RNA-binding domains (RBDs) such as the RNA recognition motif (RRM) [16] or hnRNP
K homology domain (KH) [17]. These interactions were thought to dictate the processing and
function of the bound RNA. However, emerging evidence demonstrating the prevalence of RNA
condensates in multiple cellular compartments, reviewed here [10, 18]–along with the cataloguing
of many lncRNAs with evident functions in gene regulation [19]–have shown that RNA can also
regulate its protein partners, termed riboregulation [20]. Given the importance of RNA-protein
interactions to the structure of nuclear condensates and chromatin regulation more generally,
improved mapping of RNA-protein links can enable design of separation-of-function mutants
3

that can reveal the function of condensates in chromatin biology. Given that many chromatinassociated RBPs interact with a wide range of RNA transcripts [21], efforts to probe RNAprotein interactions in chromatin regulation have tended to use protein-centric approaches. For
example some groups have identified novel chromatin-associated RBPs, using candidate-based
domain mapping to identify and remove RNA binding regions (RBRs) and determine their effect on
chromatin dynamics [22–25]. While showing promise, systematic cataloguing of RBPs requires a
more unbiased approach, particularly given that many novel RBPs lack classical RBDs [26].
When I began my dissertation work there were already several approaches to identify
RBPs in an unbiased manner. These include RNA interactome capture where mRNA-bound
proteins are enriched using poly-adenylated (polyA) RNA-based selection and identified via
mass spectrometry [27, 28]. These approaches have revealed many novel RBPs and expanded
our understanding of RBP characteristics, in particular that many RBPs lack classical RBDs,
underscoring the shortcomings of identifying novel RBPs based on similarity to existing proteins.
However, because of their reliance on polyA-based selection, these interactome capture methods
miss proteins that bind non poly-adenylated RNAs such as eRNAs or nascent RNA. Another
approach from Kramer et al. used UV crosslinking of cells and analysis of protein-RNA adducts via
mass spectrometry to identify sites of crosslinking [29]. Using this method the authors identified
257 peptides with nucleotide adducts from only 124 RBPs, likely reflecting the challenge of
unambiguously assigning unpredictable nucleotide adducts to peptide spectra [29]. We reasoned
that developing a truly unbiased approach could identify novel RBPs and generate new hypotheses
regarding chromatin biology.

1.2
1.2.1

Polycomb Repressive Complex 2 (PRC2) and RNA
Overview of PRC2

Proteins of the Polycomb Group (PcG) ensure maintenance of transcriptional repression during cell
differentiation and are essential for proper development. Mutations in PcG genes cause homeotic
transformations in body patterning and are associated with aberrant cell proliferation in multiple
cancer types [30]. PcG proteins commonly function as part of multi-subunit complexes, which in
4

metazoans chiefly comprise PRC1 and PRC2, which are recruited to chromatin where they modify
histones to deposit H2AK119 ubiquitination and H3K27 mono, di-, and tri-methyl modifications,
respectively (Figure 1.1 and [31]). Presence of these chromatin modifications are associated with
chromatin compaction and repression of transcription [32]. PRC2 is a histone methyltransferase
complex with a core complex consisting of a catalytic subunit (EZH1 or EZH2); a regulatory subunit
(EED); a chromatin-binding subunit RBBP4 or RBBP7, and a structural subunit SUZ12. In addition
to these four subunits several additional subunits have been discovered (AEBP2 [33], JARID2 [34],
PCL1-3 [35], EPOP [36, 37], and PALI1/2 [38]) that associate into two mutually exclusive holocomplexes, denoted as PRC2.1 and PRC2.2, are are required for proper PRC2 localization and
repression, reviewed in [39, 40].
The mechanisms governing the recruitment and activity of PRC1 and PRC2 are multifaceted and have attracted significant attention in recent years. As mentioned above, PRC2deposited H3K27me3 can recruit PRC1 onto chromatin at Polycomb target genes [33, 41, 42]. PRC2
can also bind to the histone mark H2AK119Ub and is dependent on the mark for proper chromatin
localization [43–45]. This suggests that there is cross-talk between the two complexes that reinforce
their proper localization. In addition to histone marks, PRC2 also recognizes un-methylated CpG
islands on genomic DNA in order to bind gene promoters. [46, 47].

PRC2.1

PALI1/2
PCL1-3

EPOP

PRC2.2

JARID2

PRC2
RbAp46/48

AEBP2

F IGURE 1.1

EED

SUZ12

H3K27me3

EZH1/2

PRC2 is a histone methyltransferase complex

Figure 1. Overview of PRC2. PRC2 consists of 4 core
5 subunits: SUZ12, RBBP6/8, EED, and catalytic
subunit EZH1/2. PRC2 methylates histone H3 to deposit the H3K27me3 modification that is required for
maintenance of transcriptional repression. EED can bind to existing H3K27me3 modifications to stimulate
PRC2 methyl-transferase activity \cite{Margueron2009}. Additional PRC2 subunits associate with the core
complex into two mutually exclusive holo-complexes, PRC2.1 and PRC2.2 \cite{Hauri2016}. These subunits
have been shown to mediate PRC2 recruitment onto chromatin and to stimulate PRC2 activity.

PRC2 consists of 4 core subunits: SUZ12, RBBP6/8, EED, and catalytic subunit EZH1/2. PRC2 methylates
histone H3 to deposit the H3K27me3 modification that is required for maintenance of transcriptional
repression. EED can bind to existing H3K27me3 modifications to stimulate PRC2 methyl-transferase activity
in a positive feedback mechanism [48]. Additional PRC2 subunits associate with the core complex into two
mutually exclusive holo-complexes, PRC2.1 and PRC2.2 [49]. These subunits have been shown to mediate
PRC2 recruitment onto chromatin and to stimulate PRC2 activity [31]

Both PRC1 and PRC2 have also been found to interact with RNA [22, 50–53], suggesting
that RNA-protein interactions also affect Polycomb function in chromatin. While we still know very
little about PRC1 interaction with RNA, there has been a concerted effort to dissect the interactions
of PRC2 with RNA and their function. [22, 23, 50, 54–59].

1.2.2

RNA-mediated PRC2 recruitment

RNA has been linked to PRC2 recruitment to chromatin through several lines of evidence. The first
observations found that PRC2 interacted specifically with lncRNAs that led to recruitment of PRC2
onto chromatin [52, 53], such as the lncRNA Xist-RepA. Xist was proposed to recruit PRC2 onto the
X chromosome during X inactivation through the RepA region [52]. However, subsequent work has
undermined this observation, finding that the Xist RepA fragment was not required for recruitment
of PRC2 to the inactive X chromosome [60]. Biochemical characterization of PRC2 affinity for
RNA showed that PRC2 has promiscuous affinity for many RNA sequences at can be found at
many actively transcribing genes, suggesting that a broader set of RNA transcripts outside of a few
specific lncRNAs interact with PRC2 [55, 59, 61]. Careful biochemical experiments have revealed
that PRC2 binds G-quadruplex RNA structures [62] with higher affinity than other RNA ligands [21,
56, 63]. Attempts to abolish PRC2-RNA interactions through site-directed mutagenesis of EZH2
resulted in reduced but still relevant nM scale affinity for G-quadruplex RNA [64], suggesting there
are other regions of the complex that contribute to RNA recognition. Yet recent evidence contradicts
the idea that RNA recruits PRC2 to chromatin, such as a recent study showing that upon application
of RNAse to cell nuclei PRC2 was enriched onto chromatin, implying that RNA competes with
chromatin for binding to PRC2 [61, 63].
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1.2.3

RNA regulation of PRC2

In addition to affecting PRC2 localization on chromatin, RNA can inhibit the methyltransferase
activity of PRC2 [56, 57]. This observation formed the basis of a ’poised inhibition’ model where
nascent RNA from actively transcribed genes can inhibit PRC2 activity and prevent inappropriate
silencing [56]. The mechanism by which RNA inhibits PRC2 has not been fully elucidated. It has
been shown that G-quadruplex RNA can compete PRC2 away from nucleosomal substrates and
inhibits histone methyltransferase activity without interfering with the automethylation activity of
EZH2 [63]. This suggested that RNA competes with DNA for binding PRC2. However in an earlier
study in Drosophila, over-expression of a Polycomb responsive element (PRE) anti-sense RNA led
to significantly lower H3K27me3 levels at the corresponding PRE without major loss of PRC2
occupancy [65]. This suggests that there may be other mechanisms of RNA-inhibition of PRC2
besides competition for initial chromatin binding, such as competition for binding to the catalytic
site, or yet to be identified allosteric effects. It is also plausible that one or more of these mechanisms
could both contribute to RNA inhibition of PRC2.

1.3
1.3.1

SARS-COV-2 diagnostics
History of COVID-19 pandemic

At the end of 2019, unusually severe cases of respiratory infection were reported in Wuhan,
China [66]. Infected individuals presented with cough, fever and flu-like symptoms that could
progress to pneumonia and respiratory insufficiency. RNA isolation and sequencing of samples
from the affected patients combined with phylogenetic analysis led to the identification of a novel
Betacoronavirus strain in the subgenus Sarbecovirus [66–68]. Based on these studies, the novel
virus was officially classified as SARS-CoV-2 (severe acute respiratory syndrome coronavirus2) and its associated disease was termed COVID-19 [69]. Similar to two other viruses of the
same family, SARS-CoV and MERS-CoV (Middle East Respiratory Syndrome), SARS-CoV was
suspected to be zoonotic [70], with the SARS-CoV-2 nsp7 protein sharing 100% amino acid identity
with an existing bat coronavirus [68]. Quickly after its identification in China, a number of similar
cases were identified worldwide. By March 2020, confirmed SARS-CoV-2 cases were present in
7

114 countries and the World Health Organization (WHO) declared the global COVID-19 outbreak
as a pandemic [71].

1.3.2

Biology of SARS-CoV-2

SARS-CoV-2 is a Betacoronavirus of the Coronaviridae family, which is named for the resemblance
of the protein spikes on their viral surface to the solar corona [72]. SARS-CoV-2 is an enveloped
single-stranded positive-sense RNA virus with a predicted broad range of hosts [73]. Its genome
consists of 6 functional open reading frames (ORFs): ORF1a/ORF1b, S, E, M and N. The ORFs are
highly conserved across members of the Betacoronavirus genus. ORF1a and ORF1b make up the
initial two-thirds of the genome sequence and encode the non-structural proteins, including those
required for viral replication. The 3’ final one-third end of the genome encodes the main structural
proteins, which are the spike glycoprotein (S), the envelope glycoprotein (E), the membrane protein
(M) and the nucleocapsid protein (N) [74]. The spike protein S interacts with the host receptor
angiotensin-converting enzyme 2 (ACE2), a protein expressed by various cell types of the lower
respiratory tract [74]. Binding of ACE2 with the SARS-CoV-2 spike protein leads to fusion of
the virion with the host cell and release of its genome into the cytoplasm. A viral-encoded RNAdependent RNA polymerase (RdRp) then amplifies the genome to generate full length positivestrand copies, as well using discontinuous RNA extension to generate a set of nested subgenomic
RNAs that serve as the templates for translation of the structural proteins [75]. The resulting fulllength viral genomes are packaged with structural proteins into viral particles and exit the host cell
via the lysosomal trafficking pathway [74].

1.3.3

Clinical features and transmission of SARS-CoV-2 disease

Estimate of Lethality
SARS-CoV-2 infection is associated with a broad spectrum of symptoms, ranging from
asymptomatic cases to severe and potentially lethal respiratory illness [76]. Respiratory damage
is due to damage to tissues of the respiratory system as well as secondary damage caused by proinflammatory cytokine responses [76]. A study of SARS-CoV-2 cases during the spring of 2020
8

in New York City used epidemiological modeling augmented by detailed population-level data to
estimate the infection-fatality risk, i.e. the likelihood of death among infected individuals. They
estimated an overall infection-fatality risk of 1.39%, with a rate as high as 14.2% among individuals
aged 75 years and older [77].

Viral Transmission
A major factor behind the severity of the SARS-CoV-2 pandemic is the high transmission rate of the
virus. A common measure of contagiousness is the basic reproduction number R0 , defined as the
average number of infections caused by one infected person in a population with no immunity. A R0
below 1 indicates that the epidemic will eventually subside. Estimates of R0 across countries show
high variability, likely reflecting the different policy responses and socioeconomic characteristics of
each country. A survey of 15 estimates of R0 in different countries from December 2019 to May
2020 showed that R0 > 1 in all countries at the time of publication [78]. The high R0 observed
for SARS-CoV-2 may be linked to the fact that a large fraction–48 to 62%–of the transmission may
involve pre-symptomatic carriers [76]. The combined potential of rapid SARS-CoV-2 transmission
and clinical complications highlight the need for effective public health responses.

1.3.4

SARS-CoV-2 detection in public health and clinical medicine

In response to the increasing number of infections, several countries have invested unprecedented
efforts in the development and conduction of testing. In the United States, the number of daily new
tests performed increased from 32,687 on May 1st 2020 to 1,661,491 as of Jan 31st 2021, showing
a positive-tested ratio of 8.4% and 8.1%, respectively [79].
Early and accurate detection of SARS-CoV-2 is key for both effective clinical treatment as
well as limiting disease transmission. Diagnostic tests are used to confirm the presence of disease,
and to inform clinical care. To these ends, effective diagnostic tests must be accurate, sensitive
and cost-effective. At the level of public health interventions, screening tests are used to detect the
presence of a pathogen in a population of subjects, regardless of whether they display symptoms.
Screening tests are designed for the frequent monitoring of disease in a larger population sample,
especially in populations at higher risk [80]. In contrast to diagnostic testing, screening tests are not
9

intended to guide individual clinical care, but instead to detect disease early . In most cases, positive
screening test results are subsequently confirmed with a diagnostic test [80]. Because SARSCoV-2 is a highly transmissible disease with prevalence in asymptomatic subjects, early detection
of cases through screening can provide individual-specific quarantine recommendations to limit
transmission. Systematic application of screening tests to an at-risk population is considered a part
of population surveillance, which can help identify novel disease clusters and refine understanding
of transmission and reveal at-risk behaviors or populations. In addition to testing, surveillance can
encompass other interventions, such as contact-tracing [81]. The broader purpose of population
surveillance tests mean they do not need to be as sensitive as diagnostic tests, and should instead
minimize costs and turn-around times while maintaining an acceptable sensitivity and accuracy
profile [82].

1.3.5

Diagnostic testing terminology

Current testing approaches focus on the detection of SARS-CoV-2 RNA or protein as well as on
the detection of markers of the host immune response (antibodies against SARS-CoV-2). For
the purpose of this dissertation, I will focus on methods aimed at detecting active SARS-CoV2 infections and refer to the following review for information on serological testing methods for
COVID-19 [83]. Before introducing the different testing methods I want to clarify some commonly
confused terminology. The limit of detection (LoD) refers to the lowest amount of virus that yields
an analytical response. Typically, the lowest analytical response is defined as the lowest analyte
signal that can be identified from noise. The FDA defines the LoD for SARS-CoV-2 molecular
tests as the level at which 19/20 replicates are positive [84]. The limit of quantification (LoQ)
applies to methods that aim to quantify an analyte, and is the lowest concentration of analyte for
which a quantitative assessment can be provided [85]. For example some testing methods may
not show a linear response at very low analyte concentrations and therefore their LoD would
be lower than their LoQ. Accuracy typically refers to the level of agreement between the results
from a test in question with a reference test. As the first COVID-19 tests developed used reversetranscription polymerase chain reaction (RT-PCR) to detect viral RNA [67], and since RT-PCR is
still the most common diagnostic method [86] this is typically the test chosen as reference. Since
10

the negative consequences of false positive (unnecessary isolation) and false negative results (risk of
transmission) are considerable, the FDA recommends that clinical testing should always be paired
with clinical evaluation [84]. Analytical sensitivity of testing is defined as the likelihood to obtaining
a positive result for any sample harboring the virus. As a corrolary, Analytic specificity refers to
the likelihood of obtaining a negative result for samples not containing the analyte in study but
containing other pathogens.

1.3.6

Sample collection and processing

Several types of biological samples have been considered as potential candidates for SARS-CoV-2
testing. The most frequently used are nasal swab, saliva, blood and serum but other sources such as
fecal samples have also been proposed as useful alternatives [87]. Sample collection and processing
should preserve integrity of the viral analyte, while protecting laboratory personnel from hazardous
exposures. Great effort has been made in developing sample collection protocols that minimize
interpersonal contact, such as point of care (POC) appointment-only collection models, drive-thru
collection models, and self-collection or self-testing models [87]. Most of the testing techniques
require a series of post-collection processing steps (most commonly RNA extraction). Depending
on the downstream analytical approach, these steps can be costly and labor-intensive. During the
early phases of the pandemic, the shortage of testing reagents posed a significant challenge to
increasing testing capacity. Alternative strategies have focused on automated extraction protocols
and extraction free testing protocols [88]. Although the latter approach could provide faster and
more inexpensive alternatives, it is typically associated with lower accuracy and sensitivity [89].
These features make them more suitable for screening and surveillance purposes compared to
diagnostic testing.

1.3.7

Survey of testing methods

Current SARS-CoV-2 molecular testing approaches can be divided into two broad categories:
methods to detect viral RNA and methods to detect viral proteins.
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Detection of SARS-COV-2 proteins
Methods to detect viral proteins are primarily immune-based assays capable of recognizing specific
antigens. Low antibody-antigen specificity is often the limiting step in the development of these
assays, since there is a risk of antibodies cross-reacting with unrelated pathogens. Sensitivity largely
varies across different tests and is highly affected by sample collection procedures. In addition,
SARS-CoV-2 viral protein levels may be below the LoD in the early phases of infection. For these
reasons, antigen tests are typically used for screening purposes and not for diagnostic purposes [87].

Detection of SARS-CoV-2 RNA
Methods to detect SARS-CoV-2 RNA are the most widely-used form of testing for diagnostic
purposes, as they are able to detect the earliest stages of infection. RT-PCR based approaches
are the current standard for diagnostic testing and are the most widely used method.

They

involve processing collected samples with an optional RNA purification step followed by reverse
transcription of RNA to cDNA and PCR amplification with specific primer sequences. Amplified
DNA can then be detected using a fluorescent dye [87]. RT-PCR is a well validated approach, but
an important factor to its success is the design of effective primer sets. Different studies have shown
that the selection of primers can affect the sensitivity of the method, likely due to differences in
abundance of coronavirus sgRNAs [90]. Studies comparing primer sensitivity for SARS-CoV-2
have found primers targeting the N, E, and Orf1ab genes demonstrate the highest sensitivity [91–
93].
Clustered regularly interspaced short palindromic repeats (CRISPR) based diagnostic
methods have recently emerged as an alternative to RT-PCR [94].

One approach, dubbed

SHERLOCK, first amplifies RNA via recombinase polymerase amplification (see paragraph below),
then transcribes the DNA back to RNA. The amplified RNA sequence can then be recognized by
a complementary RNA nucleotide (guide RNA, gRNA) and an RNA targeting CRISPR-associated
nuclease (Cas) such as Cas13. Upon binding of the gRNA to target sequence, the Cas nuclease is
activated and induces cleavage of surrounding reporter RNA probes [95]. An alternative method,
DETECTR, instead uses a DNA-recognizing nuclease Cas12a, thus omitting the need for the reverse
12

transcription step [96]. These approaches can be used in isothermal conditions, and therefore do not
require thermocyclers and are amenable to point-of-care settings, and have acceptable sensitivity to
detect viral RNA concentrations as low as 100 copies/µL in under an hour [96].
In addition to the CRISPR-based diagnostics, other isothermal amplification-based
methods have been developed to detect SARS-CoV-2 RNA, such as recombinase polymerase
amplification (RPA) and reverse transcription coupled with loop-mediated isothermal amplification
(RT-LAMP) [97, 98]. RPA uses recombinases to insert primers into dsDNA and single-stranded
binding proteins to stabilize the resulting evicted ssDNA, followed by DNA extension using a
strand-displacing polymerase [97, 99]. Similar to RPA, RT-LAMP also takes advantage of a stranddisplacing polymerase to amplify from RNA or DNA templates; however, it also uses 4-6 unique
primers to bind the target sequence, leading to rapid amplification via a series of ’cauliflowerlike’ intermediates [100, 101]. Typical RT-LAMP reactions can generate microgram quantities
of DNA in less than 30 minutes, convenient for point of care testing settings. As the RT-LAMP
reaction proceeds, insoluble magnesium pyrophosphate accumulates and increases the turbidity
of the solution, allowing for a convenient visual indicator of amplification [102]. Other readouts
include colorimetric pH indicators to monitor reaction progress [103] or fluorescent or colorimetric
intercalating dyes to detect amplified DNA [104]. Due to concerns that these generic readouts are
susceptible to artifacts, sequence-specific fluorescent readouts have been developed using quenched
fluorescent primers or molecular beacons [105–107].

High throughput sequencing-based detection of SARS-CoV-2 RNA
In addition to typical 96 or 384-well plate-based testing methods, other groups have explored using
high-throughput DNA sequencing to allow for massively parallel testing [108–114]. These methods
used modified RT-PCR or RT-LAMP protocols by incorporating a uniquely identifiable nucleotide
barcode into each sample. Following amplification, up to tens of thousands of barcoded DNA
samples can be combined and processed for sequencing on a next-generation sequencing platform.
Barcodes that appear in conjunction with viral sequences can then be deconvoluted to provide a
positive result. While these approaches require more sophisticated equipment and analysis than
standard tests, the wide and inexpensive availability of DNA sequencing capacity in academic and
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private settings make this an attractive option for large-scale testing programs. Testing protocols that
can harness this powerful capacity coupled with unsophisticated sample collection and processing
could enable a huge increase in testing capacity and more effective surveillance.

1.4

Goals

In the following chapters, I present experiments aimed at developing tools to probe RNA-protein
interactions in chromatin biology, and then adapt those tools to answer questions about how RNA
regulates PRC2 activity on chromatin. Following the emergence of COVID-19, I switched focus to
work on a diagnostic methods for SARS-COV-2, and here I present the results of that work as well.
In the first chapter, I present data on the development of a novel method to identify RNAprotein interactions using UV crosslinking and high resolution mass spectrometry. We developed
a method to identify RNA-binding proteins and RNA-binding regions (RBRs) using crosslinking
and mass spectrometry. We identify 8̃00 RBPs in mouse embyronic stem cells, including over 400
that had not been previously found to bind RNA. These novel RBPs included many with functions
related to chromatin, suggesting a greater role for RNA in chromatin regulation.
In the second chapter, I relate an additional set of experiments continuing to examine
RNA-protein interactions in chromatin function. Using a targeted version of RBR-ID on the
chromatin regulatory complex PRC2, we generated a map of multiples sites of RNA interaction
on the complex, demonstrating that all known PRC2 variants show extensive RNA-binding
activity. One of these sites fell inside an allosteric regulatory center of PRC2, and we found
that stimulatory peptides binding in this site were able to rescue RNA-mediated inhibition of
PRC2 methyltransferase activity. This study revealed new aspects of RNA regulation in PRC2
and suggested how stimulatory and inhibitory stimuli are integrated on PRC2.
In the third chapter I present a testing method we developed to detect SARS-CoV-2
and influenza RNA from saliva. The method, which we called COV-ID, is based on RT-LAMP
coupled with high-throughput sequencing and is able to detect as few as 10 copies of viral RNA
per microliter. COV-ID can be multiplexed to test for both SARS-CoV-2 and influenza in the same
assay. We performed COV-ID on ten COVID-19 clinical samples, finding 100% agreement with
14

clinical RT-PCR data. The method requires minimal sample processing and handling, and up to
tens of thousands of samples can be processed in parallel with results delivered within 24 hours.
In the final chapter I summarized the results from the preceding chapters and present my
findings with respect to subsequent advances in the field. I then discuss further experiments to build
on the current state of the field of RNA regulation of PRC2, as well as the state of viral diagnostics
in the current pandemic and in the future.
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2.1

Abstract

Interactions between non-coding RNAs and chromatin proteins play important roles in gene
regulation, but the molecular details of most of these interactions are unknown. Using proteinRNA photo-crosslinking and mass spectrometry on embryonic stem cell nuclei, we identified and
mapped, at peptide resolution, the RNA-binding regions in 800 known and previously unknown
RNA-binding proteins, many of which are transcriptional regulators and chromatin modifiers. In
addition to known RNA-binding motifs, we detected several protein domains previously unknown
to function in RNA recognition, as well as non-annotated and/or disordered regions, suggesting
that many functional protein-RNA contacts remain unexplored. We identified RNA-binding regions
in several chromatin regulators, including TET2, and validated their ability to bind RNA. Thus,
proteomic identification of RNA-binding regions (RBR-ID) is a powerful tool to map protein-RNA
interactions and will allow rational design of mutants to dissect their function at a mechanistic level.

2.2

Introduction

In addition to their central roles as messengers and translators of genetic information, RNA
molecules have key roles in gene regulation [1, 2]. Nowhere is this more evident than in the
nucleus of mammalian cells, where many classes of poorly understood non-coding RNAs (ncRNAs)
continue to be discovered [3–6].
Although some RNAs catalyze chemical reactions, they usually require association with
proteins to function properly. Thus, it is reasonable to assume that the thousands of ncRNAs
26

whose biochemical and biological roles are largely unknown exert their functions via protein-RNA
interactions. Identifying proteins that interact with a given ncRNA has become a successful strategy
to begin to dissect its biological roles; for example, the identification of Xist-associated proteins
has provided important advances in understanding how this long ncRNA (lncRNA) controls X
chromosome inactivation [7–9].
To identify RNA-binding proteins (RBPs) in a more general, unbiased way, multiple
groups have used polyA+ selection followed by mass spectrometry (MS). These studies identified
hundreds of previously unknown RBPs bound to mRNAs in human cell lines [10–13] and mouse
embryonic stem cells (ESCs) [14]. However, most small RNAs and many lncRNAs are not
polyadenylated, including abundant nuclear RNAs like MALAT1 [15, 16], enhancer-derived RNAs
(eRNAs) [17], and circular RNAs [18]. Proteins interacting with these and other polyA− ncRNAs
have thus been missed by existing approaches.
The identification of a protein as being RNA-associated is only the first step toward
understanding the role of RNA interactions in its biochemistry. Mapping RNA-binding residues
allows for the rational design of mutants to study the functional relationship between the protein and
its cognate RNAs [19, 20]. Prediction of RNA-binding regions (RBRs) within RBPs is facilitated
by the existence of well-characterized structural motifs that function as conserved RNA-binding
domains (RBDs). The distinction between these two terms is important for this study: we refer
to “RBRs” as minimal protein regions that make direct physical contacts with RNA [19], whereas
“RBDs” are well-known, conserved domains that can be predicted from the primary sequence and
typically function as RNA binders [21]. Examples of the latter category are the RNA-recognition
motif (RRM) [22], the hnRNPK-homology domain (KH) [23], and the double-stranded RNAbinding domain (dsRBD) [24].
Until recently, it was widely believed that RBPs would contain one or more known
RBDs and that the protein-RNA interaction could be assumed to take place within these domains.
However, this simple concept has been challenged as the number of “non-canonical” RBPs (proteins
that bind RNA without containing a classical RBD) continue to increase, especially for proteins that
interface with chromatin and non-coding RNAs [25]. Because the RBRs of these proteins cannot
be predicted a priori, we and others have resorted to various biochemical methods to identify them
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with candidate-based, low- throughput methods [19, 20, 26, 27].
Here, we report a high-throughput approach that exploits protein-RNA photocrosslinking
and quantitative MS to identify proteins and protein regions interacting with RNA in vivo, regardless
of the RNA polyadenylation status. As this approach not only identifies RNA- binding proteins, but
also their respective RNA-binding regions, we named the technique RBR-ID. We applied RBR-ID
to nuclei from mouse ESCs and identified RBRs within 803 proteins, more than half of which had
not previously been reported as RBPs. We validated six RBRs, two in known RBPs whose mode
of interaction with RNA was unknown and four in chromatin-associated proteins that had not been
previously shown to bind RNA. Rational mutant design informed by RBR-ID nearly abolished RNA
binding in vivo for these proteins, demonstrating the predictive power and practical utility of our
technique for characterizing functional protein-RNA interactions.

2.3
2.3.1

Results
Development and optimization of RBR-ID

UV-mediated protein-RNA photocrosslinking generates adducts of RBPs with the covalent
attachment localized at or near the site of physical interaction because of the short range of this
type of crosslinking [28]. Thus, it should be possible to detect the RBR of a protein by MS, as an
RNA-crosslinked peptide would have a different mass, causing the intensity of the signal for the
non-crosslinked peptide to be lower in the irradiated sample (Figure 2.1 A).
Comparing mass spectra of UV-irradiated ESCs pulsed or not with 4-thiouridine (4SU),
a uridine analog selectively activated by long-wavelength UV [29, 30], we observed that most
peptides were unchanged in intensity (Figure 2.1 B, black lines) but some were depleted in the 4SUtreated samples; for example, peptide 74–89 from HNRNPC (Figure 2.1 B, red lines). We performed
the experiment in three biological replicates, each acquired in duplicate MS runs, and noticed that
the same HNRNPC peptide was consistently depleted by more than 50% (Figure 2.1 C), suggesting
that 4SU incorporation and UVB-mediated crosslinking had caused a fraction of these peptides to
change mass and thus not be counted toward the peak intensity of the non-crosslinked peptide.
As HNRNPC is a well-known RBP [31] and the HRNPC74–89 peptide overlaps its RRM, we
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concluded that this analysis had the potential to reveal protein-RNA contacts in the entire proteome.
There are different ways to crosslink RNA to proteins. Conventional UV crosslinking
exploits the excitation peak of natural nucleotides in the short-wavelength UVC range (254 nm)
[32, 33], whereas incorporation of 4SU allows for more selective and less damaging crosslinking,
typically using 365 nm UV (UVA). We previously showed that some protein-RNA interactions
can only be captured with 4SU-aided crosslinking when an intermediate wavelength of 312 nm
(UVB) is used [34]. We irradiated ESCs with the three different wavelengths and compared mass
spectra obtained from isolated nuclei with those obtained from non-crosslinked samples (no 4SU
treatment for 312 and 365 nm UV; no UV irradiation for 254 nm). Irradiation with 312 nm yielded
the best compromise between sensitivity and specificity (Figure 2.1 D,E); 254 nm UVC yielded a
large number of peptides with decreased intensities but with no preference for peptides overlapping
known RRMs (Figure 2.1 D, blue dots); whereas, 365 nm UVA were too weak to consistently
deplete a large number of peptides. For example, the RNA-binding peptide HNRNPC74–89 was
significantly depleted only upon irradiation at 312 nm (Figure 2.1 D, red dot), similar to the RNAbinding peptides from SNRNP70, SPEN, and HNRNPM (Figure 2.7 A), three other well-known
RBPs. Consistent with this, 254 nm UVC identified more candidates compared to 312 nm UVB
(Figure 2.1 E), but a smaller fraction of them were annotated as RBPs, suggesting that the increased
sensitivity came at the cost of decreased specificity. Crosslinking with 365 nm UVA resulted in more
accurate identification (46% versus 40% of proteins identified were RBPs) than 312 nm UVB but
with a considerable loss in sensitivity (Figure 2.1 E). Overall, 312 nm UVB crosslinking identified
a larger fraction of all known RBPs (Figure 2.1 F), whether from previous empirically determined
lists from HeLa, HEK293, or mouse ESCs, or from digital annotations such as the GO and Toronto
RBP databases [35]. These proteome-wide observations were consistent with the higher efficiency
of 4SU-dependent protein-RNA crosslinking, as measured by RNA pull-down followed by western
blot for the U1SNRNP70 complex (Figure 2.7 B).
There was no correlation between the depletion of peptides by 4SU after UV crosslinking
and depletion of peptides by 4SU alone (Figure 2.7 C), suggesting that changes in protein isoform
representation or post-translational modification in response to the 4SU treatment could not explain
the bulk of depletion observed after UV. Furthermore, although some peptides showed an increase in
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apparent abundance upon 4SU crosslinking (Figure 2.1 D), the majority of significant UV-induced
changes were toward depletion in +4SU conditions (Figure 2.7 D).
We conclude that RBR-ID can identify known and unknown RBPs and that comparison
of 4SU-treated versus untreated samples after irradiation with 312 nm UVB is the best compromise
between sensitivity and specificity.
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See also Figure S1

2.3.2

Protein-level analyses

To increase the confidence in peptide quantification, we acquired two technical replicates each
for two additional biological replicates of 312 nm UVB irradiation ± 4SU. Despite the noise in
each individual run, once aggregated, the first set (three replicates) and second set (two replicates)
of RBR-ID results were consistent (Figure 2.2 A), suggesting that high replication could reduce
artifactual identification of RBRs due to fluctuations in the MS signal.
In total, we detected 75,441 unique peptides from 4,929 proteins in mouse ESC nuclei;
of these, 1,475 were consistently (p < 0.05) depleted by 4SU and UV, but not by 4SU alone (Table
S1). These peptides belonged to 814 proteins (corresponding to 803 unique protein symbols), which
we considered “primary hits” (Table S2). An additional set of 721 proteins identified with relaxed
requirement (0.05 < p < 0.1) was used for some of the subsequent analyses and, along with the
primary hits, constitutes our “extended” set (Table S2). GO annotations for the primary hits were
enriched for functional terms related to RNA metabolism and function, including “RNA binding”
(Figure 2.2 B; Table S3). Primary hits also showed large overlaps with a variety of existing RBP lists
(Figure 2.8 A), either empirically determined [10–14] or digitally annotated [35, 36]. Based on these
lists, 376 of the 803 primary candidates were previously known RBPs (Figure 2.2 C), a significant
overlap (p < 10−43 , hypergeometric distribution). Among the previously known RBPs that were
not recovered by RBR-ID, a large proportion ( 40%, Figure 2.8 A, compare bottom left with bottom
right) could not be detected at all in ESC nuclei, likely because they were not expressed or were
localized to the cytoplasm, as shown by their enrichment for ribosomal proteins and translation
factors (Table S4, left). Nonetheless, 865 previously known RBPs were detectable in the ESC
nuclear fraction and not recovered by RBR-ID (Figure 2.2 C). This set of proteins was also enriched
for ribosomal biogenesis and translation-related GO terms (Table S4, right), suggesting that some
might be present in the nucleus but only bind RNA in the cytosol. It is also possible that a substantial
number of true nuclear RBPs cannot be crosslinked efficiently to 4SU.
We then turned our attention to the 427 previously unknown RBPs that were identified
by RBR-ID. Even when considering only the detectable nuclear proteome as background, these
non-canonical RBPs were enriched for GO terms related to gene regulation and chromatin biology
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(Figure 2.2 D; Table S5), consistent with the notion that many chromatin-associated proteins bind
RNA [25, 37]. Non-canonical RBPs identified by RBR-ID also contained different types of protein
domains. The list of primary hits as a whole was enriched in known RBDs (RRM and KH) and RNA
helicase domains, DEAD and DEAH (Figure 2.2 E; Table S6), whereas the 427 unknown RBPs were
enriched for chromatin-related domains, such as bromodomain and chromodomain, (Figure 2.2 F;
Table S7), which bind acetylated and methylated histones, respectively [38], and the SNF2-related
domain found in ATP-dependent chromatin remodelers [39].
To estimate the confidence of identification for these proteins, we calculated an RBR-ID
“score” for each peptide that captured both the extent of depletion (i.e., the log-converted foldchange between 4SU-treated and non-treated cells) and the consistency across replicates (i.e., the
p value for the depletion; see Experimental Procedures). The previously unknown 427 RBPs had
a distribution of RBR-ID scores comparable to that of the known 376 RBPs recovered RBR-ID
(Figure 2.2 G).
We validated the unknown RBPs by performing photoactivatable-ribonucleosideenhanced crosslinking and immunoprecipitation (PAR-CLIP) using conventional 365 nm UVA [30].
We tested five candidate RBPs from the set of 427 previously unknown primary hits and four of
them (RARG, CDKN2AIPNL, PCED1B, and PCGF2/MEL18) showed 4SU-dependent radioactive
labeling (Figure 2.8 B) indicative of RNA binding in vivo. A fifth one (CCDC115) was undetectable
by PAR-CLIP, either because it was a false positive or because epitope tagging and overexpression
interfered with its RNA binding activity. We also confirmed that NANOG, which was in the
extended set, crosslinked to RNA in vivo (Figure 2.8 C), indicating that these additional candidates
might also comprise previously unknown RBPs.
Thus, RBR-ID identified a considerable portion of previously known nuclear RBPs and
at least 427 unknown, non-canonical RBPs enriched for GO terms and protein domains related to
chromatin function.
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2.3.3

Known and unknown RBPs with chromatin-related function

Confirming the GO and domain enrichment analysis, visual inspection of the primary list of proteins
identified by RBR-ID revealed many with chromatin-related functions whose moonlighting RNAbinding activities have been reported by candidate-based approaches (Table 1) but were missed
by previous unbiased RBP identification endeavors. This included EZH2, the catalytic subunit
of Polycomb repressive complex-2 (PRC2), which is responsible for formation of facultative
heterochromatin and interacts with lncRNA [26, 40–42] and nascent transcripts [34]. We also
recovered SUZ12, another subunit of PRC2 that binds RNA [43, 44], and HP1, a central component
of constitutive heterochromatin and known RNA binder [45], as well as four chromatin factors
whose binding to RNA was only recently reported: CTCF, ATRX, HDAC1, and DNMT3 [27, 46–
50].
Among the many candidate chromatin proteins identified by RBR-ID that have not
previously been reported to bind RNA, we noted TET1 and TET2, two methylcytosine oxidases
required for the epigenetic process of DNA demethylation [51].

Name

Functions

References

ATRX

Chromatin remodeling

Sarma et al. [49]

CBX1/3/5 (HP1 α/β/γ)

Heterochromatin binding

Maison et al. [45] and Muchardt et al. [52]

CTCF

Chromatin organization

Saldaña-Meyer et al. [27], Kung et al.
[48], and Sun et al. [50]

DNMT3A

DNA methylation

Holz-Schietinger & Reich [47]

EZH2

Histone methylation

Kaneko et al. [26], Rinn et al. [40], Tsai
et al. [41], and Zhao et al. [42]

HDAC1

Histone deacetylation

Castellanos-Rubio et al. [46]

SUZ12

Histone methylation

Beltran et al. [43] and Kanhere et al. [44]

TET1

DNA demethylation

-

TET2

DNA demethylation

-

TABLE 2.1

Examples of Chromatin Factors Identified as RBPs
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2.3.4

High-resolution mapping of RNA-interacting residues in vitro

We reasoned that the real power of RBR-ID would rely in its ability to identify not only RNAbinding proteins, but also their RNA-binding regions. We first sought to characterize a well-defined
protein-RNA interaction in a fully reconstituted system. We chose the phage MS2 coat protein
(MS2-CP) and its cognate stem-loop RNA (MS2-SL), a well-known protein-RNA pair with several
high-resolution crystal structures available [53–55].
We incubated recombinant MS2-CP and MS2-SL RNA transcribed in vitro in the presence
or absence of 4SU, subjected the complexes to UVB irradiation, and analyzed the crosslinks using
MS (Figure 2.3 A). Incorporation of 4SU did not affect the ability of the coat protein to interact
with the RNA (Figure 2.9 A). Similar to what we had observed in vivo (Figure 2.7 B), UVB were
more efficient than UVA, although at the cost of some low-level background crosslinking even in
absence of 4SU (Figure 2.3 B; Figure 2.9 B). Analysis of extracted ion chromatograms revealed a
subset of peptides whose intensity was decreased in the 4SU sample (Figure 2.3 C). We generated
three biological replicates for this in vitro RBR-ID assay and acquired them in technical duplicates.
The most consistently depleted peptide corresponded to the 57–66 region of MS2-CP (Figure 2.3
D), which contains several residues known to form hydrogen bonds with RNA [54, 55].
Next, we calculated RBR-ID scores (combining extent and consistency of depletion) for
each residue and plotted them along the primary sequence of MS2-CP. The RBR-ID score was a
good metric for protein-RNA crosslinking, as positive scores precisely mapped to the known RBR of
the protein (Figure 2.3 E), with the peak corresponding to glutamic acid 63, which forms hydrogen
bonds with a uridine at position -5 in the stem loop [55].
The availability of crystal structures for the MS2-CP–MS2-SL complex allowed us to
visualize the RBR-ID score in a more direct and powerful way. We converted the scores into a
heat-map and used it to color the surface of the MS2 protein from the crystal structure [55], which
revealed that the highest RBR-ID scores mapped to the pocket where most RNA contacts occur
(Figure 2.4 A).
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2.3.5

Mapping of RBRs in vivo

We returned to our in vivo RBR-ID dataset from ESCs and assessed its precision in mapping
RNA-interacting residues in known protein-RNA complexes in vivo at a proteome-wide level. We
analyzed the subunits of the U1 small nuclear ribonucleoprotein (snRNP), a component of the
spliceosome for which a high-resolution crystal structure was obtained [56]. The mouse U1 snRNP
is composed of a polyA− ncRNA, U1, and ten protein subunits; we recovered four in the primary
RBR-ID candidate list and four more in the extended list (Figure 2.4 B).
We calculated the single-residue RBR-ID scores for the identified subunits and used them
to color the respective regions of the crystal structure. For the U1-70K subunit, our approach
correctly identified two primary sites of RNA interactions, one within the conserved RRM that
caps stem-loop I of the U1 RNA (Figure 2.10 A) and another within the stretch of residues that
wraps around the ring formed by the Sm subunits to reach U1-C (Figure 2.4 C). Here, the highest
RBR-ID scores were directly adjacent to uridine 137, which forms hydrogen bond contacts with the
protein (Figure 2.4 C).
To determine whether spatial RBR mapping was also accurate for proteins in the extended
RBR-ID candidate list, we analyzed the SmD2 subunit of the U1 snRNP particle (Figure 2.4 B),
which contacts uridine 131 within U1 using H62 and N64. Even for this protein from the extended
list, RBR-ID mapped the interacting region with great accuracy, with a peak in signal at the site of
interactions as seen in the crystal structure (Figure 2.4 D). Similarly, the highest scores for SmB
were near histidine 37, which interacts with uridine 129 (Figure 2.10 B).
To further validate the power of RBR-ID to identify known RBPs in vivo, we analyzed
the subunits of RNA polymerase I and II (Figure 2.4 E,F), protein complexes responsible for
transcription of rRNA and mRNA, respectively [57]. The two large subunits that form opposite sides
of the active center cleft were recovered in both cases, as well as several of the smaller subunits.
Interestingly, we recovered both subunits forming the “stalk” structure of RNA pol II (Figure 2.4
E), which were previously shown to crosslink to RNA in vitro [58, 59]. We also recovered the
corresponding protein subunit from RNA pol I, RPA43 (Figure 2.4 F), suggesting that interactions
of the polymerase stalk with nascent RNA might be a conserved feature in these related complexes.
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2.3.6

Domain-level analyses on RBR-ID candidates

The mapping accuracy of RBR-ID was not restricted to the specific protein-RNA complexes
discussed above, but extended to the entire proteome. Peptides overlapping RRM domains showed a
strong bias for high RBR-ID scores compared to mock scores calculated from samples not irradiated
with UV (Figure 2.5 A, left). Because the RRM domain is relatively frequent in mouse proteins, we
also analyzed the distribution of RBR-ID scores for a control domain with similar frequency, the
Ploop containing nucleoside triphosphate hydrolase (Interpro: IPR027417), which did not show the
same bias (Figure 2.5 A, right). This demonstrated the selectivity of RBR-ID for a bona fide RBD
in a proteome-wide manner.
Compared to all detected peptides, the primary list of RBR-ID peptides overlapped
significantly with known RBDs but also contained a large proportion of peptides mapping to
domains with no known RNA-related function ( 59%) or no domain annotations at all ( 23%, Figure
2.5 B). RBR-ID hits were enriched in peptides overlapping the three best- known RBDs—RRM,
dsRBD, and KH [21]—as well as DEAD and DEAH RNA helicase domains (Figure 2.5 C). We
also analyzed a list of non-classical RBDs [12] and found many of them enriched (Figure 2.5 D). In
particular, the SAP domain, previously thought to mediate DNA binding [60], was enriched more
than 5-fold compared to background. The reclassification of the SAP domain as a putative RBD was
previously suggested based on its occurrence in empirically identified RBPs [12]. The enrichment
of peptides overlapping the SAP domain in our RBR-ID candidate list provides direct evidence that
this domain participates in RNA binding in vivo. Annotated domains enriched in the RBR-ID list,
but not typically considered as possible RBDs (Figure 2.5 E), contained a few domains typically
associated with chromatin-related functions, such as the high mobility group domain (HMG) and
chromodomain, as well as domains known to participate in nuclear processes but whose function
remain nebulous, such as DZF [61–63] and DUF1605 [64, 65].
Peptides that scored high in our RBR-ID screen, but could not be assigned to annotated
domains, showed a slight tendency toward higher isoelectric points (Figure 2.5 F; Figure 2.11 A),
consistent with a frequent role for positively charged amino acid in mediating direct interactions
with RNA [66]. However, we saw no global correlation between the isoelectric point of a peptide
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and its RBR-ID score, excluding the possibility that crosslinking to RNA strongly favored patches
of positive amino-acids in a non-specific fashion (Figure 2.11 B). Peptides identified by RBR-ID
were also more likely to fall in protein regions predicted to be disordered (Figure 2.5 G; Figure 2.11
C), suggesting that in some cases the disordered regions might directly serve as RNA binding sites.
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(A) All detected peptides were sorted according to their RBR-ID score (UV312 ± 4SU) or a control score (no UV ± 4SU).
The frequency of peptides overlapping the RRM domain (left) or a control, non-RNA binding domain (IPR027417, right)
in these ranked lists is shown.
(B) Categories of Interpro annotations for all peptides detected (left) or peptides in the primary list from RBR-ID (right).
(C–E) Enrichment of selected domains in the top-tier RBR-ID peptides compared to the full list of detected peptides.
Classical (C) and non-classical (D) RNA-binding domains are shown as well as enriched domains not previously reported to bind RNA (E).
(F) Tukey boxplot of the isoelectric point for the indicated sets of peptides. P-value is from a Student’s t-test. Tot, all
detected peptides in the nuclear proteome; new RBRs, peptides in the primary candidate lists that did not overlap known
RBDs; RRM, all detected peptides overlapping with the RRM domain.
(G) Percentage of peptides overlapping with disordered regions from IUPred (Dosztanyi et al., 2005; Oates et al., 2013).
Values are shown for all detected peptides (tot), all top-tier RBR-ID peptides not mapping to a known RNA-binding
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See also Figure S5.
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(A) All detected peptides were sorted according to their RBR-ID score (UV312 ± 4SU) or a control score (no
UV ± 4SU). The frequency of peptides overlapping the RRM domain (left) or a control, non-RNA binding
domain (IPR027417, right) in these ranked lists is shown. (B) Categories of Interpro annotations for all
peptides detected (left) or peptides in the primary list from RBR-ID (right).(C–E) Enrichment of selected
domains in the top-tier RBR-ID peptides compared to the full list of detected peptides. Classical (C) and
non-classical (D) RNA-binding domains are shown as well as enriched domains not previously reported to
bind RNA (E). (F) Tukey boxplot of the isoelectric point for the indicated sets of peptides. p value is from a
Student’s t test. Tot, all detected peptides in the nuclear proteome; uRBRs, peptides in the primary candidate
lists that did not overlap known RBDs; RRM, all detected peptides overlapping with the RRM domain. (G)
Percentage of peptides overlapping with disordered regions from IUPred (Dosztányi et al., 2005; Oates et al.,
2013). Values are shown for all detected peptides (tot), all top-tier RBR-ID peptides not mapping to a known
RNA-binding domain (uRBRs), and all peptides overlapping RRM domains. p value is from a chi-square
test. See also Figure 2.11. Experiments and Data generated by C.S.H. and S.S.

2.3.7

Validation of RBRs in vivo

To validate the RBRs predicted by RBR-ID, we selected proteins for which the RBR was previously
unknown. We started with L1TD1, a protein whose RNA-binding activity had been previously
reported but not mapped [14, 67]. The RBR- ID score plot pointed to a small region at residues
833–848 in the C terminus as a likely site for RNA interaction (Figure 2.6 A). We expressed epitopetagged L1TD1 and a truncation mutant lacking the predicted RBR (ΔRBR) in HEK293 cells and
performed PAR-CLIP using conventional 365 nm UVA [30]. We observed a radioactive signal that
overlapped with the L1TD1 band (Figure 2.6 B) and could be assigned to protein-RNA crosslinks
because its intensity was reduced after treatment with RNase A (Figure 2.6 C). Importantly, the
mutant lacking the region predicted to interact with RNA by RBR-ID showed much lower PARCLIP signal despite equal expression levels and pull-down efficiencies for wild-type (WT) and
mutant protein (Figure 2.6 B), suggesting that this region is a primary site of RNA interactions.
Next, we sought to validate a predicted RBR within a protein previously not known to
interact with RNA. RBR-ID identified a nine-residue peptide adjacent to the catalytic domain of
TET2 as the most likely site of RNA interaction (Figure 2.6 D). Indeed, a C- terminal fragment
encompassing this predicted RBR was sufficient to bind to RNA in vitro (Figure 2.12 A) and in
vivo (Figure 2.6 E,F), and the identified RBR was required for the interaction, as demonstrated by
the drastically reduced PAR-CLIP signal in the ΔRBR mutant (Figure 2.6 E). We made similar
observations for MYCN and its predicted RBR (Figure 2.12 B).
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To validate additional candidate RBRs with a crosslinking-independent method, we
switched to a native RNA immunoprecipitation assay [19]. Although lack of crosslinking renders
this technique more prone to non-specific interactions, we reasoned that differences in RNA
immunoprecipitation efficiency between WT and ΔRBR versions of the same protein would
strongly suggest that the predicted RBR mediated binding to RNA.
Epitope-tagged versions of stem cell transcription factors POU5F1/OCT4 and NANOG
as well as Polycomb protein MEL18 co-purified with RNA (Figure 2.12 C-E), and deletion of their
predicted RBR impaired RNA binding (Figure 2.12 C-F), suggesting that the regions identified by
RBR-ID were mainly responsible for RNA interactions.
Therefore, RBR-ID correctly identified six RBRs within two known (L1TD1 and OCT4)
and four previously unknown (TET2, MYCN, MEL18, and NANOG) RBPs and guided the design
of protein mutants that showed reduced RNA binding, demonstrating the validity of the predictions
and the practical utility of RBR identification.
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Figure 6. Validation of RBRs in L1TD1 and TET2
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2.4

Discussion

Interactions with RNA constitute an important regulatory layer for the protein machinery that
controls chromatin structure and gene expression. To obtain a mechanistic understanding of the
biological and biochemical roles of these protein-RNA interactions, comprehensive lists of proteins
bound to various classes of RNAs are needed, as well as detailed mapping of the protein regions
involved. In vivo photocrosslinking followed by MS allows for the identification of hundreds of
protein-RNA interactions in an unbiased manner and with peptide-level resolution.

2.4.1

Rationale for the development of RBR-ID

The identification of RBRs within non-canonical RBPs, such as Polycomb proteins SCML2 and
JARID2, [19, 20], as well as CTCF [27], were important steps toward defining the biochemical
roles of their interactions with RNA. Using ΔRBR mutants is particularly advantageous when the
RBR of a given protein interacts with many RNAs so that depleting individual RNAs generally does
not cause overt phenotypes. For example, a subset of the protein-RNA interactions within the PRC2
complex lack sequence specificity despite high affinities [68, 69], suggesting that the presence of
any RNA, not a particular transcript, modulates the enzymatic activity of this complex [34, 70].
Mapping the RBRs of these non-canonical RBPs one at a time using recombinant protein
fragments was a slow and labor-intensive strategy prone to in vitro artifacts. RBR-ID allowed us to
identify the potential RBRs of 376 known and 427 unknown RBPs in ESC nuclei. These data will
help focus future experiments on proteins and protein regions with the highest likelihood of forming
protein-RNA contacts in vivo.

2.4.2

Advantages and limitations of RBR-ID

Previous endeavors to identify RBPs have relied on enrichment of complexes containing
polyadenylated RNA [10, 12, 14]. Because of this experimental step, those approaches require
up to 108 –109 cells. RBR-ID can be performed with starting populations of 106 cells, making
comparisons between cellular states (e.g., different differentiation trajectories) and studies in
primary cells technically feasible.
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Kramer et al. (2014) previously developed an MS pipeline capable, like RBR-ID, of
assigning RNA binding sites within proteins based on UV crosslinking. They utilized their approach
on human RBPs in a semi-artificial in vitro system, and even in those controlled conditions,
crosslinks were identified in only 64 peptides from 49 proteins. This low number of RBPs was
likely due to the difficulties in the positive identification of the complex mass spectra created by the
heterogeneous products of protein-RNA crosslinking [71].
While our manuscript was being revised, Hentze and colleagues used a different technique
to map RBRs in HeLa cells [72]. Their approach relies on two sequential oligo-dT pull-downs and
therefore might have lower false positive rates than RBR-ID; however, it can only be used to identify
RBPs that bind polyA+ RNA and requires 10–100 times more input material than RBR-ID.
The potential for false positives in RBR-ID should be curtailed by extensive replication, as
was done for the experiments presented here. This is made possible by the low sample requirements,
as only 2 µg of total nuclear protein were used per replicate. Even with replication, RBR-ID hits,
as in any unbiased screen, will contain some false positives and therefore any candidate should be
validated before pursuing the functional significance of its interactions with RNA. Identification
by RBR-ID requires efficient protein-RNA crosslinks at a site of 4SU incorporation and therefore
a substantial false negative rate is also to be expected, as shown by the missed identification of
some known RBPs (Figure 2.2 C). This limitation could be mitigated in the future by utilizing other
nucleotide analogs (e.g., 6-thio- guanine; [30]), different crosslink strategies, and/or more sensitive
MS instruments.

2.4.3

Non-canonical RNA binding in chromatin proteins

Using RBR-ID, we identified 803 RBPs as well as their likely RBRs. Over 50% of these proteins
were not present in previous lists from polyA+ RNA purifications or annotation databases. Among
these are several chromatin proteins that have been identified by candidate-based approaches, such
as EZH2, SUZ12, and CTCF [26, 40, 41, 44], but were missed in previous unbiased screens, either
because they bind to polyA− ncRNAs or because the stoichiometry of their interactions with RNA
is too low for pull-down purification. These 427 unknown nuclear RBPs were enriched for GO
annotations related to chromatin structure, chromosome organization, and transcriptional regulation.
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This observation lends further support to the idea that protein-RNA crosstalk plays a central role in
epigenetic regulation [1, 2, 5, 25].
At the peptide level, several domains of interest were enriched, including the
chromodomain, which was proposed as a potential RBD [73], before its role in recognizing lysine
methylation was discovered [74]. Our RBR-ID data suggest that some chromodomains might indeed
moonlight as RNA binders. A conspicuous number of putative RBRs map to protein regions that
lack domain annotations. Although some of these might reflect incomplete annotation, the slight, but
significant, enrichment of predicted disordered regions suggests that some of them might mediate
RNA contacts, as in the case of FMRP and LAF-1 [75, 76]. This is particularly relevant in light of
the prominent role of RBPs with disordered regions in disease [77].

2.4.4

Use of RBR-ID predictions

The validation of the RBR of TET2 provides an example of the utility of our RBR-ID dataset
as a resource. In Drosophila, the TET2 homolog dTET is partially responsible for cytosine
hydroxymethylation on RNA [78]. Although no RNA-binding evidence has been obtained for the
Drosophila protein, the fact that mouse TETs can use RNA as a substrate in vitro [79] suggests that
this function might be conserved in mammals. The presence of both TET1 and TET2 in the list
of primary RBR-ID candidates strongly supports this hypothesis. Furthermore, the identification
and validation of the TET2 RBR provides a useful starting point to study the biological role of this
biochemical function for the TET family of epigenetic regulators.

2.4.5

Outlook and conclusion

We applied RBR-ID to ESC nuclei and identified hundreds of RBRs within proteins previously
unknown to bind RNA. Because the approach is easily implemented and versatile, we anticipate
that variations on this theme will provide even more comprehensive and precise lists of RBRs than
the one presented here. Improvements on MS instrumentation and quantification methods, such as
“Tandem Mass Tagging” [80], will increase sensitivity, and alternative photoactivatable nucleotides
and protease treatments could expand the range of crosslinked peptides, improving resolution.
RBR mapping data are available at http://rbrid.bonasiolab.org. We anticipate that the
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community will find this a useful resource to design functional experiments aimed at decrypting the
complex regulatory language of protein-RNA interactions on chromatin and elsewhere in cells.
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2.8
2.8.1

Methods
RNA immunoprecipitation

Nuclear extracts were incubated with hemagglutinin (HA) antibody for 3 hr at 4°C and
immunocomplexes recovered with protein G Dynabeads. Beads were washed in RIP-W buffer
(20 mM Tris [pH 7.94° C], 1 mM MgCl2, 200 mM KCl, and 0.05% IGEPAL CA-630) twice and
incubated with TURBO DNase to eliminate potential bridging effects of protein- DNA and DNARNA interactions. After two additional washes, RNA was eluted from the beads with TRIzol and
purified. We quantified the RNA abundance after immunoprecipitations by measuring the intensity
of the bands with ImageJ and normalizing to the IgG background.

2.8.2

PAR-CLIP

HEK293 cells were transiently transfected, pulsed with 100 µM 4-SU for 24 hr, crosslinked with
400 mJ/cm2 UVA (365 nm), and lysed in CLIP buffer (20 mM HEPES [pH 7.4], 5 mM EDTA,
150 mM NaCl, and 2% Empigen) with protease inhibitors, DNase, and RNase inhibitor. HA
and StrepTag-fused proteins were first bound to StrepTactin beads in CLIP buffer for 3 hr at 4°C.
Beads were washed five times using CLIP buffer and eluted with 2 mM biotin. Next, proteins were
incubated with HA antibody overnight at 4°C and recovered with protein G Dynabeads. DNA was
removed with DNase, and crosslinked RNA was dephosphorylated with Antarctic phosphatase and
labeled with T4 PNK and [γ-32P] ATP. Labeled complexes were resolved on 4%–12% bis-tris gels,
transferred to nitrocellulose membrane, and imaged. For NANOG PAR-CLIP, we used E14Tg2A
(E14) ESCs pulsed with 500 µM 4-SU for 2 hr and crosslinked with 400 mJ/cm2 UVB (312 nm).

2.8.3

RBR-ID

Cells were pulsed with 500 µM 4SU for 2 hr and crosslinked with 1 J/cm2 UVA, 1 J/cm2 UVB, or
800 mJ/cm2 UVC. We verified that 2 hr was sufficient to incorporate 4SU in virtually all coding
and non-coding transcripts by 4SU sequencing (data not shown). Cells were lysed in buffer A (10
mM Tris [pH 7.94° C], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, and 0.2 mM PMSF) with 0.2%
IGEPAL CA-630 for 5 min on ice to isolate nuclei, which were lysed in 9 M urea and 100 mM
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Tris (pH 8RT). The lysate was diluted in 50 mM ammonium bicarbonate and reduced with 5 mM
dithiothreitol for 45 min at 56°C. Cysteines were alkylated with 20 mM iodoacetamide for 30 min.
Trypsinization was performed at an trypsin:sample ratio of 1:100 overnight at 37°C and blocked
with 1% trifluoroacetic acid. Peptides were desalted, dried, and resuspended in 0.1% formic acid
prior to MS analysis. Crosslinked RNA was removed with Benzonase.

2.8.4

GO and Interpro enrichment

For protein list comparisons, all proteins identifiers were converted to official mouse symbols using
the Biomart database (version 84). One-to-one human-mouse orthologs were mapped directly,
whereas one-to-many and many-to-many homologs were reduced to one- to-one by considering
the protein with highest percentage of homology, according to the Biomart database (version 84).
For GO and Interpro annotation, tables were downloaded from the Uniprot and Interpro websites
directly. Enrichment values and statistics were obtained using the DAVID web server [81] either
using the unique Uniprot accession identifiers or the converted symbols, when needed.

2.8.5

Cells

E14Tg2A.4 mESC lines (E14 mESCs) and HEK 293 cells were cultured as described previously
[26]. KH2 ESCs expressing the reverse tetracycline-controlled transactivator (rtTA) [82] were
maintained in standard mouse ESC (mESC) culture conditions. For RNA immunoprecipitation
experiments, stable KH2 lines were generated by transfection of the relevant pINTAN3 constructs
and selecting with 50 µg/ml Zeocin (InvivoGen, CA). Transgene expression was induced with 2
µg/ml doxycycline for 24 h.

2.8.6

Plasmids and sequences

The construction of the backbones for pGEX-6P1 was described previously [83]. The DNA
sequence for MS2-CP was synthesized by IDT and subcloned into the pGEX-6P1 expression vector.
pINTON3 vector was based on the pINTO system [84] containing three N-terminal epitope tags
(FLAG, HA, and Twin-Strep-Tag). For expression inHEK 293 cells, we cloned into pINTON3
L1td1, Mycn, Rarg, Cdkn2aipnl, and Pced1b from mouse cDNA and the catalytic domain of Tet2
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from a plasmid kindly provided by Rahul Kohli (University of Pennsylvania) [85]. Pou5f1, Pcgf1,
Pcgf2, and Nanog were cloned from mouse cDNA into the pINTAN3 vector, which is based on the
Tet-On 3G system (Clontech, CA) and encodes three different N-terminal epitope tags: Flag, HA,
and Twin-Strep- Tag [34]. Truncations were obtained by PCR. All oligonucleotide and synthetic
DNA sequences used are in Digital Supplemental Table S8.

2.8.7

Antibodies information

The following antibodies were used for Western blots:

SNRNP70 (#sc-9571 Santa Cruz

Biotechnologies, TX), GST (#sc-33613; Santa Cruz Biotechnologies), FLAG (#F1804; SigmaAldrich, MO), HA (#901501 BioLegend, CA). Antibody against HA (#ab9110 Abcam, UK) was
used for PAR-CLIP experiment and RNA immunoprecipitation.

2.8.8

Recombinant protein expression and purification

GST fusion MS2-CP were induced with 0.1 mM IPTG and expressed in BL21(DE3) cells for 24 h
at 16°C and purified using glutathione-sepharose 4 Fast Flow beads (GE Healthcare Life Sciences,
PA). The beads were washed with PBS in a column, and the proteins were eluted in the presence of
10 mM glutathione. The purified proteins were dialyzed against 20 mM Tris pH 7.5, 100 mM KCl
and 10% glycerol. Recombinant, FLAG-fused TET2-CD was kindly provided by Rahul Kohli [85].

2.8.9

In vitro RNA pull-down assays

RNA fragments were in vitro transcribed using the HiScribe kit (New England Biolabs, MA)
and purified by TRIzol (Thermo Fisher). The 5’-terminal HOTAIR RNA fragment used was as
previously described [19]; template information for MS2-SL and random 100 nts RNA fragments
is in Digital Supplemental Table S8. For the binding assays, recombinant proteins were incubated
with total E14 RNAs or in vitro transcripts in 1 ml RIP buffer (20 mM Tris pH 8, 0.2 mM EDTA,
100 mM KCl, 3 mM MgCl2, 0.05% IGEPAL CA-630) with the addition of 2 u/µl murine RNAse
inhibitor (New England Biolabs) for 30 min at 4°C. Protein-RNA complexes were pulled down
using glutathione-sepharose 4 Fast Flow beads (GE) or FlagM2 beads (Sigma). After three washes
with RIP buffer, proteins were eluted from the beads in Laemmli sample buffer and nucleic acid
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with TRIzol. RNAs were resolved on polyacrylamide/urea gels and visualized with SYBR gold
(Thermo Fisher).

2.8.10

RNA immunoprecipitation

Nuclear extracts were obtained using an established protocol [86] with minor modifications to
minimize RNAse activity. Briefly, cells were washed with PBS and with Buffer A (10 mM Tris
pH 7.94oC, 1.5 mM MgCl2, 10 mM KCl, protease inhibitors, phosphatase inhibitors) and lysed
in Buffer A plus 0.2% IGEPAL CA-630 for 5 min on ice. Nuclei were isolated by centrifugation
at 2,500g for 5 min and lysed in Buffer C (20 mM Tris pH 7.94ºC, 25% glycerol, 400 mM NaCl,
1.5 mM MgCl2, 10 mM EDTA, 0.4 u/µl murine RNAse inhibitor, protease inhibitors, phosphatase
inhibitors) for 30 min at 4oC.
Lysates were cleared at 18,000g for 30 min then incubated with HA antibody for 3 h at
4oC. Immunocomplexes were recovered by adding 7 µl of protein G-coupled Dynabeads (Thermo
Fisher) per µg of antibody used and incubating for 1 h at 4oC. Beads were washed in RIP-W buffer
(20 mM Tris pH 7.94oC, 1 mM MgCl2, 200 mM KCl, 0.05% IGEPAL CA-630) twice and incubated
with 2 u of TURBO DNase (Thermo Fisher) in 20 µl RIP-W buffer for 10 min at room temperature,
to eliminate potential bridging effects of protein–DNA and DNA–RNA interactions. After two
additional washes in RIP-W buffer RNA was eluted from the beads with TRIzol and collected by
precipitation with isopropanol. Residual DNA was removed with TURBO DNAse for 20 min at
37oC.
To quantify the RNA abundance after immunoprecipitations, we measured the intensity
of the smears using ImageJ and normalized to the background observed in the IgG pull-down.

2.8.11

PAR-CLIP

HEK 293 cells were transiently transfected with plasmids using Lipofectamine 3000 reagent
(Thermo Fisher) and pulsed with 100 µM 4-SU (Sigma) for 24 h. Cells were crosslinked with 400
mJ/cm2 UVA (365 nm) using a Spectrolinker (Spectroline, NY) and lysed in CLIP buffer (20 mM
HEPES pH 7.4, 5 mM EDTA, 150 mM NaCl, 2% Empigen) with protease inhibitors (Roche), 20
U/ml Turbo DNase (Thermo Fisher), and 200 U/ml murine RNase inhibitor (New England Biolabs).
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Tagged proteins were first bound to BSA-blocked Strep-Tactin beads (IBA, Germany) in CLIP
buffer for 3 h at 4°C. Beads were washed 5 times using CLIP buffer and eluted in CLIP buffer with
2 mM biotin (Sigma), protease inhibitors (Roche Life Science, IN), and murine RNase inhibitor
(New England Biolabs). Eluted proteins were incubated with HA antibody (Abcam) in CLIP buffer
overnight at 4°C. Immunocomplexes were recovered with protein G- coupled dynabeads for 45 min
at 4°C. DNA was removed with TURBO DNase (2 U in 20 µl). Crosslinked RNA was labeled by
incubations with 5 U Antarctic phosphatase and 5 U T4 PNK (both from New England Biolabs) in
presence of 10 µCi [γ-32P] ATP (PerkinElmer, MA). Labeled material was resolved on 8% Bis-Tris
gels, transferred to nitrocellulose membrane, and exposed to autoradiography films for 1–24 hr.
For NANOG PAR-CLIP, E14 ESCs were transiently transfected with plasmids using
Lipofectamine 3000 reagent (Thermo Fisher) and pulsed with 500 µM 4SU (Sigma) for 2 h. Cells
were crosslinked with 400 mJ/cm2 UVB (312 nm) using a Spectrolinker.

2.8.12

In vitro RBR-ID

GST-fused MS2-CP was incubated with MS2-SL RNA in binding buffer (1 mM ATP, 10 mM
HEPES pH 7.2, 3 mM MgCl2, 5% glycerol, 1 mM DTT, 100 mM KCl) for 30 min at 4°C.
RNA- protein complex were crosslinked with 1 J/cm2 UVB (312 nm) using a Spectrolinker. The
complexes were treated with RNase A (1 µg/µl) for 30 min at 37°C and the protein digested
with trypsin or chymotrypsin. For trypsin digestion, proteins were diluted in 50 mM ammonium
bicarbonate (NH4 HCO3 , pH 8) and incubated with 5 mM dithiothreitol (DTT) for 45 min at 56°C
for disulfide bond reduction. This was followed by 20 mM iodoacetamide (IAA) incubation for 30
min in the dark for alkylation of the free cysteines. Trypsin was then added at an enzyme:sample
ratio of 1:20, overnight at 37°C. For chymotrypsin digestion, proteins were diluted in 100 mM
Tris pH 8, 10 mM CaCl2, and incubated with 5 mM dithiothreitol (DTT) for 45 min at 56°C for
disulfide bond reduction. This was followed by 20 mM iodoacetamide (IAA) incubation for 30 min
in the dark for alkylation of the free cysteines. Samples were then digested using chymotrypsin
at an enzyme:sample ratio of 1:20, overnight at 25°C. Reactions were blocked by adding 1%
trifluoroacetic acid. Desalting was performed by using in-house packed Stage tips made of C18
material. Eluted peptides were dried and resuspended in 0.1% formic acid prior to nanoLC-MS
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analysis.

2.8.13

In vivo RBR-ID

Cells were pulsed with 500 µM 4SU (Sigma) for 2 h and then crosslinked with 1 J/cm2 UVA (365
nm), 1 J/cm2 UVB (312 nm), or 800 mJ/ cm2 UVC (254 nm) using a Spectrolinker. We verified
that 2 hours was sufficient to incorporate 4SU in virtually all coding and non-coding transcripts
by 4SU-sequencing (data not shown). Cells were lysed in Buffer A (10 mM Tris pH 8, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF) with 0.2% IGEPAL CA-630 for 5 min on ice
to isolate nuclei. Nuclei were washed with Buffer A and lysed in denaturing lysis buffer (9 M urea,
100 mM Tris pH 8). Lysate was diluted in 50 mM ammonium bicarbonate (NH4HCO3, pH: 8.0)
and incubated with 5 mM dithiothreitol (DTT) for 60 min at 25°C for disulfide bond reduction.
This was followed by 20 mM iodoacetamide (IAA) incubation for 30 min in the dark
for alkylation of the free cysteines. Samples were then digested using trypsin at an enzyme:sample
ratio of 1:100, overnight at 37°C. Reaction was blocked by adding 1% trifluoroacetic acid. Desalting
was performed by using in-house packed Stage tips made of C18 material. Eluted peptides were
dried and resuspended in 0.1% formic acid prior MS analysis. Crosslinked RNA was removed with
Benzonase (250 U in 20 µl).

2.8.14

In vitro denaturing protein–RNA pull-downs

GST fusion MS2-CP were incubated with MS2-SL RNA in binding buffer (1 mM ATP, 10 mM
HEPES pH 7.2, 3 mM MgCl2, 5% glycerol, 1 mM DTT, 100 mM KCl) for 30 min at 4°C. RNAprotein complex were crosslinked with 1 J/cm2 UVA (365 nm), 1 J/cm2 UVB (312 nm), or 800
mJ/ cm2 UVC (254 nm) using a Spectrolinker. Biotin-labeled DNA probes were hybridized to
crosslinked RNA in hybridization buffer (500 mM NaCl, 1% SDS, 50 mM Bis-Tris pH6.7, 10 mM
EDTA, 10% formamide) with protease inhibitor for 4 h at 37°C. DNA probes and protein–RNA
complexes were recovered by incubating with streptavidin-conjugated dynabeads (Thermo Fisher)
for 30 min at 37°C. After three washes with wash buffer (2X SSC, 0.5% SDS, 0.4 mM PMSF),
proteins were eluted by PBS with 0.5 µg/µl RNase A.
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2.8.15

In vivo denaturing protein–RNA pull-downs

Cells were pulsed with 4SU (Sigma) for 2 h and then crosslinked with 1 J/cm2 UVA (365 nm), 1
J/cm2 UVB (312 nm), or 800 mJ/ cm2 UVC (254 nm) using a Spectrolinker. Cells were lysed in
lysis buffer (50 mM Bis-Tris pH 6.7, 10 mM EDTA, 1% SDS) with protease inhibitor. A further
sonication step with a Bioruptor (Diagenode, NJ) was performed to homogenize the cell lysates.
Biotin-labeled DNA probes (Digital Supplemental Table S8) were hybridized to crosslinked RNA
in hybridization buffer (500 mM NaCl, 1% SDS, 50 mM Bis-Tris pH 6.7, 10 mM EDTA, 10%
formamide) with protease inhibitor for 4 h at 37°C. DNA probes and protein–RNA complexes were
recovered by incubating with streptavidin-conjugated dynabeads for 30 min at 37°C. After three
washes with wash buffer (2X SSC, 0.5% SDS, 0.4 mM PMSF), proteins were eluted by PBS with
0.5 µg/µl RNase A.

2.8.16

Bottom-up nanoLC-MS/MS

Samples were analyzed by using a nanoLC-MS/MS setup. NanoLC was configured with a 75 µm ID
x 17 cm Reprosil-Pur C18-AQ (3 µm; Dr. Maisch GmbH, Germany) nano-column using an EASYnLC nanoHPLC (Thermo Fisher). The HPLC gradient was 0-30% solvent B (A = 0.1% formic
acid; B = 95% acetonitrile, 0.1% formic acid) over 120 min for the nuclear proteome experiments
and over 45 min for the recombinant protein (MS2-CP) analysis. The gradient proceeded from
30% to 85% solvent B in 5 minutes and 10 min isocratic at 85% B. The flow rate was set to 300
nL/min. NanoLC was coupled with an Orbitrap Fusion mass spectrometer (Thermo Fisher) for the
proteome experiments or with an Orbitrap Elite (Thermo Fisher) for the single protein analysis.
Spray voltage was set at 2.3 kV and capillary temperature was set at 275 °C. Full scan MS spectrum
(m/z 350−1200) was performed in the Orbitrap with a resolution of 120,000 (at 200 m/z) with an
AGC target of 5x105 . For the proteome experiment in the Orbitrap Fusion the Top Speed MS/MS
option was set to 2.5 sec, and the most intense ions above a threshold of 50,000 counts were selected
for fragmentation. Fragmentation was performed with higher-energy collisional dissociation (HCD)
with normalized collision energy of 32, an AGC target of 104 and a maximum injection time of 120
msec. For the single protein experiment in the Orbitrap Elite the top 10 most intense ions above
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a threshold of 10,000 counts were selected for fragmentation. Fragmentation was performed with
collisional induced dissociation (CID) with normalized collision energy of 35, an AGC target of 104
and a maximum injection time of 150 msec. MS/MS data for both experiment types were collected
in centroid mode in the ion trap mass analyzer (normal scan rate). Only charge states 2-5 were
included.

2.8.17

MS analysis

All MS/MS spectra were processed through the MaxQuant program (Cox and Mann, 2008).
Parameters for MS/MS database searching included the following: precursor mass tolerance
4.5 ppm; product mass tolerance 0.5 Da; enzyme trypsin; missed cleavages allowed 2; static
modifications carbamidomethyl (C); variable modifications none; label-free quantification method
iBAQ (for protein reports); database used was Mus musculus (Uniprot, September 2015, including
not reviewed proteins) for the proteome searches, and a custom database including MS2-CP and
RNase A for in vitro RBR-ID. PSMs and protein false discovery rate was filtered for < 0.01. Match
between runs was enabled using a tolerance of 1 min to extend the peptide identification to MS
signals not identified in some of the replicates.

2.8.18

RBR-ID analysis

For each peptide, the maximum intensity of the corresponding extracted chromatogram calculated
by MaxQuant was considered and inter-run variability was accounted for by normalizing for the sum
of all peptide intensities in each MS run. To calculate the extent of crosslinking-induced depletion
we calculated the log2-converted ratio of the mean intensity of each peptide in the +4SU samples
divided by the mean intensity of the same peptide in -4SU samples. The list of primary hits contains
all peptides showing depletion (i.e. log2(fold-change) < 0 with a P-value < 0.05 (Student’s t test).
For the extended list we relaxed the P-value requirement to 0.1. For both the primary and extended
list we removed peptides that passed the same cutoffs when comparing signals for +4SU and -4SU
in absence of UV.
RBR-ID scores were calculated by combining the extent of depletion and the P-value
according to the following formula:
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RBR-ID score = log2



normalized+4SU intensity
normalized−4SU intensity



× (log10 (P-value))2 .

For residue level RBR-ID scores, we summed the RBR-ID score of each peptide
overlapping any given amino acid and smoothed the resulting curve using Friedman’s ‘super
smoother’ [87].

2.8.19

GO and Interpro enrichment

For protein list comparisons, all proteins identifiers were converted to official mouse symbols using
the Biomart database (version 84). One-to-one human-mouse orthologs were mapped directly,
whereas one-to-many and many-to-many homologs were reduced to one-to-one by considering
the protein with highest percentage of homology, according to the Biomart database (version 84).
For GO and Interpro annotation, tables were downloaded from the Uniprot and Interpro websites
directly. Enrichment values and statistics were obtained using the DAVID web server [81] either
using the unique Uniprot accession identifiers or the converted symbols, when needed.

2.8.20

Data availability

MS raw data are available at the Chorus database (https://chorusproject.org) under project number
1128. Peptide lists and RBR-ID score plots are available at http://rbrid.bonasiolab.org.
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3.1

Abstract

Polycomb repressive complex 2 (PRC2) is a histone methyltransferase that maintains cell identity
during development in multicellular organisms by marking repressed genes and chromatin domains.
In addition to four core subunits, PRC2 comprises multiple accessory subunits that vary in their
composition during cellular differentiation and define two major holo-PRC2 complexes: PRC2.1
and PRC2.2. PRC2 binds to RNA, which inhibits its enzymatic activity, but the mechanism of
RNA-mediated inhibition of holo-PRC2 is poorly understood. Here we present in vivo and in vitro
protein–RNA interaction maps and identify an RNA-binding patch within the allosteric regulatory
site of human and mouse PRC2, adjacent to the methyltransferase centre. RNA-mediated inhibition
of holo-PRC2 is relieved by allosteric activation of PRC2 by H3K27me3 and JARID2-K116me3
peptides. Both holo-PRC2.1 and -PRC2.2 bind RNA, providing a unified model to explain how
RNA and allosteric stimuli antagonistically regulate the enzymatic activity of PRC2.

3.2

Introduction

PRC2 is a histone methyltransferase (HMTase) that methylates H3 histones at lysine 27 to form
the H3K27me3 mark of facultative heterochromatin (reviewed in [1–4]). The H3K27me3 mark is
essential for the epigenetic maintenance of transcriptional repression at developmentally expressed
genes. The core PRC2 complex includes a histone methyltransferase subunit—EZH2 or EZH1;
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the regulatory subunit EED; one histone-binding subunit—RBBP4 or RBBP7; and SUZ12, which
serves as a scaffold [5–7]. The recruitment of PRC2 to chromatin and its HMTase activity are tightly
regulated. For instance, after EZH2 introduces the H3K27me3 histone mark, the methylated histone
peptide binds to a regulatory site within EED to stimulate the methyltransferase activity of PRC2
[8] through allosteric activation [9–12].
The function of PRC2 is also regulated by its accessory subunits: sub-stoichiometric
subunits of PRC2 that are differentially expressed during development [1, 2]. For instance, JARID2
is methylated by PRC2 at lysine 116 (JARID2-K116me3) and then binds to the regulatory center in
EED to allosterically activate PRC2 during de novo methylation at target genes [11]. AEBP2 and
the three polycomb-like (PCL) proteins—PHF1, PHF19 and MTF2—facilitate DNA binding by
PRC2 through direct interactions [13–17]. EPOP (previously termed C17ORF96 or esPRC2p48) is
another accessory subunit of PRC2 that facilitates gene repression [18, 19]. Unbiased proteomic
studies identified these factors as the most abundant accessory subunits of PRC2 [18–22] and
determined that they form two types of holo-PRC2 complexes, including the core subunits and
different accessory subunits [21]: PRC2.1 includes one of the PCL accessory subunits (PHF1,
PHF19 or MTF2) and EPOP or PALI 1/2, while PRC2.2 includes AEBP2 and JARID2 [21].
Direct interactions with RNA have been proposed to recruit PRC2 to target genes for
epigenetic repression, to evict it from active genes and to retain it in a poised state at lowly expressed
genes (reviewed in [23–27]). More recently, RNA was shown to inhibit the HMTase activity of
PRC2 [28–30]. Experiments using isolated subunits, partial complexes and the core PRC2 complex
attributed RNA binding to the core subunits EZH2, EED and SUZ12 [30–35]. Yet, the question of
how RNA inhibits different types of holo-PRC2 complexes remains unanswered. RNA competes
for nucleosome [36] and DNA binding by PRC2 and the automethylation activity of EZH2 is not
affected by RNA [15], suggesting that the competition with DNA might explain the inhibitory effect
of RNA on PRC2 [15]. This, however, leaves an unresolved conundrum: how does PRC2 overcome
RNA inhibition at target genes while within the RNA-rich environment of the nucleus? Moreover, an
earlier study demonstrated that RNA inhibits the HMTase activity of PRC2 also toward biotinylated
histone tail peptides [29], which is inconsistent with a model whereby RNA inhibits PRC2 activity
exclusively by competing with DNA binding. This suggests the possibility that RNA may inhibit the
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methyltransferase activity of PRC2 via multiple mechanisms. Testing this possibility is important
not only for the understanding of how RNA regulates the HMTase activity of PRC2 at the molecular
level, but also because PRC2 methylates non-histone substrates, including transcriptional regulators
([37] and references therein).
Here, we show that RNA binds and inhibits both types of holo-PRC2 complexes—PRC2.1
and PRC2.2. Using in vivo UV crosslinking and mass spectrometry in mouse embryonic stem
cells (mESCs), we have mapped RNA-binding regions on the core complex to both regulatory and
catalytic centers. In vitro studies on active holo-PRC2 complexes have confirmed binding of RNA
to the regulatory site of PRC2, at the interface between EZH2 and EED, near the catalytic center.
In agreement with this observation, RNA-mediated inhibition of PRC2 is relieved by peptides that
bind to the allosteric regulatory center and RNA inhibited the methyltransferase activity of PRC2
also toward DNA-free substrates. Based on these findings, we provide a mechanistic framework
to explain how RNA-mediated inhibition of the two major types of holo-PRC2 complexes takes
place and further generalize it for RNA-mediated inhibition of methyltransferase activity toward
non-histone substrates.

3.3
3.3.1

Results
RNA binds both PRC2.1 and PRC2.2 in vivo

We previously used protein–RNA crosslinking and mass spectrometry for RNA-binding region
identification (RBR-ID) in the nuclear proteome of mESCs [38]. Through reanalysing these data,
we detected significant peptide hits within core PRC2 subunits EZH2 and SUZ12, consistent with
previous observations [30–35]. We also identified the accessory PRC2.2 subunit AEBP2 (Figure
3.8 A), consistent with our own previous work [34, 39]. However, we did not detect peptides within
JARID2, which is known to crosslink to RNA in vivo [28]. We reasoned that the low coverage of
this and other PRC2 subunits in the whole nuclear proteome (Figure 3.8 A) might have limited our
ability to detect protein-RNA interaction sites in this complex.
To overcome this obstacle, we developed a ‘targeted’ variant of RBR-ID and utilized an
immunoprecipitation step to focus the mass spectrometry analysis on PRC2 (Figure 3.1 A, Figure
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3.8 B and Digital Supplemental Tables S9 and S10). The portion of mass spectrometry signal that
could be attributed to PRC2 increased 100-fold, from 0.4% in the proteome-wide data to 40% in the
targeted RBR-ID experiments (Figure 3.8 C), which allowed us to identify several additional PRC2
peptides that crosslinked to RNA (Figure 3.1 B and Figure 3.8 D). We recovered multiple significant
hits in all core subunits, in the PRC2.1 accessory subunits MTF2 and PALI, and in both accessory
subunits of PRC2.2—AEBP2 and JARID2 (Figure 3.1 B and Figure 3.8 A). These hits accumulated
on the catalytic lobe of PRC2 (Figure 3.1 C, D and Figure 3.8 E) and several mapped to domains
previously proposed to bind to RNA, such as the EZH2 RBR (residues 342–368, [32]), the JARID2
RBR (residues 332–358, [28]), the EZH2 CXC and SET domains35, and the RRM-like beta-sheet
domain of SUZ12 [5]. In addition to these, we noticed a highly significant crosslinked peptide on
EED, very close to the regulatory center, near the stimulatory recognition motif9 (SRM) of EZH2
(Figure 3.1 B, D; EED 336–355 is highlighted).
Thus, our targeted RBR-ID approach not only identified interactions between RNA and
the PRC2.2 subunits AEBP2 and JARID2 [15, 28, 30, 34, 38, 39], but also MTF2 (also known as
PCL2) and PALI—accessory subunits of the PRC2.1 complex that were previously not known to
bind RNA. This strongly suggests that PRC2.1 also binds RNA in vivo.
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in apparent peptide abundance caused by the crosslink with RNA (6). (B) Volcano plot of peptide intensities
comparing material from 4SU-pulsed and control (-4SU) cells. The dashed horizontal line indicates the P
value of 0.05. Peptides on core and accessory PRC2 subunits are highlighted. P values were calculated using
paired or unpaired two-sided Student’s t-tests (see Methods) from three independent experiments and ten
total replicates. (C) Mapping to PRC2 subunits of RNA-interacting peptides detected by targeted RBR-ID
(blue circles, this study) or proteome-wide RBR-ID [38] (red circles). Known protein domains, including
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peptide in the catalytic center is shown in black. Experiments and Data generated by R.W-T. and R.L.

3.3.2

RNA binds and inhibits both PRC2.1 and PRC2.2 in vitro.

To further investigate the molecular nature and biochemical function of PRC2-RNA interactions
in the context of holo-PRC2 complexes, we continued our studies in vitro, by reconstituting the
human core PRC2 complex and a PRC2 complex with either human AEBP2 (PRC2–AEBP2) or
the PCL protein PHF19 (PRC2–PHF19) (Figure 3.2 A). Given that PRC2 preferably binds to RNA
that contains short repeats of consecutive guanines [34], and since fluorescence anisotropy requires
a small labeled ligand, we quantified affinity of PRC2 for an RNA composed of four UUAGGG
repeats (G4 24 RNA, Figure 3.2 B and Table 3.1). These four repeats originate from TERRA
RNA, fold into a G-quadruplex RNA structure and bind PRC2 in cells [34, 40]. As a negative
control, we used a size-matched mutant RNA without G-tracts, composed of four UGAGUG repeats
(G4 mt 24 RNA, Figure 3.2 B and Table 3.1). In good agreement with earlier observations [39],
the affinity of the core PRC2 complex to RNA (Kd=129±6nM) increased by approximately 2-fold
when AEBP2 is in the complex (Kd=54.6±3.8nM). Strikingly, the addition of PHF19 increased the
affinity of PRC2 to RNA by nearly 4-fold compared to that of the core PRC2 complex alone. The
affinity of PRC2-PHF19 (Kd=34.0±1.8nM) to RNA was even greater than that of the PRC2–AEBP2
complex. The PRC2.1 accessory subunits MTF2 and EPOP also increased the affinity of PRC2 for
RNA, with the PRC2– MTF2–EPOP complex having an approximately 2-fold higher affinity for
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TABLE 3.1

Affinities of PRC2 complexes to G4 24 and G4 mt 24 RNA
Protein
PRC2
PRC2–AEBP2
PRC2–PHF19
PRC2
PRC2–AEBP2
PRC2–PHF19

RNA
G4 24
G4 24
G4 24
G4 mt 24
G4 mt 24
G4 mt 24

Kd (nM)
129 ± 6
54.6 ± 3.8
34.0 ± 1.8
n.d.
n.d.
n.d.

Hill
0.92 ± 0.03
0.88 ± 0.04
1.01 ± 0.04
n.d.
n.d.
n.d.

RNA (Kd=40.9±3.9nM) compared to PRC2–MTF2 (Kd = 82.4 ± 9.8 nM) and approximately 3-fold
higher compared to core PRC2 (Kd=129±6nM; Figure 3.2 B, Table 3.1 and Figure 3.9 G–i). These
results indicate that both PRC2.1 and PRC2.2 holo-complexes bind to RNA. None of the PRC2
complexes bound to the mutant RNA (triangles in Figure 3.2 B and Table 3.1), indicating that the
RNA-binding specificity of PRC2 toward this G-tract motif34 is preserved in the presence of a PCL
subunit.

Since the PCL protein MTF2 interacts with RNA in vivo and in vitro and the
PRC2–PHF19 complex interacts with RNA in vitro, we wished to determine if PCL proteins allow
for RNA-mediated inhibition of PRC2. We performed in vitro histone methyltransferase assays
using recombinant nucleosome substrates in the presence or absence of a 256-base-long RNA
that includes ten UUAGGG repeats flanked by sequences devoid of G-tracts (G4 256 RNA, see
Methods), which also bound to PRC2 with nanomolar affinity (Figure 3.10 K, L). In agreement with
previous studies, the RNA inhibited the HMTase activity of the core PRC2 complex [29, 30, 41], the
PRC2–AEBP2 complex [15] and the PRC2–AEBP2–JARID2 complex [15, 28] toward nucleosome
substrates (Figure 3.2 C and Figure 3.9 A). We then performed the same experiments with three
reconstituted human PRC2.1 complexes: PRC2–PHF1, PRC2– PHF19 and PRC2–MTF2–EPOP
(Figure 3.2 A and Figure 3.9 C, D). Despite variations in the baseline activity, RNA exerted an
inhibitory effect regardless of which PCL protein (PHF1, PHF19 or MTF2) was present or whether
EPOP was included (Figure 3.2 D and Figure 3.9 B, J, K). This indicates that RNA inhibits the
HMTase activity of PRC2 even when assembled with its accessory subunits to form either the
PRC2.1 or PRC2.2 complexes.
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(A) Coomassie blue-stained SDS–PAGE (top) and gel filtration chromatography (bottom, HiPrep 16/600
Sephacryl S-400 HR) of the PRC2 complexes that were used for binding assays. (B) Fluorescence anisotropy
used to quantify the affinity of PRC2 complexes to G4 24 and G4 24 mutant (mt) RNAs. Data represent
the mean of three independent experiments that were carried out on different days, error bars represent
standard deviation. See Table 1 for dissociation constants (Kd) and Hill coefficients. (C) and (D), HMTase
assays of PRC2.2 (C) and PRC2.1 (D) complexes toward nucleosome substrates were carried out in the
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methylation levels of H3 were determined by 14C-autoradiography (bottom). Bar plots represent the mean
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3.3.3

RNA binds to the allosteric regulatory center of PRC2

Under the notion that RNA binds to the PRC2 core complex and to the two types of holo-PRC2
complexes with similar affinity (up to 4-fold Kd, Figure 3.2 B and Table 3.1), specificity and
inhibitory activity, we reasoned that RNA inhibits PRC2 through interactions with the core PRC2
subunits. To determine the site of PRC2 that binds to the inhibitory G-tract-containing RNA, we
combined an in vitro UV crosslinking method [34] with the RBDmap approach [42] for mapping
protein-RNA interactions using mass spectrometry (Figure 3.3 A and Methods). We used this
approach to detect protein-RNA interactions between the reconstituted PRC2–AEBP2 complex
and the G4 256 RNA (Figure 3.3 B and Figure 3.10 A) that, similar to the G4 24 RNA, binds
to PRC2 with high affinity (Figure 3.10 K, L). Remarkably, most of the RNA-linked peptides
that were identified in independent in vitro RBDmap replicates clustered within the same site
at the interface between EED and EZH2 (Figure 3.3 B and Digital Supplemental Table S11),
overlapping the mouse EED peptide 336–355 identified in vivo by RBR-ID (Figure 3.1 D). These
results are also in agreement with earlier UV crosslinking experiments that were carried out
with SDS–polyacrylamide gel electrophoresis (SDS–PAGE), without high-resolution mapping, and
identified EED and EZH2 as the two subunits that crosslinked to RNA within the context of an
assembled PRC2–AEBP2 complex [34]. Intriguingly, this RNA-binding site overlaps with the
regulatory site that was previously shown to regulate the HMTase activity of PRC2 through allosteric
stimulation [9–12] (Figure 3.3 B).
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(A) Schematic representation of the in vitro RBDmap workflow (see Methods): in vitro reconstituted
protein–RNA complexes are crosslinked, followed by tandem proteolytic digestion and LC–MS/MS to reveal
peptides adjacent (blue) to the protein–RNA crosslink (red). RNA is shown in orange. (B) RBDmap results:
amino acids within the PRC2–AEBP2 structure were colored in blue, orange or red if they resided within
peptides that were crosslinked to RNA in 1, 2 or 3 independent RBDmap experiments, respectively. A
methylated peptide in the regulatory center is colored magenta and the substrate peptide in the catalytic center
is colored black (PDB accession: 6C23 and 5WAI). (C) and (D), Validation using point mutations. The purity
and integrity of the mutant complexes were assessed using SDS–PAGE and gel filtration chromatography
(HiPrep 16/600 Sephacryl S-400 HR) (C). Fluorescence anisotropy was used to quantify the affinity of the
mutants to G4 24 RNA (D). The resulting dissociation constant (Kd), Hill coefficients and the derived ΔΔG
are indicated together with details of the mutated amino acids in EZH2 and EED in Table 3.2. Error bars
in (D) represent standard deviation based on three independent experiments that were done on different
days. (E) The impaired capacity of the mutants to bind RNA is represented in a ΔΔG heat map using
the PRC2–AEBP2 structure. Mutated amino acids are mapped to the structure and ΔΔG color code is
indicated (bottom). (F) Mean HMTase activity of indicated PRC2 mutants toward H3 histones (black bars)
or nucleosomes (gray bars) normalized to the activity of wild-type PRC2–AEBP2 (dashed line). Error bars
represent standard deviation based on three independent experiments. P values were determined using paired
two-tailed Student’s t-test; *P < 0.05. See Figure 3.10 for HMTase radiograms and gel scans, SDS–PAGE
analyses and mass spectrometry intensities resulting from the RBDmap process and additional mutants that
were assayed. Source data are available in Digital Supplemental Table S14. Data and analysis generated by
collaborators.

To validate this finding, we introduced point mutations in EZH2 and EED within the
identified RNA-binding site or its vicinity (mt1–8).

We reconstituted mutant PRC2–AEBP2

complexes (Figure 3.3 C and Figure 3.10 B) and measured their affinity to G4 24 RNA (Figure
3.3 D, E, Table 3.2 and Figure 3.10 C, D). The mutations reduced the affinity of PRC2 to RNA
(Figure 3.3 E, Table 3.2 and Figure 3.10 D-G), with ΔΔG in the range of 1.1–2.7 kJ mol−1 .The
mutations mt1–3 and mt6–7 caused the largest reduction in affinity (ΔΔG 1.8–2.7 kJ mol−1 , Figure
3.3 D, E, Table 3.2 and Figure 3.10 C-G, which supports a direct function of the mutated amino acids
in RNA binding. Importantly, these mutations did not lead to adverse effects on complex assembly
(Figure 3.3 C and Figure 3.10 B) or on PRC2 activity toward histone substrates, and only mt3,
mt5 and mt8 displayed a negative impact on the activity of PRC2 toward nucleosome substrates
(Figure 3.3 F and Figure 3.10 H-J). The mutant mt4 displayed a positive effect on HMTase activity,
possibly by stabilizing PRC2 in a conformation resembling its allosterically stimulated state, given
its location near the regulatory center. The mutants led to only a modest reduction in the affinity of
PRC2 to RNA and even in the case of the complex bearing the most effective set of mutations, as
determined by its in vitro affinity for RNA (mt1, 3-fold reduction of affinity), we could not detect
any change in the extent of RNA-mediated inhibition (Figure 3.11 A-D ). This is consistent with
82

TABLE 3.2

Affinities of PRC2 complexes to G4 24 and G4 mt 24 RNA

PRC2–AEBP2 Mutation sites
mutant
WT
n/a
mt1
EZH2 R27A/R31A/F165A
EED R355A
mt2
EZH2 H129A/K156A/H158A
EZH2 G159A/R161A
EED R306A
mt3
EZH2 R16A/K17A/R18A/K20A
mt4
EZH2 K661A
mt5
EZH2 Y133A/T144A
EZH2 F145A/Y153A
EED Y308A

Kd (nM)

Hill

60.5 ± 2.2
173 ± 7

1.03 ± 0.04
0.87 ± 0.03

ΔΔG
mol−1 )
0
2.65

141 ± 8

0.91 ± 0.04

2.13

124 ± 7
102 ± 4
93.7 ± 6.3

0.91 ± 0.04
0.99 ± 0.04
0.89 ± 0.05

1.81
1.32
1.10

(kJ

our photocrosslink mapping (Figs. 1d and 3b), and previous hydrogen deuterium exchange analyses
[35], which pointed to multiple relatively large RNA-binding surfaces within PRC2 that might be
involved in RNA mediated inhibition of the complex (see below).

In addition to mutations guided by our RBDmap results (Figure 3.3 B), we assayed two
RNA-binding-deficient mutants, mt4 (Figure 3.3 C-E) and mt8 (Figure 3.10 C,D,G) that reside
externally to the regulatory site and were previously analyzed [35]. In the original study, these
mutants were tested in the context of the minimal PRC2 core complex (EZH2, EED and the VEFS
domain of SUZ12) and found to reduce the affinity of PRC2 to RNA by up to 12-fold Kd [35].
Within the PRC2–AEBP2 complex, mt4 and mt8 exhibited an affinity change of approximately
2-fold (ΔΔG of 1.3 and 1.1 kJ mol−1 , respectively). These results are in good agreement with
our observations and those of others that AEBP2 and regions of SUZ12—beyond the VEFS domain
[5]—interact with RNA (Figure 3.1) and that AEBP2 increases the affinity of PRC2 for RNA (Figure
3.2 B and Table 3.1).
Our results thus indicate that amino acids within the allosteric site of PRC2 and in
its immediate vicinity are directly involved in RNA binding. These findings reinforce previous
observations of dispersed RNA-binding sites in EZH2 [35], but also show additional significant
protein-RNA contacts within the regulatory subunit EED, and point to the regulatory site of PRC2
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TABLE 3.3 Affinities of PRC2–AEBP2 complexes to G4 24 RNA in the presence or absence
of stimulatory peptides
Competitive peptide

Sequence

Kd (nM)

Hill

No peptide
JARID2-K116me3

n/a
KRPRLQAQRK(me3)
FAQSQ
TKAARK(me3)
SAPAT

19.2 ± 2.7
46.7 ± 6.9

0.79 ± 0.06
0.88 ± 0.08

ΔΔG
mol−1 )
0
2.24

22.5 ± 3.1

1.05 ± 0.12

0.4

H3K27me3

(kJ

n
11
6
4

as an important determinant for RNA binding.

3.3.4

Stimulatory peptides relieve RNA-mediated inhibition of PRC2

Given the location of a prominent RNA-binding site within the regulatory center of PRC2, we
wished to determine the regulatory interplay between peptide ligands that bind to this site and
stimulate PRC2 (H3K27me3 and JARID2-K116me3) and inhibitory RNAs (for example, G4 256
RNA and G4 24 RNA). Both stimulatory peptides H3K27me3 and JARID2-K116me3 peptides
could significantly overcome RNA-mediated inhibition by G4 24 and G4 256 RNAs (Figure 3.4
A-C, Figure 3.11 A-D). Quantitative binding assays indicated that the JARID2-K116me3 peptide
competed with RNA for binding to PRC2, decreasing the ΔG by 2.24 kJ mol–1, but the H3K27me3
peptide did not (Figure 3.4 D and Table 3.3). This is consistent with the observation that the longer
JARID2-K116me3 peptide extends into the pocket formed at the EED–EZH2 interface (Figure 3.4
E,F, in purple), which was identified as a primary site of PRC2-RNA interactions by both RBR-ID
(Figure 3.1) and RBDmap (Figure 3.2), whereas the short H3K27me3 peptide used in these assays
did not (Figure 3.4 F, in green). Similarly, the PRC2 allosteric inhibitor A395 [43] does not bind to
the RNA-binding surface (Figure 3.11 I) and it did not compete with RNA binding (Figure 3.11 G,
H).
These data indicate that stimulatory peptides of PRC2 relieve the inhibitory activity of
RNA, possibly through allosteric modulation and, at least for JARID2-K116me3, in part through
competition with RNA at the regulatory center.
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(A) HMTase assays of PRC2 in the presence (+) or absence (–) of 80 µM H3K27me3 peptide and in the
presence (+) or absence (–) of 4.0 µM G4 256 RNA. (B) HMTase activities of PRC2 in its basal and stimulated
states, relative to the HMTase activity of an RNA-free PRC2 within the same state: bar plot based on the
same data as in (A) after normalizing each RNA-containing sample (gray bars in (A)) to the corresponding
RNA-free sample (black bars in (A)) to yield the relative HMTase activity of PRC2 in either its stimulated
(H3K27me3 peptide, in green) or basal (no peptide, in blue) state. (C) HMTase activities, relative to an
RNA-free sample, of PRC2–AEBP2 in its stimulated (10 µM JARID2-K116me2 peptide, in magenta, or 80
µM H3K27me3 peptide, in green) or its basal (no peptide, in blue) state and in the presence of RNA as
indicated (relative activities were calculated as in (B). Error bars in (A)-(C) represent standard deviations
based on three independent experiments. All bar plots are represented means. P values were determined
using unpaired two-tailed Student’s t-test; *P < 0.05. (D) The affinity of the PRC2–AEBP2 complex to G4
24 RNA was quantified using fluorescence anisotropy in the presence or absence of 100 µM H3K27me3 or
10 µM JARID2-K116me3 peptides. The KCl concentration in the binding buffer was reduced to 100 mM
(rather than 200 mM KCl that was used in Figure 3.2 B,C) to mimic the conditions used in the HMTase
assays presented in this figure. Error bars represent standard deviations in 11, 6 and 4 independent replicates
for the binding curves plotted in blue, purple and green, respectively. Values are represented means. See
Table 3 for dissociation constants and Hill coefficients. (E) The stimulatory peptides’ binding sites in PRC2
(coordinates: PDB 6C23): Orange and red represent RNA-linked polypeptides (color code as in Figure 3.3 B),
after superimposing the JARID2-K116me3 peptide (magenta, from PDB: 6C23) and the H3K27me3 peptide
(dark green, from PDB: 3IIW). (F) Close-up of the two peptides’ binding sites. Source data are available in
Digital Supplemental Table S15. Data and analysis generated by collaborators.
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3.3.5

RNA inhibits PRC2 in a DNA-independent manner

The RNA binding sites that we identified in PRC2 using RBDmap and targeted RBR-ID are adjacent
to and, in some cases, overlap the substrate-binding site in the methyltransferase center (Figure
3.12 A). We therefore wished to determine if RNA can inhibit the methyltransferase activity of
PRC2 through a mechanism other than competition for nucleosomes [36] or DNA binding [15]. We
repeated the HMTase assays using DNA-free H3 histones as substrates (Figure 3.5 A), rather than
nucleosomes. In agreement with the hypothesis of a DNA-independent RNA-mediated inhibition
of PRC2, G4 256 RNA inhibited the activity of both PRC2.2 (Figure 3.5 A, left) and PRC2.1
(Figure 3.5 A, right) toward H3 substrate. Unlike the longer G4 256 RNA, the G4 24 RNA did not
inhibit PRC2 activity toward H3 histones (Figure 3.12 D, E and Digital Supplemental Table S12),
suggesting that its observed inhibitory effect in the context of nucleosomal substrates (Figure 3.4
C) relies on competition with nucleosomal DNA [15]. This indicates that although a 24-baselong G-quadruplex RNA is sufficient to bind PRC2 (Figure 3.2 and [34]) and inhibit HMTase
toward nucleosome substrates (Figure 3.4 C), longer RNAs might be required for methyltransferase
inhibition toward non-nucleosome substrates. Contributing factors would probably be an increased
affinity of the long RNA for PRC2 (G4 256 RNA, Kd=1.09±0.13nM; Figure 3.10 K, L) over
the short RNA (G4 24 RNA, Kd = 19.2 ± 2.7 nM; Figure 3.4 D and Table 3.3) and additional
steric hindrances that are probably offered by the longer RNA. Although PRC2 activity toward H3
histones outside nucleosomes has limited biological significance, these data indicate that RNAmediated HMTase inhibition of PRC2 can take place independent of competition for DNA or
nucleosome binding. Indeed, the JARID2-K116 unmethylated peptide, as well as the H3K27M
oncogenic peptide that binds to the catalytic site but not the regulatory center of PRC2 ([10];
Figure 3.12 A), reduced the affinity of PRC2 for RNA (Figure 3.12 B, C). This suggests that these
peptides can directly compete with RNA binding at the catalytic site of the complex in addition
to the regulatory center, further supporting our mapping of protein-RNA interactions to this region
(Figure 3.1 and Figure 3.13 E).
We next assayed the methyltransferase activity of PRC2 toward two non-histone
substrates of PRC2—human TBP (hTBP) and mouse ID2 (mID2)[37] —and confirmed inhibition
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of PRC2 activity by RNA also for these substrates (Figure 3.5 B). Collectively, these results
demonstrate that RNA can inhibit the methyltransferase activity of PRC2 toward a DNA-free
substrate, including non-histone substrates.
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DNA-independent RNA-mediated inhibition of PRC2

(A) HMTase assays carried out in the presence of 0.5 µM PRC2 complexes as indicated, 4 µM H3 histone
substrate and in the presence or absence of 1 µM G4 256 RNA. The bar plot (bottom) represents the activity,
as recorded by densitometry after SDS–PAGE (top). (B) HMTase assays were carried out in the presence of
0.5 µM PRC2–AEBP2, 1 µM H3 or non-histone substrates human TBP (hTBP, 20 µM) or mouse ID2 (mID2,
15 µM), and in the presence or absence of 8 µM G4 256 RNA. The bar plot (right) represents the activity,
as recorded by densitometry after SDS–PAGE (left). In all plots within the figure, bars represent means and
error bars represent standard deviation based on three independent experiments and P values were determined
using unpaired two-tailed Student’s t-test; *P < 0.05. Complete gel scans are shown in Figure 3.12. Source
data are available in Digital Supplemental Table S16. Data and analysis generated by collaborators.
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3.3.6

The regulatory center and the RNA-binding site are exposed in PRC2.1

Since RNA binds and inhibits both PRC2.1 and PRC2.2 (Figure 3.2), we hypothesized that the
PRC2.1 complex adopts a similar architecture to PRC2–AEBP2, leaving the regulatory site exposed.
We mapped protein-protein interactions within PRC2–PHF19 and PRC2–MTF2–EPOP using
bis(sulfosuccinimidyl)suberate (BS3) crosslinking with mass spectrometry (BS3 XL–MS, Figure
3.6 B, C). For a direct comparison, we also mapped interactions within the PRC2– AEBP2 complex
(Figure 3.6 A), including the 216 amino acids that complete the N-terminal domain of the canonical
AEBP2 isoform but were not included in previous structural investigations into PRC2–AEBP2 [5,
7]. Distances between crosslinked lysine pairs within PRC2 core subunits were measured using the
high-resolution structure of the PRC2–AEBP2–JARID2 complex5 and resulted in similar distance
distributions for the three complexes (Figure 3.13 A, B), supporting a similar structural organization
of the core subunits in the PRC2.1 and PRC2.2.
We next mapped crosslinking sites of the accessory subunits PHF19, MTF2 and EPOP
from the PRC2–PHF19 and the PRC2– MTF2–EPOP complexes to the core subunits (Figure 3.6
D, see Methods for a full description). We identified interactions between the C-terminal ‘reversed
chromodomain’ (RC domain) [44] of the PCL proteins PHF19 and MTF2 to the C2 domain of
SUZ12 (Figure 3.6 B, C), in good agreement with binding assays from previous studies [6, 44].
Importantly, no interactions were detected between PCL proteins and domains of core subunits
within the catalytic lobe of PRC2. Although the C-terminal of EPOP crosslinked to residues within
the catalytic lobe of PRC2, under the SRM of EZH2, amino acids in the regulatory center or the
RNA-binding site were not crosslinked (Figure 3.6 C, D and Figure 3.13 C).
While the structure of the N-terminal portion of EED was never determined, our BS3
XL–MS results indicate that it resides within the vicinity of the N-terminal of EZH2 in all the
examined PRC2 complexes (Figure 3.6 A–C). Similar crosslinking was previously observed in
the PRC2–AEBP2–JARID2 complex [5]. In addition to mutual protein-protein crosslinks (BS3
XL–MS: green lines in Figure 3.6 A–C), the N-terminal portions of EED and EZH2 cluster multiple
RNA–protein crosslinked peptides (RBDmap: blue and red spots in Figure 3.6 A). The simplest
explanation for these observations is that the N-terminal regions of EZH2 and EED reside in close
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proximity and form a single RNA-binding site that is probably exposed in both the PRC2.1 and
PRC2.2 complexes. This is in good agreement with the ability of an RNA containing short repeats
of consecutive guanines to bind the two types of holo-PRC2 complexes with similar affinity and
specificity, and to inhibit the methyltransferase activity of both of them (Figure 3.2), possibly
through an identical mechanism.
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(A)-(C), BS3 XL–MS results for PRC2–AEBP2 (A), PRC2–PHF19 (B) and PRC–MTF2–EPOP (C). Core
subunits are colored gray, accessory subunits are indicated in assorted colors and selected domains are shown
in dark colors (see Figure 3.13 D, middle structure, for the same view with the core subunits in assorted
colors). Green lines represent inter-molecular protein-protein BS3 crosslinks. Blue, orange and red boxes on
the protein representation in a represent RNA–protein crosslinks that were identified in 1, 2 or 3 independent
RBDmap experiments, respectively (same data as in the three-dimensional representation in Figure 3.3 B).
(D) Accessory proteins and RNA-binding sites within the holo-PRC2 complex: surface view of PRC2
was generated as in Figure 3.3 B. AEBP2 (cyan) and JARID2 (yellow) fragments are shown as a ribbon
representation and the N terminus of MTF2 that was determined crystallographically (PDB: 5XFR) is in light
blue, to approximate scale. EPOP (pink) and the C-terminal region of MTF2 (light blue) are indicated as
blobs, to approximate scale. Green lines indicate crosslinks between PRC2 core subunits to PCL proteins and
EPOP. Residues within core PRC2 subunits that were crosslinked to EPOP are indicated in pink. Residues
within core PRC2 subunits that reside at the termini of unstructured loops that were crosslinked to PCL
proteins are indicated in light blue and linked with dashed arcs. Protein-RNA contacts that were determined
in two or three independent RBDmap replicates (see Figure 3.3 for complete data) are indicated in orange
and red, respectively. Other key functional centers or structural features are highlighted using dashed black
circles. See Figure 3.13 for distance histograms of BS3 XL–MS and different views of the structure presented
in (D). Data and analysis generated by collaborators.

3.4

Discussion

The recruitment of PRC2 to chromatin and its regulation at target genes are determined by
interactions with multiple factors, including accessory proteins, specific DNA sequences and RNA
[2].

Among the protein factors, unbiased proteomic approaches identified JARID2, AEBP2,

EPOP, PALI and PCL proteins as key accessory subunits that were reproducibly identified across
studies and experimental systems [20–22, 45], albeit in relative abundances that change across
developmental stages [20]. Our study indicates that, regardless of subunit composition, RNA
binds to and inhibits various subtypes of PRC2 complexes in vivo and in vitro (Figs. 1 and 2).
Mechanistically, this is achieved through exploiting multiple surfaces on the catalytic lobe of the
core complex, including the regulatory center formed at the interface of EED and EZH2 (Figure
3.3), which is exposed both within the PRC2.1 and PRC2.2 (PRC2–AEBP2–JARID2) complexes
(Figure 3.6). It implies that PRC2 can bind RNA throughout various stages of development, even
when the composition of its accessory subunits varies significantly (Figure 3.7 B).
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A model for RNA-mediated inhibition of PRC2

(A) Stimulatory effectors of PRC2—JARID2-K116me3 and H3K27me3—relieve the inhibitory activity of
RNA simultaneously with HMTase stimulation. This process provides a molecular mechanism to overcome
RNA- mediated inhibition during the nucleation, spreading and propagation of the H3K27me3 mark at
polycomb-target genes [8, 11, 46]. (B) A model for RNA-mediated inhibition of PRC2 during development:
RNA binds to the allosteric regulatory center of PRC2 and inhibits methyltransferase activity toward
histone and non-histone substrates, either when PRC2 is in complex with AEBP2 and JARID2 (PRC2.2)
or PHF1, PHF19, MTF2, PALI and EPOP (PRC2.1). RNA-mediated inhibition of PRC2 provides a failsafe mechanism to prevent substrate methylation by RNA-bound PRC2 at non- target genes, even if the
stoichiometry of its common accessory subunits changes during development.

3.4.1

One face of PRC2 clusters binding sites for multiple regulatory factors

Our analysis of PRC2.1 complexes, together with data from previous structural investigations into
the architecture of the PRC2–AEBP2–JARID2 complex [5, 6], indicates that binding sites for
multiple ligands and factors cluster on one face of PRC2 (Figure 3.6 D and Figure 3.13 C, D).
This face also contains binding sites for the PRC2.1 and PRC2.2 accessory subunits that regulate
the recruitment of PRC2 to chromatin [1–3]. The same face also includes the catalytic site and
the allosteric regulatory center that stimulates HMTase activity upon binding of methylated H3
or JARID2 peptides [8, 11, 12]. All these stimulatory, regulatory and catalytic modules are
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concentrated on the same face, along with the most prominent RNA-binding region identified by
both RBR-ID and RBDmap (Figure 3.13). This structural organization might provide RNA with a
simple means to block methyltransferase activity and to simultaneously interact with other RNAbinding regions of EZH2 such as the CXC and SET domains [35], as well as with the accessory
subunits JARID2 [28], AEBP2 [38], MTF2 (Figure 3.1) and possibly other PCL proteins (Figure
3.2).

3.4.2

Interplay of RNA and stimulatory peptides at the allosteric regulatory center

Amino acids of EED and EZH2 involved in allosteric activation of PRC2 [8–11], such as for
example EZH2 F145 [12], reside within the main RNA-binding site identified by RBR-ID and
RBDmap or in its immediate vicinity (Figure 3.6). The RNA-binding site is also in the immediate
vicinity of the SRM (Figure 3.6 D), which stabilizes the methyltransferase center within EZH2 [9]
during allosteric activation [8]. Here, we report that allosteric stimulation of PRC2 though either
H3K27me3 or JARID2-K116me3 peptides relieve RNA-mediated inhibition (Figure 3.4), providing
a direct link between the RNA-binding site that we identified in the regulatory center of PRC2 and
the process of effector-induced stimulation.

3.4.3

The methylated form of JARID2 relieves RNA-mediated inhibition of PRC2

The JARID2-K116me3 stimulatory peptide was assigned a significant role in nucleating the
H3K27me3 mark [11], which in turn stimulates PRC2 selectively at repressed polycomb-target
genes [8] to allow for the nucleation and, eventually, spreading and propagation of the H3K27me3
mark [8, 11, 46]. It is plausible that RNA-mediated inhibition of PRC2 is suspended at new PRC2
target sites through stimulatory interactions with the JARID2-K116me3 moiety (Figure 3.7 A).
The PRC2-JARID2 complex, in the absence of AEBP2 and when compared to PRC2,
was previously reported to have reduced affinity for RNA and increased HMTase activity in the
presence of RNA [30], suggesting that JARID2 weakens PRC2-RNA interactions and relieves
catalytic inhibition. Yet these results were seemingly in contrast with those of two other studies:
one showing that inclusion of JARID2 in the PRC2-AEBP2 complex does not alter its RNA-binding
activity [15] and the other demonstrating that JARID2 binds RNA in vivo and that an RNA-binding
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region within JARID2 is required for the recruitment of PRC2 to target genes [28]. Our data herein
reconciles these findings and is consistent with a model whereby a PRC2-AEBP2-JARID2 complex
can bind RNA and be inhibited by it (Figure 3.2), but interactions with the methylated form of
JARID2 (JARID2-K116me3) relieve RNA-mediated inhibition (Figure 3.4).

3.4.4

Multi-modal inhibition of PRC2 by RNA

The mechanistic details of RNA-mediated PRC2 inhibition are of great importance to understand
the biological meaning of the still poorly understood PRC2-RNA interactions. The fact that RNA
does not inhibit the prominent automethylation activity of EZH2 (Figure 3.9 A, B and 3.5 and ref.
[15]) previously suggested a model whereby RNA inhibits PRC2 by competing with nucleosomal
DNA for binding [15]. Indeed, some of the amino acids that were altered within our mt1 and mt3
mutants, which showed decreased RNA affinity, were previously identified as part of a nucleosomebinding site [47]. Yet, most of the mutated amino acids that affect RNA binding in our experiments
(Figure 3.3 D and Table 3.2) do not interact with nucleosomes [47], but rather reside within the
regulatory center or its immediate vicinity (Figure 3.3 E). Moreover, recent investigations into the
automethylation of EZH2 [48, 49] suggest that it occurs intramolecularly (in cis). Thus, this activity
benefits from a high local substrate concentration that could overcome RNA-mediated inhibition.
It is thus possible that additional bases, beyond the mere G-quadruplex motif, sterically block the
substrate-binding site of PRC2. Indeed, a direct—and possibly inhibitory—interaction between
RNA and the SET domain in vivo is supported by our targeted RBR-ID data (Figure 3.1 C, D), in
vitro by the competition of JARID2 and H3 substrate peptides for RNA binding—presumably at the
catalytic site (Figure 3.12 B, C)—and indirectly by hydrogen deuterium exchange results from an
independent study [35]. Therefore, RNA can inhibit PRC2 through different mechanisms, including
competition for nucleosome binding [36], competition for DNA binding [15] and through blocking
methyltransferase activity directly.

3.4.5

Implications for RNA-mediated regulation of PRC2 in vivo

The observation that RNA inhibits the methyltransferase activity of PRC2 independent of
competition with nucleosomes or DNA impacts previously proposed models for RNA-mediated
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regulation of PRC2, especially those envisioning long non-coding RNAs that recruit PRC2 to
target genes through direct interactions (reviewed in [23, 25, 26, 50]). These models had already
been challenged (see [26] for a critical review) by recent observations that RNA prevents PRC2
from binding nucleosomes [36] or DNA [15], but the possibility remained that lncRNA-PRC2
interactions might tether PRC2 at target genes long enough to nucleate K27 methylation, even
while DNA binding was inhibited by the presence of RNA. However, our observations show that the
methyltransferase activity of PRC2 is inhibited independently of its ability to bind DNA, suggesting
that even after being recruited to a given target gene, the presence of the RNA would continue to
inhibit H3K27me3 deposition, unless RNA-mediated inhibition is relieved by a stimulatory effector.
However, it is possible that some transcripts regulate PRC2 function via a different mechanism.
Specifically, we note that despite a striking overlap of RNA-binding signal on the EED 336-355
peptide, several peptides recovered in vivo by RBR-ID on various subunits were not detected by
RBDmap in vitro. It is tempting to speculate that RBR-ID-only peptides comprise regions of
PRC2.1 and PRC2.2 that interact with RNAs that we did not test in vitro. Thus, other RNAs might
have different regulatory functions in the context of Polycomb silencing. A thorough investigation
of separation-of-function mutants suggested by our mapping experiments will be required to test
this intriguing hypothesis.
Future studies may reveal if the inhibitory activity of RNA binding to PRC2 could be
relieved by specific transcripts, during specific stages of development, in disease states or at specific
loci, and possibly through the involvement of cell-type-specific factors beyond the most abundant
accessory subunits of PRC2 [20–22]. The location of an exposed RNA-binding site within the
allosteric center of the two common forms of holo-PRC2 complexes provides means for RNAmediated regulation of PRC2 in most cell lineages and during most stages of normal development
and suggest a mechanism by which stimulatory peptides relieve RNA-mediated inhibition to allow
de novo methylation at PRC2 target loci.
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3.8
3.8.1

Methods
Targeted RBR-ID

For label-free experiments, mESCs were cultured on gelatincoated dishes in KnockOut DMEM
(Gibco, no. 10829018) supplemented with 15% FBS (Gibco, no. 10437028), 100 mM non-essential
amino acids (Sigma, no. M7145), 0.1 mM 2-mercaptoethanol (Gibco, no. 21985023), 1 mM lglutamine (Sigma, no. G7513), 100 U ml–1 leukemia inhibitory factor (Millipore, no. ESG1107),
3 µM CHIR99021 (Millipore, no. 361559), 1 µM PD0325901 (Millipore, no. 444966), 50 U ml–1
penicillin and 50 µg ml–1 streptomycin.
For SILAC-assisted quantification, cells were cultured in medium containing 15%
dialyzed FBS (Thermo Fisher Scientific, no. 88440), 2 mM proline and 0.47 mM conventional or
heavy isotope-labeled amino acids (Arginine-10 + Lysine-8). Following several passages in heavy
media, cell extracts were analyzed via mass spectrometry and only used if ¿98% labeling could be
confirmed. Cells were crosslinked as previously described [38, 51]. Briefly, cells treated for 2 h
with 500 µM 4-thiouridine (4SU) were crosslinked with 1 J cm–2 UVB light. SILAC-labeled cell
extracts were prepared as follows: cells were lysed in 50 mM Tris (pH 8 at 25 °C), 150 mM NaCl,
1% IGEPAL CA-630, 0.2 mM EDTA, 2 mM MgCl2, 1 µg ml–1 aprotinin, 1 µg ml–1 leupeptin, 1
µg ml–1 pepstatin and 0.2 mM PMSF, then treated with 2,500 U ml–1 Pierce Universal nuclease
(Thermo Fisher Scientific, no. 88700) for 30 min at 25 °C. Extracts were sonicated briefly, then
NaCl was added to bring the final concentration to 300 mM and extracts were rotated at 4 °C for
30 min to complete lysis. Extracts were centrifuged at 18,000g for 10 min at 4 °C and supernatants
were collected. We quantified cell extracts via Bradford protein assay and prepared 1:1 mixtures
of ± 4SU-treated heavy and light labeled extracts. For label-free quantification replicates, nuclear
extracts were prepared from cells as previously described [38, 51]. Polyclonal anti-EZH2 antibody
was generated by immunizing rabbits with a fragment of mouse EZH2 spanning amino acids 1 to
370 (Uniprot Q61188) and affinity purifying using the same antigen. Immunoprecipitations were
performed by adding EZH2 antibody to extracts and incubating overnight at 4 °C, then recovering
protein–antibody complexes with protein G Dynabeads (Thermo Fisher Scientific, no. 10003D)
pre-blocked with 1 mg ml–1 BSA. Beads were washed three times with immunoprecipitation wash
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buffer (20 mM Tris (pH 7.9 at 4 °C), 0.2 mM EDTA, 200 mM KCl and 0.05% IGEPAL CA-630). To
elute bound proteins, 0.1 M glycine (pH 2.4) was added to beads and incubated at 25 °C with gentle
shaking for 10 min, then the eluate was transferred to a fresh tube containing 0.1 M Tris (pH 8 at 25
°C) to neutralize. Fractions of eluted proteins were taken for western blot, and the remainder diluted
in trypsin digestion buffer (final: 50 mM NH4HCO3 (pH 8), 1 mM MgCl2 and 1 mM CaCl2) or
chymotrypsin digestion buffer (final: 100 mM Tris (pH 8 at 25 °C), 1 mM MgCl2 and 10 mM
CaCl2). To remove crosslinked RNA, 12.5 µg ml–1 RNase A was added to samples and incubated
for 30 min at 37 °C. To reduce proteins, samples were treated with 5 mM dithiothreitol for 60 min
at 25 °C, then cysteines were alkylated with 14 mM iodoacetamide for 30 min in the dark, before
additional reduction with 5 mM dithiothreitol for an additional 15 min in the dark. Proteins were
digested with trypsin or chymotrypsin at a protease:sample ratio of 1:20 and incubated overnight at
37 °C or 25 °C, respectively. Peptides were quenched with formic acid and desalted on C18 stage
tips, then dried and resuspended in 0.1% formic acid before mass spectrometry analysis.
For mass spectrometry, a reverse phase gradient with a nano-LC was performed on a C18
column with a 2–60% binary gradient (mobile phase A: 0.1% formic acid in aqueous; mobile phase
B: 80% acetonitrile, 0.1% formic acid) for 90 min. The gradient continued to 95% over 2 min
and held for 13 min at 95% mobile phase B. MS was performed using a Thermo Orbitrap Fusion
instrument and MS/MS data were collected in centroid mode using the Orbitrap mass analyzer.
Fragmentation of peptides for MS/MS was performed using higher energy collisional dissociation
and only charge states of 2–5 were included for fragmentation. MS/MS spectra were processed
through MaxQuant [52] using a FASTA file comprising PRC2 complex proteins. SILAC and
unlabeled samples were processed with the same parameters. To generate the protein-level analyses
shown in Digital Supplemental Table S10, MS/MS spectra were processed using a mouse proteome
FASTA file.

3.8.2

RBR-ID analysis

After removal of suspected contaminants, MaxQuant peptide abundances were normalized by the
mean of all peptide intensities in each MS run, or in the case of SILAC data by the mean heavy or
light labeled peptide intensity in each run. For each peptide, a log2 -converted ratio was calculated
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between samples treated with or without 4SU to assess depletion mediated by RNA-crosslinking.
P values for peptides observed only in SILAC samples were analyzed via a paired, twosided Student’s t-test, while an unpaired two-sided Student’s t-test was performed for peptides
common between SILAC and label-free quantification samples, to account for missing values in
the data matrix. RBR-ID scores, which reflect both the degree and consistency of 4SU-mediated
depletion of a peptide38, were calculated as follows. To visualize targeted RBR-ID scores on
the high-resolution structure of the human PRC2–AEBP2, RBR-ID scores at each residue were
calculated as the sum of the RBR-ID scores of all overlapping identified peptides, and then mouse
peptide sequences were aligned to the corresponding human protein sequence using ClustalOmega.
Since a large number of amino acids were not resolved in the high-resolution cryo-EM structure of
the PRC2–AEBP2– JARID2 complex (PDB: 6C23)5, and in order to allow for maximal coverage
of this complex, the crystal structure of SUZ12–RBBP4–JARID2–AEBP2 (PDB: 5WAI)[6] was
superimposed on this structure and the non-catalytic lobe of 6C23 was omitted, with the exception
of SUZ12 amino acids 497–518, which is absent in 5WAI6.

3.8.3

Protein expression and purification

The full-length sequences encoding human EZH2, SUZ12, RBBP4, EED, AEBP2 and
JARID2 (UniProtKB: Q15910-2, Q1502-1, Q0902-1, O7553-1, Q6ZN18-2 and Q92833-1,
respectively) were cloned into a pFastBac1 expression vector with PreScission-cleavable N-terminal
hexahistidine-MBP tags as previously described [19, 20]. The full-length sequences of PHF1
(O43189-2), MTF2 (Q9Y483-1), PHF19 (Q5T6S3-1) and EPOP (A6NHQ4-1) were synthesised
(see Digital Supplemental Table S17) and sub-cloned by Gen9 using XmaI and XhoI sites into the
expression vector pFB1.HMBP.A3.PrS.ybbR 20 (derived from the pFastBac1 vector), under the
N-terminal hexahistidine-MBP tag and PreScission-cleavable sites (both cohesive ends introduced
to the insert using BsaI). For expression and purification of the PRC2-PHF1 and PRC2-AEBP2JARID2 complexes, genes encoding for PRC2 core subunits EZH2, EED, SUZ12, RBBP4 and
the accessory subunit AEBP2 (UniProtKB accession as above) were sub-cloned using the Gibson
Assembly® Master Mix (NEB #E2611L) into a pFBOH-MHL baculovirus expression vector (a
gift from the lab of Dr. Yufeng Tong, University of Toronto, Addgene #62304) that was digested
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using BseRI, to obtain a fusion with a TEV-cleavable N-terminal hexahistidine tag (see Digital
Supplemental Table S17 for cloning primers). Mutation plasmids of N-terminal hexahistidineMBP-tagged EZH2 and EED were generated by Pfu polymerase and Takara PrimeSTAR HS
DNA Polymerase (Clontech #R045A). Baculovirus stocks were generated as per manufacturer’s
instructions (ThermoFisher). The titter of each baculovirus stock was quantified using the MTT
assay (Promega #G3580). Baculovirus stocks were combined according to the optimal ratio and
used to co-infect Trichoplusia ni insect cells at 2 × 106 cells/mL in Insect-XPRESS media (Lonza
#12-730Q). Infected cells were incubated for 64 hours at 27 °C and 110 rpm before harvesting by
centrifugation (20 min at 4 °C using Beckman JLA-8.1000 rotor at 1500 RCF). The harvested cells
were snap-frozen with liquid nitrogen and stored at -80 °C until purification.
For the purification of all PRC2 complexes, with the exception of the PRC2-PHF1 and
PRC2-AEBP2-JARID2 complexes (see below), harvested cells were lysed in an ice-cold buffer
containing 10 mM Tris-HCl pH 7.5 at 25 °C, 250 mM NaCl, 0.5 % Nonidet-P40 (NP40), 1 mM
TCEP and protease inhibitor cocktail (200X ethanol solution containing 30 g/L PMSF, 0.25 g/L
Pepstatin A, 0.05 g/L Leupeptin hemisulfate salt and 60 g/L Benzamidine·HCl). The cleared lysates
of all the other PRC2 complexes, with the exception of PRC2-PHF1 and PRC2-AEBP2-JARID2,
were batch-bound to amylose resin (NEB #E8021), washed using 10 column volumes (c.v.) of icecold lysis buffer, 10 c.v. of high salt wash buffer (10 mM Tris-HCl pH 7.5 at 25 °C and 500 mM
NaCl) and 10 c.v. of low salt wash buffer (10 mM Tris-HCl pH 7.5 at 25 °C and 150 mM NaCl)
before proteins were eluted using ice-cold MBP elution buffer (10 mM Tris-HCl pH 7.5 at 25 °C,
150 mM NaCl, 10 mM maltose and 1 mM TCEP). The eluents were supplemented with NaCl, to a
final concentration of 250 mM, before incubation with PreScission protease overnight at 4 °C.
Further purification of tag-free complexes was performed at 4-8 °C, as previously
described [21]. In brief, after tag-cleavage complexes were loaded onto a 5 mL HiTrap Heparin
HP column (GE #17040701) in buffer A (10 mM Tris-HCl pH 7.5 at 25°C and 150 mM NaCl)
and were eluted over a 10 c.v. gradient into 50% buffer B (10 mM Tris-HCl pH 7.5 at 25 °C, 2
M NaCl). Complex-containing fractions were concentrated using 30 kDa Amicon Ultra centrifugal
filter and loaded onto a HiPrep 16/60 Sephacryl S-400 HR size exclusion column (GE Healthcare)
and fractionated using a buffer containing 20 mM HEPES (pH 7.5 at 25°C), 200 mM NaCl and 1
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mM TCEP. The peak fractions were pooled, concentrated using a 30 kDa Amicon Ultra centrifugal
filter, snap-frozen in liquid nitrogen and stored at -80 °C as single-use aliquots.
The PRC2-PHF1 and PRC2-AEBP2-JARID2 complexes were purified by tandem affinity
purification with a workflow that was designed to allow for near-stoichiometric incorporation of the
accessory subunit of interest: first, Ni-NTA agarose was used to purify all complexes; in the second
affinity chromatography step, MBP tags on the accessory subunits were used for affinity purification
of nearly-stoichiometric complexes, using amylose resin; next, complete removal of hexahistidineMBP tags from the accessory subunits and hexahistidine tags from the core subunits was done using
PreScission and TEV proteases, respectively, and unincorporated subunits and cleaved tags were
next removed using subsequent Heparin affinity and gel filtration chromatography. Specifically,
harvested cells were lysed in an ice-cold lysis buffer supplemented by 10 mM imidazole before
being applied to Ni-NTA resin (Qiagen #30210). The resin was washed using 10 c.v. of lysis buffer
as above, 10 c.v. of high salt wash buffer as above, supplemented by imidazole to 25 mM, and low
salt wash buffer as above, then proteins were eluted with 5 c.v. of elution buffer (10 mM Tris-HCl pH
7.5 at 25 °C, 150 mM NaCl, 250 mM imidazole and 1 mM TCEP). The eluents were subsequently
loaded onto amylose resin by gravity flow, washed with 5 c.v. of low salt wash buffer and eluted
with MBP elution buffer, as above. Eluate was supplemented with NaCl to a final concentration
of 250 mM before adding TEV and PreScission proteases for tag-cleavage, followed by overnight
incubation at 4 °C. Subsequent Heparin affinity and gel filtration chromatography was performed as
above.
Plasmids for FLAG-tagged hTBP (N-terminal FLAG tag, pFastBac1 backbone) and mID2
(C-terminal FLAG tag, pFastBac1 backbone) were a gift from the lab of Dr. Robert Kingston,
Harvard University. Baculovirus stock preparation and mID2-flag protein expression was carried
out as described above. Next, cells were harvested as above and snap-frozen in liquid nitrogen
before purification using M2 agarose beads (Sigma-Aldrich #A2220) as previously described [22].
The eluent from the M2 beads was buffer exchanged by centrifugation using a 10 kDa Amicon Ultra
centrifugal filter into buffer containing 20 mM Tris-HCl (pH 7.5 at 25°C), 500 mM NaCl and 1 mM
TCEP and stored at -80 °C before use. The ratio of absorbance at 260 nm to 280 nm was 0.58,
indicating no nucleic acid contamination.
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For the purification of hTBP, human TBP gene was sub-cloned from the baculovirus
expression plasmid above to the pGEX-MHL E. coli expression vector (a gift from the lab of Dr.
Yufeng Tong, University of Toronto) with an N-terminal GST tag (vector was digested using BseRI
and sequences of the cloning primers are specified in Digital Supplemental Table S17) and cloning
was done using Gibson Assembly® Master Mix. The resulting plasmid, coding for GST-hTBP
fusion, was transformed into the BL21(DE3) E.coli strain and grown in LB media at 37 °C, up to an
OD600 of 0.6 where induction was carried out using 0.2 mM IPTG. Protein expression was carried
out for 14-18 h at 17 °C with shaking at 180 rpm. Harvested cells were lysed by sonication in an
ice-cold buffer containing 10 mM Tris-HCl (pH 7.5 at 25 °C), 500 mM NaCl, 1 mM DTT, 10%
glycerol and 1 mM PMSF. The cleared lysate was applied to glutathione-agarose beads (SigmaAldrich #G4510) for batch purification, washed with 10 c.v. of lysis buffer and elution was carried
out using 5 c.v. of lysis buffer supplemented with 10 mM reduced glutathione. The protein was
further purified on a Superdex 200 10/300 GL size exclusion column (GE Healthcare) at 4-8 °C, in
buffer containing 20 mM HEPES (pH 7.5 at 25 °C), 200 mM NaCl and 1 mM TCEP to separate
out soluble aggregates. Protein-containing fractions were pooled, concentrated and stored at -80
°C before use. The ratio of absorbance at 260 nm to 280 nm was 0.59, indicating no nucleic acid
contamination.

3.8.4

Fluorescence anisotropy assay

The 3’ fluorescein labeled G4 24 RNA (UUAGGG)4 and G4 mt 24 RNA (UGAGUG)4 were
synthesized by Integrated DNA Technologies, Inc. RNA was incubated for 2 min at 95 °C in 10
mM Tris-HCl pH 7.5 (at 25 °C) and was then immediately snap-cooled on ice for 2 min. Next, RNA
was allowed to fold for 30 min at 37 °C in binding buffer (50 mM Tris-HCl pH 7.5 at 25 °C, 200
mM KCl, 2.5 mM MgCl2, 0.1 mM ZnCl2, 2 mM 2-mercaptoethanol, 0.1 mg ml–1 bovine serum
albumin (NEB, no. B9000S), 0.05% Nonidet P40 (Roche, no. 11754599001) and 0.1 mg ml–1
fragmented yeast tRNA (Sigma, no. R5636)).
For assaying the RNA-binding affinity in the presence or absence of stimulatory or
substrate peptides, binding buffer was adjusted to mimic conditions used for HMTase assays with
these peptides and consisted of 50 mM Tris-HCl pH 7.5 (at 25 °C), 100 mM KCl, 2 mM 2101

mercaptoethanol, 0.05% Nonidet P40 (Roche, no. 11754599001) and 0.1 mg ml–1 bovine serum
albumin (NEB, no. B9000S). Serial dilutions of the protein were made separately, in the same
buffer, and combined with the RNA solution for a final reaction volume of 40 µl containing
5 nM fluorescently-labeled RNA and the desired final protein concentration.

Samples were

equilibrated at 30 °C for 30 min before measurement. Fluorescence anisotropy data were collected
using a PHERAstar plate reader (BMG Labtech) at 30 °C (excitation wavelength λex = 485 nm,
emission wavelength λem = 520 nm). The background was subtracted from protein-free samples.
Kd, Hill and standard error values were calculated with GraphPad Prism 7 software using nonlinear regression for specific binding with Hill slope function. For comparison between different
complexes, non-linear regression was carried out using the background-subtracted anisotropy
values. For comparison between wild type and mutants of the same complex, RNA fraction bound
was calculated using the background-subtracted anisotropy of the fully-bound wild-type protein
sample, which were run on the same plate. Independent replicates of all fluorescent anisotropy
experiments were performed on different days.

3.8.5

Electrophoretic mobility-shift assay (EMSA)

EMSA was performed using 3 2P end-labeled RNA as previously described [34, 53].

3.8.6

Mapping protein-RNA interactions of an in vitro reconstituted complex using
RBDmap

The RBDmap workflow was adopted from [42] and was modified to allow for mapping of proteinRNA interactions in an in vitro reconstituted complex. DNA templates for in vitro transcription
of G4 256 RNA were generated through PCR amplification using a synthetic gene (GenScript,
see Digital Supplemental Table S17 for the sequence) and forward and reverse primers that were
designed to form a 5’ T7 promoter and a 3’ 25-mer polyA region, respectively (see Digital
Supplemental Table S17 for primer sequences). Thirty microliters of 5 µM RNA in 20 mM TrisHCl (pH 7.5 at 25 °C) was incubated for 2 min at 95 °C and was then snap-cooled on ice for 2 min.
Then 90 µl of ice-cold Milli-Q ultrapure water and 30 µl of ice-cold 5X RNA-binding buffer (250
mM Tris-HCl (pH 7.5 at 25 °C), 500 mM KCl, 12.5 mM MgCl2, 0.5 mM ZnCl2 and 10 mM 2102

mercaptoethanol) was added to a final volume of 150 µl. The RNA was then allowed to fold at 37 °C
for 30 min. Separately, PRC2–AEBP2 was prepared at 4 °C by adding purified protein stock to 1X
binding buffer, as above, to a final volume of 150 µl. The entire RNA solution was then combined
with the entire protein solution in a single well of a 24well plate to final concentrations of 0.5 µM
G4 256 RNA and 1.0 µM PRC2–AEBP2. The mixture was then incubated at room temperature
for 30 min to allow for the formation of ribonucleoprotein complexes. The 24-well plate was then
placed onto an aluminum block within a container of ice and was irradiated by UV (254 nm, 6
rounds of 0.83 J cm−2 each) in a UVP CL-1000 Ultraviolet Crosslinker (Scientifix, no. CL-1000)
with the top of the 24-well plate at a distance of 10 cm below five 8-watt tube lamps. Digestion
of the crosslinked ribonucleoprotein complexes by ArgC (Promega, no. V1881) and LysC (NEB,
no. P8109S) was then performed by adding 5 µl of 100 ng µL−1 ArgC or LysC stock solution to
the appropriate samples, after which the samples were incubated at room temperature overnight. As
input sample, 30 µl was taken and stored at 4 °C until RNase digestion of all samples was performed
(see next paragraph below). The remaining sample was applied to 1 ml of oligo d(T)25 magnetic
beads (NEB, no. S1419S) that were pre-washed withand pre-incubated in 1X RNA-binding buffer
for 10 min at 25 °C with gentle agitation. After applying the sample, the beads were incubated
with gentle agitation for 10 min at room temperature, and then for 1 h at 4 °C before capture with
a magnet. The supernatant was kept for SDS–PAGE analysis (‘flow-through’). All steps from
this point until the elution were done at 4 °C. After removal of the flow-through, the beads were
transferred into a 50 ml conical tube and resuspended with 17 ml of buffer 1 (20 mM Tris-HCl pH
7.5 at 25 °C, 500 mM LiCl, 0.5% lithium dodecyl sulfate (w/v) (Sigma-Aldrich, no. L9781), 1 mM
EDTA and 5 mM DTT) with gentle agitation for 5 min before capture by a magnet. The beads
were then washed twice as above with bead buffer 2 (20 mM Tris-HCl pH 7.5 at 25 °C, 500 mM
LiCl, 0.1% lithium dodecyl sulfate, 1 mM EDTA and 5 mM DTT) and twice with bead buffer 3
(20 mM Tris-HCl pH 7.5 at 25 °C, 500 mM LiCl, 1 mM EDTA and 5 mM DTT). Then the beads
were washed twice with bead buffer 4 (20 mM Tris-HCl pH 7.5 at 25 °C, 200 mM LiCl, 1 mM
EDTA and 5 mM DTT) as above, and residual bead buffer 4 was used to transfer beads to a 1.7 ml
microcentrifuge tube before capture by a magnet, and the remaining bead buffer 4 was removed.
RNA-linked polypeptides were then eluted by heating at 55 °C for 2 min in 300 µl of bead elution
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buffer (20 mM Tris-HCl pH 7.5 at 25 °C and 1 mM EDTA) before capturing the beads using a
magnet, and transferring the supernatant (‘eluate’) to another tube. Beads were discarded and never
reused in order to avoid cross-contamination.
The ‘input’ and ‘eluate’ samples were then processed for mass spectrometric analysis.
The minimal amount of RNase A that was required in order to completely digest the RNA was
determined empirically. The appropriate amount of RNase A (Thermo Fisher Scientific, no.
EN0531) was then added to the samples, followed by a 1 h incubation at 37 °C. The pH was
then adjusted to 8.0 by adding 1 M TrisHCl (pH 8.0 at 25 °C). Disulfide bonds were reduced by
adding TCEP (tris(2carboxyethyl)phosphine hydrochloride) to a final concentration of 10 mM and
the samples were incubated for 30 min at 65 °C. Free thiol groups were alkylated by adding 2chloroacetamide (Sigma, no. C0267) to a final concentration of 40 mM and samples were incubated
for 20 min at room temperature in the dark. The pH of each sample was adjusted again to 8.0
using 1 M Tris-HCl (pH 8.0 at 25 °C). Trypsin was added to each sample at a trypsin:protein
mass ratio of 1:4, where protein mass before crosslinking was considered. The samples were then
incubated for 14–18 h at 37 °C, in an orbital shaker at 200 r.p.m. Next, additional trypsin was
added, using the same amount as above, and the samples were incubated for additional 2 h at 37 °C
in an orbital shaker at 200 r.p.m. The digestion was stopped by the addition of formic acid to pH 3.0.
Tryptic peptides were purified using OMIX C18 pipette tips (Agilent Technologies) according to the
manufacturer’s instructions. The samples were then dried using a centrifugal vacuum concentrator
(Labconco Acid-Resistant CentriVap Concentrator, no. 7810041; CentriVap -105 Cold Trap, no.
7385037; Javac Vector LT-5 High Vacuum Pump, no. VectorLT), and stored at -80 °C until mass
spectrometric analysis.
Before mass spectrometric analysis, the peptides were resuspended in 20 µl of 0.1%
formic acid, sonicated in a sonicator water bath for 10 min (Grant Instruments XUBA3 Analog
Ultrasonic Bath) and centrifuged for 5 min at 21,000g. The samples were then transferred to mass
spectrometric vials and analyzed by LC–MS/MS within 48 h.
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3.8.7

Tandem mass spectrometry for RBDmap

The peptides were analysed by LC-MS/MS on an Orbitrap Fusion Tribrid Instrument connected
to an UltiMate 3000 UHPLC liquid chromatography system (Thermo-Fisher Scientific). Peptides
reconstituted in 0.1% formic acid were loaded onto a trap column (Acclaim PepMap100 C18 NanoTrap, 2 cm × 100 µm i.d., 5 µm particle size and 300 Å pore size; Thermo-Fisher Scientific) at
15 µL/min for 3 min before switching the trap column in-line with the analytical column (Acclaim
C18 PepMap RSLC Nanocolumn, 50 cm × 75 µm i.d., 3 µm particle size and 100-Å pore size;
Thermo-Fisher Scientific) and the mass spectrometer. The separation of peptides was performed at
250 nL/min using a non-linear gradient over 65 min, starting at 2.5% Buffer B (80% acetonitrile,
0.1% formic acid) and 97.5% Buffer A (0.1% formic acid) and ending at 42% Buffer B. Data were
collected in positive mode using data-dependent acquisition. The precursor scan, which covered a
range of 375–2000 m/z at a resolution of 120,000, was followed by up to 12 subsequent MS/MS
scans measured at a resolution of 60,000. Higher-energy collisional dissociation (HCD) was used to
fragment precursor ions with a charge state of 2-7. Other instrument parameters were: (i) injection
times of 118 ms for both ms1 and ms2 scans, (ii) AGC (automatic gain control) target of 1×106 and
0.4×106 for ms1 and ms2 scans, respectively, (iii) ion intensity threshold of 1×105, (iv) dynamic
exclusion of 30 s and (v) collision energy of 32%.
For data analysis, resulting Thermo Scientific mass spectrometer binary data files (.raw)
were analysed using the Andromeda search engine [54] implemented into the MaxQuant software
package (version 1.6.0.1) [52]. Only the assayed protein sequences were added to the search
database. Acetylation of N-termini of proteins and oxidation of methionines were considered as
variable modifications, whilst carbamidomethylation was specified as a fixed modification. False
discovery rates of 1% for the peptide spectrum match level were applied by searching a reverse
database and peptides that were detected with low confidence (Andromeda score < 20) were
eliminated. Tryptic peptides that passed the quality assurance criteria were used to identify the
adjacent RNA-linked peptide based on the protease that was used prior to the oligo d(T)25 magnetic
bead purification and trypsin digestion (either LysC or ArgC, see above) combined with the location
of arginine and lysine residues that are flanking the sequence of the identified tryptic peptide, as
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previously described [42]. Tryptic peptides were considered for unambiguous identification of their
adjacent RNA-linked peptide only if their C-terminal residue (either lysine or arginine) was different
than the C-terminal residue of their N-terminally adjacent tryptic peptide. R scripts used for data
analysis downstream of Andromeda can be obtained at https://github.com/egmg726/crisscrosslinker.
PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.) was
used to visualise the RNA-linked peptides in the structure of PRC2-AEBP2 using PDB accessions
6C23 [5] and 5WAI [6], as described for targeted RBR-ID data visualisation above. The JARID2
fragment in the non-catalytic lobe was not shown since JARID2 protein was not used in the RBDmap
experiment.

3.8.8

Bis(sulfosuccinimidyl)suberate crosslinking mass spectrometry

0.5 to 1.0 µM PRC2 complex with its accessory subunits was crosslinked with 5–20 µg BS3 (Thermo
Fisher Scientific, no. 21585) in 20 mM HEPES pH 7.5 (at 25°C), 150 mM NaCl, 1 mM TCEP, in
a total reaction volume of 85 µl. Reactions were allowed to proceed for 30 min at 25 °C before
Tris-HCl pH 8.0 (at 25 °C) was added to a final concentration of 30 mM, to quench the reaction,
for 15 min at 25°C. Crosslinking efficiency was assessed by subjecting a portion of the product to
10% SDS–PAGE. The crosslinked product solutions were adjusted to pH 8.0 by adding 20 µl of 1
M Tris-HCl pH 8.0 (at 25 °C), reduced in 10 mM TCEP for 30 min at 60 °C and then alkylated
in 40 mM 2-chloroacetamide for 20 min at 25 °C in the dark. Mixtures were then digested with
1:100 trypsin:protein mass ratio overnight at 37°C with shaking on a Thermomixer (Eppendorf).
Protein digestions were stopped by acidification through adding formic acid to 1% (v/v). Digested
peptides were purified using OMIX C18 Mini-Bed pipette tips according to the manufacturer’s
instructions, dried in a vacuum concentrator and reconstituted into 20 µl of 0.1% formic acid before
mass spectrometric analysis.
The peptides were analyzed by LC–MS/MS on an Orbitrap Fusion Tribrid Instrument
connected to an UltiMate 3000 UHPLC liquid chromatography system (Thermo Fisher Scientific)
as described above for RBDmap.
pLink and pLink2 [55] were used to identify BS3-crosslinked peptides with a false
discovery rate of 0.05. In addition, the crosslinked peptides were kept for downstream structural
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analysis only if they had been identified in at least two independent replicates or if they had
been identified with a P value of less than 10− 4. Two-dimensional representations of crosslinked
peptides and proteins were generated using xiNET [56]. R scripts used for data retention and
analysis downstream of pLink can be downloaded from GitHub: https://github.com/egmg726/
crisscrosslinker.

3.8.9

Nucleosome reconstitution

Mononucleosomes were reconstituted as previously described [57]. In brief, recombinant histones
were purified from inclusion bodies and reconstituted into histone octamers. Histone octamers
and 182-base-pair ‘601’ DNA were combined in a buffer containing 20 mM Tris-HCl pH 7.5 (at
25 °C), 2M KCl, 1mM EDTA, 1mM DTT and were dialyzed for 55h at 4–8°C against a buffer
consisting of 20 mM Tris-HCl pH 7.5 (at 25 °C), 25 mM KCl, 1 mM EDTA and 1 mM DTT with
a salt concentration that was gradually reduced during the process. The quality of reconstituted
nucleosomes was assessed by a 4% TBE (trisborate EDTA) gel and negative stain EM.

3.8.10

Negative stain EM

Negative stain EM experiments were carried out for assessing mononucleosome samples. Two
microliters of 0.03 mg ml–1 mononucleosome solution were applied to a glow-discharged
continuous carbon grid (EMgrid Australia) and incubated for 30 s before blotting with filter paper
and immediately staining by successive incubations, two times for 15 s and one time for 30 s, in
drops of 2% (w/v) uranyl acetate. The stain was removed by blotting with filter paper and the grid
was air-dried before imaging. The grid was imaged at a magnification of ×52,000 using an FEI
Tecnai 12 transmission electron microscope operating at 120 keV.

3.8.11

HMTase activity assays

Unless indicated otherwise, the HMTase activity assays were performed as previously described
[15] with minor modifications. Briefly, RNAs were folded as described for binding assays above and
were then allowed to bind PRC2 in RNA-binding buffer (50 mM Tris-HCl pH 7.5 at 25 °C, 100 mM
KCl, 2.5 mM MgCl2, 0.1 mM ZnCl2 and 2 mM 2-mercaptoethanol) at 25 °C for 30 min. Each 10
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µl HMTase reaction contained 500 nM PRC2 complex, RNA as indicated throughout the text, 4 µM
H3.1 histone protein (NEB M2503S) or 2 µM mononucleosomes (see ‘Nucleosome reconstitution’
above for in vitro nucleosome reconstitution), and 5.0 µM S-[methyl-1 4C]-adenosyl-l-methionine
(PerkinElmer, no. NEC363050UC). The reactions were incubated for 1 h at 30 °C in HMTase buffer
(77.5 mM Tris-HCl pH 8.0 at 30 °C, 155 mM KCl, 3.88 mM MgCl2, 0.2 mM ZnCl2, 3.1 mM 2mercaptoethanol, 0.1 mg ml–1 BSA (NEB B9000) and 5% v/v glycerol). For HMTase assays in the
presence or absence of stimulatory peptides, reaction buffer consisted of 50 mM Tris-HCl (pH 8.0
at 30 °C), 100 mM KCl, 2.5 mM MgCl2 , 0.1 mM ZnCl2 , 2 mM 2-mercaptoethanol, 0.1 mg ml−1
bovine serum albumin and 5% v/v glycerol. The reactions were then stopped by adding 4× LDS
sample buffer (Thermo Fisher Scientific, no. NP0007) to a final concentration of 1×. Samples were
then incubated at 95 °C for 5 min and the samples were subjected to 16.5% SDS–PAGE. Gels were
first stained with InstantBlue Coomassie protein stain (Expedeon, no. ISB1L) and then vacuumdried for 60 min at 80 °C with the aid of a VE-11 electric aspirator pump (Jeio Tech). Dried gels
were exposed to a storage phosphor screen (GE Healthcare) for 1–8 days and the signal was acquired
using a Typhoon Trio imager (GE Healthcare). Densitometry was carried out using ImageJ [58].
Relative HMTase activities of mutant PRC2 complexes were obtained through a normalization to
the signal obtained from the corresponding wild-type PRC2 complex that was loaded in a different
lane on the same gel. All experiments were performed in triplicate.
For assaying RNA inhibition of non-histone substrates, experiments were performed as
above, with the exception that the final reaction buffer was 25 mM HEPES pH 8.0 (at 25 °C), 40
mM KCl, 50 mM NaCl, 3 mM MgCl2 , 2 mM 2-mercaptoethanol and 10% v/v glycerol.

3.8.12

Structures used for visualization

The high-resolution cryo-EM structure of the PRC2–AEBP2–JARID2 complex (PDB accession
6C23) [5] and the crystal structure of SUZ12–RBBP4–JARID2–AEBP2 (PDB accession 5WAI) [6]
were used for PRC2 data representation as described above. The coordinates of the EED-bound
H3K27me3, H3K27M and A395 are from PDB accessions 3IIW [8], 5HYN [10] and 5K0M [43],
respectively. The coordinates of MTF2 were obtained from PDB accession 5XFR [16].

108

3.8.13

Cell lines

RBR-ID experiments were carried out in E14Tg2A.4 (E14) mESCs that were obtained from the
Reinberg Laboratory, as previously used by Kaneko et al. [41]. When cultured in the described
conditions, these E14 cells display the typical morphology of mESCs. In addition, we have
accumulated extensive genomic and functional data that confirm their pluripotent state and identity.
All cell lines used in the Bonasio Laboratory are routinely tested for mycoplasma. The E14 cells
used in these experiments tested negative as recently as October 2017.

3.8.14

Statistics and reproducibility

All P values were calculated using paired or unpaired two-tailed Student’s t-test, as explicitly
indicated in the respective figure legends. P values were given when P < 0.05. All binding curves
and bar plots represent means averaged across the number of samples indicated in the respective
figure legend.

3.9

Code availability

R scripts used for XL–MS and RBDmap data analysis downstream of pLink and Andromeda,
respectively, can be downloaded from GitHub: https://github.com/ egmg726/crisscrosslinker.

3.9.1

Data availability

LC–MS raw data for targeted RBR-ID experiments have been deposited at the Chorus project
(https://chorusproject.org) with ID 1560. Mass spectrometry data for RBDmap and BS3 XL–MS
experiments were deposited at FigShare with DOIs https://doi.org/10.26180/5c3d9751c64ae and
https://doi.org/10.26180/5c3d8dd45651b, respectively. Source data for Figures 3.2 - 3.5 and Figures
3.9 - 3.12 are available within Digital Supplemental Table S13-S16, respectively.

3.10

Supplementary Data
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F IGURE 3.8

Additional information about targeted RBR-ID (related to F IGURE 3.1)
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(A) Summary table of PRC2 RBR-ID data. PRC2 proteins, their Uniprot database accession IDs, percent
sequence coverage, and the number of significantly (P < 0.05) depleted RNA-binding peptides identified by
RBR-ID are shown for nuclear proteome data [38] and targeted RBR-ID (this study). Because PALI1 was
discovered after our proteome-wide study [45], we reanalysed the dataset separately to include its sequence
in the database. (B) Western blot from representative PRC2 immunoprecipitation for core subunits EED
and EZH2 and accessory subunit JARID2 (uncropped blots are in Digital Supplemental Table S12). (C)
Comparison of the portion of mass spectrometry signal mapping to PRC2 subunits in proteome-wide data1
compared to a representative experiment of SILAC-based targeted RBR-ID. Data are plotted as a percentage
of all detected peptides. (D), Volcano plot of peptides in the proteome and targeted RBR-ID data, displaying
mean log2-fold changes in ±4SU samples against log-transformed P value, calculated using paired Student’s
t-test. PRC2 peptides from proteome and targeted RBR-ID are displayed in red and blue respectively.
Horizontal dashed line represents P = 0.05. e, RBR-ID score plots (see He, C. et al., Mol Cell. 64, 416-430,
2016)[38] for all PRC2 subunits shown in Figure 3.1 and discussed in this study. Protein domain schematic
is shown below each linear plot. Experiments and Data generated by R.W-T. and R.L.
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F IGURE 3.9
3.2)

PRC2 complex purification and nucleosome reconstitution (related to F IGURE

(A)-(B) Full Coomassie blue-stained SDS-PAGE and the corresponding radiogram as shown in Figure 3.2
C,D. (C) Coomassie blue-stained SDS-PAGE gel shows the purity of PRC2 complexes used for HMTase
assays in Figure 3.2 C,D. (D) Gel filtration chromatography (Sephacryl S-400 HR resin) of the PRC2
complexes that were used for HMTase assays in Figure 3.2 C,D. Only fractions corresponding to assembled
PRC2 complexes were collected and used. (E) Mononucleosomes used for HMTase assays in Figure 3.2
C and 2D were analysed on a 4% polyacrylamide TBE gel and visualised by SYBR Green I post-staining.
(F) Mononucleosome homogeneity was assessed using negative stain electron microscopy (representative
micrograph at x52,000 magnification). (G) A Coomassie blue-stained SDS-PAGE gel shows the purity of
PRC2-MTF2 and PRC2-MTF2-EPOP complexes. (H) Fluorescence anisotropy was carried out to compare
the RNA-binding affinities of PRC2-MTF2 and PRC2-MTF2-EPOP. Error bars represent standard deviation
based on three independent experiments that were performed on different days. (I) Resulting dissociation
constants (Kd) and Hill coefficients are indicated, including the corresponding standard errors. Data for
PRC2 was imported from Fig 2B, for a direct comparison. (J)-(K) HMTase assays of the indicated complexes
were carried out in the presence or absence of 8.0 µM G4 256 RNA. (J) A representative Coomassie bluestained SDS-PAGE and the corresponding radiograms. (K) Quantification of HMTase activities from (K),
with error bars representing standard deviation calculated from three independent experiments. P values
were determined using unpaired two-tailed Student’s t-test; *, P<0.05. Data and analysis generated by
collaborators.
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F IGURE 3.10 Direct and unbiased detection of protein-RNA interactions within the PRC2AEBP2 complex (related to F IGURE 3.3)
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a, Evidence of UV cross-linking, analysed using 18% SDS-PAGE and visualised by Coomassie blue and
silver staining. MW: Molecular weight marker; Pre: input before adding LysC or ArgC protease; Inp: input;
FT: flow-through; EL: eluate. Scatterplots (bottom) indicate intensities identified by MS/MS for each of
the peptides in the input (x-axis) and eluate (y-axis) in four independent RBDmap experiments (in assorted
colours). Although the recovered peptides were obtained in quantities below the detection limit of SDS-PAGE
(EL lanes in all gels), they were detected by MS/MS only in the +UV sample, indicating the stringency of
the purification process. b, PRC2-AEBP2 mutants were evaluated by 10% SDS-PAGE and gel filtration
chromatography (Sephacryl S-400 HR resin). c, Fluorescence anisotropy used to quantify the affinity of the
mutants to G4 24 RNA. The resulting dissociation constant (Kd), Hill coefficients and the derived ΔΔG are
indicated together with details of the mutated amino acids in EZH2 and EED. Error bars in (c) represent
standard deviation based on three independent experiments that were performed on different days. Standard
errors are indicated in (d) when applicable. e-g, The impaired RNA-binding activity of the mutants and
their position on the surface of PRC2 is represented in a G heat map using the PRC2-AEBP2 structure
(regulatory and substrate peptides are coloured in magenta and black respectively). h, Bar plot represents the
relative HMTase activities of PRC2-AEBP2 mutations toward the H3 substrate compared to the wild-type,
which is indicated as a dashed grey line. Error bars indicate standard deviations as measured across three
independent experiments. P values were determined using unpaired two-tailed Student’s t-test; *, P<0.05. I,J,
Representative Coomassie blue-stained SDS-PAGE and the corresponding radiograms used for the HMTase
assays are in Figure 3.3 G and Figure 3.10 H. K, The affinity of PRC2-AEBP2 to 32 P-radiolabeled G4 256
RNA was quantified using EMSA. Data points represent three-fold dilutions of PRC2-AEBP2 starting from
50 nM. l, Quantification was done by fitting the EMSA data to an equilibrium binding curve. Error bars
indicate standard deviation based on three independent experiments that were performed on different days.
The resulting dissociation constant (Kd), Hill coefficient and standard errors are indicated. Data and analysis
generated by collaborators.
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F IGURE 3.11
F IGURE 3.4)

Stimulatory peptides relieve RNA-mediated inhibition of PRC2 (related to

a,b, HMTase assays were carried out in the presence of 0.5 µM wild-type (WT) or mutant 1 (mt1) PRC2
or PRC2-AEBP2, 2.0 µM nucleosome substrate, in the presence (+) or absence (-) of 80 µM H3K27me3
peptide and in the presence (+) or absence (-) of 4.0 µM G4 256 RNA. Representative Coomassie bluestained SDS-PAGE (top) and the corresponding radiograms (middle) are presented, with bar plots (bottom)
representing the HMTase activities quantified based on three replicates. The data represented by black bars
in panels (c) and (d) were used to generate Figure 3.4 A. e,f, Representative Coomassie blue-stained SDSPAGE and the corresponding radiograms used for quantifying the HMTase activities presented in Figure
3.4 C. f, HMTase assays were carried out in the presence of 0.5 µM PRC2-AEBP2, 2.0 µM nucleosome
substrate and G4 24 RNA (e) or G4 256 RNA (f) at concentrations of either 0, 4 or 8 µM and stimulatory
peptides, as indicated. g, Fluorescence anisotropy used to quantify the affinity of PRC2-AEBP2 to G4 24
RNA in the presence or absence of 10 µM of the EED inhibitor A395 or the negative control A395N. Error
bars represent standard deviation based on three independent experiments that were performed on different
days. h, Resulting dissociation constants (Kd), Hill coefficients and the derived ΔΔG values are indicated.
Standard errors are indicated. i, The coordinates of A395, as previously identified by X-ray crystallography
(PDB: 5K0M, He, Y. et al., Nat Chem Biol. 13, 389-395, 2017), are presented on the high-resolution cryo-EM
structure of PRC2 (PDB: 6C23) by superimposing EED from both structures. Orange and red spots represent
RNA-linked polypeptides that were identified in 2 or 3 independent RBDmap experiments respectively. Data
and analysis generated by collaborators.
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F IGURE 3.12

DNA-independent RNA-mediated inhibition of PRC2 (related to F IGURE 3.5)
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a, The location of a substrate peptide (JARID2-K116, in black; PDB 6C23) and an oncogenic inhibitory
peptide (H3K27M, in brown; PDB 5HYN) within PRC2 (in grey; PDB 6C23) with respect to RNA-linked
polypeptides that were identified using RBR-ID (score of > 5; in pink), RBDmap (identified in 2 or 3
independent experiments; represented in orange and red respectively) or in both assays (in yellow). b, The
affinity of PRC2-AEBP2 to G4 24 RNA was quantified using fluorescence anisotropy in the presence or
absence of a substrate peptide (10 µM JARID2-K116 or 100 µM H3 histone peptide) or an oncogenic peptide
(100 µM H3K27M); see panel c for a colour code. c, Resulting dissociation constants (Kd), Hill coefficients,
the derived ΔΔG values and the number of independent replicates (n) are indicated. Peptide sequences are
indicated, with the substrate lysines in red; highlighted in grey, are amino acids that were previously traced
in the catalytic centre, using high resolution cryo-EM (JARID2-K116; PDB 6C23) or x-ray crystallography
(H3K27M; PDB 5HYN). d,e, HMTase assays were carried out in the presence of 0.5 µM PRC2-AEBP2 or
PRC2-AEBP2-JARID2, 4.0 µM H3 histone substrate and in the presence or absence of G4 256 RNA or G4
24 RNA at concentrations as indicated under the bar plot. The bar plot represents the relative activity with
respect to the no-RNA sample, as recorded by densitometry after SDS-PAGE. See Digital Supplemental Table
S16 for the uncropped images of the gels and radiograms. f, Uncropped images of the gels shown in Figure
3.5 A. Data and analysis generated by collaborators.

F IGURE 3.13 One face of PRC2 clusters binding sites of multiple regulatory factors (related
to F IGURE 3.6)
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a, Histogram of distances that were measured between cross-linked lysine pairs within the PRC2 core
subunits. BS3 XL-MS data was generated using the three PRC2 complexes as indicated in the colour key
(see Figure 3.6 A-c for cross-linking sites) and distances were measured between lysine pairs within the highresolution cryo-EM structure of the PRC2-AEBP2-JARID2 complex (PDB: 6C23). b, Randomised distances
histogram was generated after randomly selecting N lysine pairs and measuring the distances between them
over the same structure as in (a), where N is the number of observed cross-linked lysine-pairs in each of the
datasets used in (a). c, Front (centre) and, rear (left) views, and 20° rotation with respect to the front view
(right), of the PRC2-AEBP2-JARID2 structure presented in Figure 3.6 D, using the same colour code as in
Figure 3.6. d, The structure as shown in (c), represented in assorted colours according to the four PRC2 core
subunits. AEBP2 and JARID2, as well as the regulatory and substrate peptides, are coloured according to
the same colour key as in Figure 3.6 D. e, RNA-linked peptides that were identified using targeted RBR-ID
(RBR-ID score > 5) were mapped to the high-resolution structure of PRC2 (PDB: 6C23 and 5WAI). f, RNAlinked peptides that were identified using RBDmap in 2 or 3 replicates are presented on the same structure
and views as in (e), for a direct comparison. Data and analysis generated by collaborators.
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4. COV-ID: A LAMP SEQUENCING APPROACH FOR
HIGH-THROUGHPUT CO-DETECTION OF SARS-COV-2 AND
INFLUENZA VIRUS IN HUMAN SALIVA
This chapter is adapted from a submitted manuscript:
Robert Warneford-Thomson, Parisha P. Shah, Patrick Lundgren, Jonathan Lerner, Benjamin S.
Abella, Kenneth S. Zaret, Jonathan Schug, Rajan Jain, Christoph A. Thaiss, and Roberto Bonasio*.
COV-ID: A LAMP sequencing approach for high-throughput co-detection of SARS-CoV-2 and
influenza virus in human saliva. medRxiv. 2021 [1].
*corresponding author

4.1

Abstract

The COVID-19 pandemic has created an urgent need for rapid, effective, and low-cost SARS-CoV2 diagnostic testing. Here, we describe COV-ID, an approach that combines RT-LAMP with deep
sequencing to detect as few as 5–10 virions of SARS-CoV-2 in unprocessed human saliva. Based on
a multi-dimensional barcoding strategy, COV-ID can be used to test thousands of samples overnight
in a single sequencing run with limited labor and laboratory equipment. The sequencing-based
readout allows COV-ID to detect multiple amplicons simultaneously, including key controls such
as host transcripts and artificial spike-ins, as well as multiple pathogens. Here we demonstrate
this flexibility by simultaneous detection of 4 amplicons in contrived saliva samples: SARS-CoV2, influenza A, human STATHERIN, and an artificial SARS spike-in. The approach was validated
on clinical saliva samples, where it showed 100% agreement with RT-qPCR. COV-ID can also be
performed directly on saliva adsorbed on filter paper, simplifying collection logistics and sample
handling.

4.2

Introduction

Within the first year of the COVID-19 pandemic SARS-CoV-2 has swept across the world, leading
to more than 70 million infections and over 1.5 million deaths worldwide (as of December 2020). In
many countries, non-pharmaceutical interventions, such as school closures and national lockdowns,
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have proven to be effective, but could not be sustained due to economic and social impact [2, 3].
Regularly performed population-level diagnostic testing is an attractive solution [4], particularly as
asymptomatic individuals are implicated in rapid disease transmission, with a strong overdispersion
in secondary transmission [5]. Maintenance of population-level testing can be successful in isolating
asymptomatic individuals and preventing sustained transmission [6, 7]; however, considerable
barriers exist to the adoption of such massive testing strategies. Two such barriers are cost and
supply constraints for commercial testing reagents, both of which make it impractical to test large
numbers of asymptomatic individuals on a recurrent basis. A third major barrier is the lack of “userfriendly” protocols that can be rapidly adopted by public and private organizations to establish highthroughput surveillance screening. In addition, while COVID-19 testing of symptomatic individuals
might be effective during the summer season, when other respiratory infections are rare, new
strategies are urgently needed to facilitate rapid differential diagnosis between SARS-CoV-2 and
other respiratory viruses in winter.
Recent adaptations of reverse transcription and polymerase chain reaction (RT-PCR) to
amplify viral sequence and perform next-generation DNA sequencing have opened promising new
avenues for massively parallel SARS-CoV-2 detection. In general, sequencing-based protocols
use libraries of amplification primers to tag reads originating from each individual patient sample
with a unique index that can be identified and deconvoluted after sequencing, thus allowing
pooling of tens of thousands of samples in a single assay. SARSeq, SPAR-Seq, and Swabseq, directly amplify the viral RNA by RT-PCR and simultaneously introduce barcodes [8–10].
While effective, these methods rely on individual PCR amplification of each patient sample,
thus requiring a large number of thermal cyclers for massive scale-up. An alternative approach,
ApharSeq, addresses this bottleneck by annealing barcoded RT primers to viral RNA and pooling
samples prior to amplification but the need for specialized oligo-dT magnetic beads might constitute
a separate adoption barrier for this method [11]. Finally, several recent methods have been
designed to take advantage of the extreme sensitivity and isothermal conditions of loop-mediated
isothermal amplification (LAMP)[12–14], but these methods either require additional manipulation
to introduce barcodes [12, 13] or do not allow for convenient multiplexing [15]. In this study, we
present COV-ID, a method for SARS-CoV-2 identification based on LAMP, which enables large125

scale diagnostic testing at low cost and with minimal on-site equipment. COV-ID is a robust method
that can be used to test tens of thousands of samples for multiple pathogens with modest reagent
costs and 2–4 laboratory personnel, generating results within 24 hours. COV-ID uses unpurified
saliva or saliva adsorbed on filter paper as input material, thus enabling the massively parallel,
inexpensive testing required for population-level surveillance of the COVID-19 pandemic (Figure
4.1 A).

4.3
4.3.1

Results
Two-step amplification and indexing of viral and human sequences via RTLAMP and PCR

The molecular basis for COV-ID is reverse transcription loop-mediated isothermal amplification
(RT-LAMP), an alternative to PCR that has been used extensively for viral DNA or RNA detection
in clinical samples [15–18], including SARS-CoV-2 [19, 20]. RT-LAMP requires 4–6 primers that
recognize different regions of the target sequence [21, 22] and proceeds through a set of primed and
self-primed steps to yield many inverted copies of the target sequence spanning a range of molecular
sizes (Figure 4.5). The forward inner primer (FIP) and backward inner primer (BIP), which
recognize internal sequences, are incorporated in opposite orientation across the target sequence in
the final amplified product (Figure 4.5). Previous studies have shown that the FIP and BIP tolerate
insertion of exogenous sequence between their different target homology regions [23]. We exploited
this flexibility and introduced 1) patient-specific barcodes as shown previously [12, 14, 23] and 2)
artificial sequences that allowed for PCR amplification of a small product compatible with Illumina
sequencing library construction (Figure 4.1 , Figure 4.5 ). These innovations allowed us to pool
individually barcoded RT-LAMP reactions and amplify them in batch via PCR, while introducing
unique P5 and P7 dual indexes in different pools, thus enabling two-dimensional barcoding and
dramatically increasing method throughput (see Table 4.1 for PCR primer sequences). To minimize
pool variability, we titrated PCR primers to 100 nM and performed pool PCRs to completion,
resulting in each pool being amplified to the same approximate concentration. Uniquely amplified
and barcoded pools were mixed into a single “super-pool” and sequenced on an Illumina NextSeq
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or similar instrument (Figure 4.1 A). Combining individual barcodes embedded in the product at
the RT-LAMP step with dual indexes introduced at the pool level during the PCR step allows for
deconvolution of thousands or tens of thousands of samples in a single sequencing run.
To determine whether introduction of these exogenous sequences inhibited the isothermal
amplification step, we performed RT-LAMP on inactivated SARS-CoV-2 virus using an extensively
validated primer set against the N2 region of the nucleocapsid protein [24] including either the
conventional BIP and FIP primers or their modified version re-engineered for the COV-ID workflow
(Figure 4.1 B). Although the appearance of the amplified viral product was slightly delayed when
using COV-ID primers, all reactions reached saturation rapidly and without detectable amplification
of negative controls (Figure 4.1 C). Next, we tested whether COV-ID is compatible with RT-LAMP
using newly designed primers against a host (human) transcript and whether the second step of
COV-ID, direct library construction and indexing via PCR amplification (Figure 4.1 D), yields the
desired product. For this, we designed RT-LAMP primers against the human beta-actin (ACTB)
transcript including sequences necessary for COV-ID (Figure 4.1 B, S1). After RT-LAMP, reactions
were diluted 100-fold before PCR with barcoded Illumina adapters. A PCR product of the expected
size was visible in reactions containing total HeLa RNA, while no PCR product was observed in
the absence of template (Figure 4.1 E). Sanger sequencing of the PCR product confirmed that RTLAMP followed by PCR generated the product expected by the COV-ID method design, including
the sample barcode introduced during the RT-LAMP step (data not shown).
Thus, our data show that RT-LAMP is tolerant of sequence insertions in the BIP and
FIP primers that allow introduction of LAMP-level barcodes as well as sequences homologous to
Illumina adapters for direct amplification, indexing, and library construction via PCR.
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Figure 1. Barcoding and PCR amplification of RT-LAMP products

F IGURE 4.1

Barcoding and PCR amplification of RT-LAMP products

(A) Overview of COV-ID. Saliva is collected and inactivated prior to RT-LAMP performed with up to 96 individual sample
barcoded primers. LAMP reactions are pooled and further amplified via PCR to introduce Illumina adapter sequences and
pool-level dual indexes. A single thermal cycler can amplify 96 or 384 such pools and the resulting “super-pool” can be
sequenced overnight to detect multiple amplicons from 9,216 or 36,864 individual patient samples (number of reads in parenthesis assume an output of ~450M reads from a NextSeq 500).
(B) Schematic of the RT-LAMP (step I) of COV-ID. Selected steps of RT-LAMP reaction are shown to illustrate how the LAMP
barcode, shown in yellow, and the P7 and P7 homology sequences (blue and pink, respectively) are introduced in the final
LAMP product. A more detailed version of the LAMP phase of COV-ID, including specific sequences, is illustrated in Fig. S1.
(C) Conventional RT-LAMP primers (solid lines) or primers modified for COV-ID (dotted lines) were used for RT-LAMP of
SARS-CoV-2. The numbers of inactivated SARS-CoV-2 virions per µL is indicated in the color legend.
(D) Schematic of the PCR (step II) of COV-ID. Following RT-LAMP, up to 96 reactions are pooled and purified and Illumina
libraries are generated directly by PCR with dual-indexed P5 and P7 adapters in preparation for sequencing.
(E) COV-ID primers targeting beta-actin mRNA were used for RT-LAMP with HeLa total RNA. LAMP was diluted 1:100, amplified via PCR and resolved on 2% agarose gel.

128

(A) Overview of COV-ID. Saliva is collected and inactivated prior to RT-LAMP performed with up to 96
individual sample barcoded primers. LAMP reactions are pooled and further amplified via PCR to introduce
Illumina adapter sequences and pool-level dual indexes. A single thermal cycler can amplify 96 or 384 such
pools and the resulting “super-pool” can be sequenced overnight to detect multiple amplicons from 9,216 or
36,864 individual patient samples (number of reads in parenthesis assume an output of 450M reads from a
NextSeq 500). (B) Schematic of the RT-LAMP (step I) of COV-ID. Selected steps of RT-LAMP reaction are
shown to illustrate how the LAMP barcode, shown in yellow, and the P7 and P7 homology sequences (blue
and pink, respectively) are introduced in the final LAMP product. A more detailed version of the LAMP
phase of COV-ID, including specific sequences, is illustrated in Figure 4.5. (C) Conventional RT-LAMP
primers (solid lines) or primers modified for COV-ID (dotted lines) were used for RT-LAMP of SARS-CoV2. The numbers of inactivated SARS-CoV-2 virions per µL is indicated in the color legend. (D) Schematic of
the PCR (step II) of COV-ID. Following RT-LAMP, up to 96 reactions are pooled and purified and Illumina
libraries are generated directly by PCR with dual-indexed P5 and P7 adapters in preparation for sequencing.
(E) COV-ID primers targeting ACTB mRNA were used for RT-LAMP with HeLa total RNA. LAMP was
diluted 1:100, amplified via PCR and resolved on 2% agarose gel. Experiments and Data generated by R.WT.

4.3.2

Sequencing-based detection of SARS-CoV-2 RNA from saliva using COV-ID

We next evaluated the utility of COV-ID to detect viral RNA in saliva. Unpurified saliva has
been shown to be a viable template for nucleic acid amplification via RT-PCR [25], recombinase
polymerase amplification (RPA)[26] as well as RT-LAMP [27, 28]. We prepared human saliva for
RT-LAMP using a recently described treatment that inactivates SARS-CoV-2 virions, saliva-borne
RNases and LAMP inhibitors (Figure 4.2 A) [28]. We performed RT-LAMP followed by PCR
(Figure 4.1 ) on inactivated saliva spiked with water or 1,000 total copies of inactivated SARS-CoV2 virus. We observed a single band of the expected size in reactions performed on saliva spiked
with virus but not in control reactions (Figure 4.2 B). The sequence of the amplified and barcoded
viral product was confirmed by Sanger sequencing (Figure 4.6 B). Next, we subjected the libraries
to deep sequencing. Reads aligned uniformly to the N gene, the region targeted by the N2 primer
set, in COV-ID libraries constructed from viral samples but not in control libraries (Figure 4.2 C).
In several SARS-CoV-2 FDA approved tests, parallel amplification of a host (human)
amplicon is implemented as a metric for sample integrity and quality. That is, if no human RNA
is amplified from a clinical sample, no conclusion can be drawn from a negative test result [29].
However, in most tests, viral and human amplicons must be detected separately, resulting in a
multiplication of the number of reactions to be performed. We reasoned that the deep sequencing
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nature of COV-ID would allow for simultaneous detection of viral, human, and other control
amplicons, without increasing the number of necessary reactions. In fact, given that the PCR
handles inserted in the BIP and FIP are the same for all RT-LAMP amplicons (Figure 4.1 D), the
same P5 and P7 Illumina primers allow the simultaneous amplification of all RT-LAMP products
obtained with COV-ID-modified primer sets. To identify a suitable human control, we compared
conventional RT-LAMP primers for the mRNA of ACTB [24] or STATHERIN (STATH), a gene
expressed specifically in saliva [30]. To determine which of the two RT-LAMP primer sets was
a better proxy to measure RNA integrity in saliva samples, we assayed for amplification of the
respective products in presence or absence of RNase. Whereas addition of RNase A abolished the
STATH signal, it was ineffectual for ACTB (Figure 4.6 A), suggesting that amplification of genomic
DNA made considerable contributions to the RT-LAMP signal observed for the latter. Therefore,
we utilized STATH mRNA as a human control in subsequent experiments.
We used COV-ID-adapted primer sets for N2 and STATH (Table 4.1 ) in multiplex on
inactivated saliva spiked with a range of SARS-CoV-2 from 5 to 10,000 virions/µL. Subsequently,
each RT-LAMP reaction was separately amplified via PCR using a unique P5 and P7 index
combination, pooled, quantified, and deep-sequenced to an average depth of 6,000 reads per
sample. After read trimming, alignment, and filtering (see Methods), 76% of reads from saliva
COV-ID reactions were informative (Figure 4.6 C). In order to differentiate SARS-CoV-2 positive
and negative samples, we calculated the ratio between N2 reads and reads mapping to the human
STATH control. Using the highest N2/STATH read ratio in control (SARS-CoV-2 negative saliva)
as a threshold, 95% (19/20) of samples with spiked-in virus were correctly classified as positives
(Figure 4.2 D). Using COV-ID, we consistently detected SARS-CoV-2 in saliva samples containing
as low as 5 virions per µL, a sensitivity comparable and in some cases superior to those of established
testing protocols [31].
Scaling COV-ID to handle higher sample numbers requires pooling samples immediately
following RT-LAMP prior to the PCR step (Figure 4.1 A). We designed 32 unique 5-nucleotide
barcodes for several target LAMP amplicons (Figure 4.6 D and Table 4.2 ). We first individually
validated each barcode and primer combination by real-time fluorescence and PCR efficiency.
Certain barcodes inhibited the RT-LAMP reaction, possibly due to internal micro-homology and
130

increased primer self-hybridization [32]. Nonetheless, out of 32 barcodes tested in 3 separate
RT-LAMP reactions (N2, ACTB, and STATH), 25 successfully amplified all three target RNAs
(Figure 4.6 D). Saliva samples spiked with various concentrations of inactivated SARS-CoV2 were amplified via barcoded RT-LAMP, then optionally pooled prior to PCR and sequencing
(Figure 4.6 E). CoV-2/STATH ratios demonstrated no loss of sensitivity or specificity in the pooled
samples compared to the individual PCRs. To test the potential of COV-ID on patient samples,
we tested 10 saliva specimens, collected and previously analyzed at the Hospital of the University
of Pennsylvania (see Methods). We carried out multiplex barcoded RT-LAMPs on each sample
(COV-ID step I, Figure 4.1 B), pooled the reactions and then constructed libraries via PCR (COVID step II, Figure 4.1 D). After deep sequencing, analysis of N2/STATH ratios showed 100%
(10/10) concordance with viral copy numbers generated by a standard clinical test (RNA purification
followed by RT-qPCR) (Figure 4.2 E), demonstrating the effectiveness of the COV-ID approach.
Taken together, our data show that COV-ID can be utilized to detect viral and human amplicons
in multiplex directly from saliva samples that can be batch amplified and deconvoluted after deep
sequencing.

131

A

B

N2

SARS virions
(per µL)

0

103

300–

2.5 mM TCEP
1 mM EDTA
95˚C 5’

RT-LAMP
65˚C 1 hr

Expected
product
(218 bp)

200–

PCR
1 hr

75–

C

SARS
(virions/µL)

0
103

b1
b2
b1
b2

N gene
103

0 SARS-CoV-2

0
103
0
103

1,280 SARS-CoV-2

0
103
0
A G A C A A G G A A C T G A T T A C A A A C A T T G G C C G C A A A T T G C A C A A T T T G C C C C C A G C G C T T C A G C G T T C T T C G G A A T G T C GC G C A T T G G C A T G G A A G T C A C A C C T T C G G G A A C G

R

D

G

T

D

Simulated samples
(saliva + inactivated virus)

2

Y

K

H

W

P

Q

I

A

Q

F

A

P

S

A

E

S

A

F

F

G

M

S

R

I

G

M

E

V

T

P

S

G

Clinical saliva samples
106

Read ratio (SARS / STATH)

101

100

10–1
10–2

0.002
10–3

104
102
100
10-2
10

0.002

-4

10-6

0

80
16
0
32
0
64
0
1,
28
10 0
,0
00

40

20

5

10

10-8

0

Read ratio (SARS / STATH)

10

Q

BEI virus (virions per µL)

100

102

104

106

108

qPCR-based copy estimate

Figure 2. Sequencing-based detection of SARS-CoV-2 in saliva samples
(A)FSaliva
preparation.
Crude saliva was inactivated
via TCEP/EDTA
addition and 95ºC
incubation
prior to RT-LAMP.
IGURE
4.2 Sequencing-based
detection
of SARS-CoV-2
in saliva
samples
(B)(A)
RT-LAMP
by COV-ID
PCRsaliva
performed
on saliva.
with and without
addition
1,000incubation
copies of inactivatSalivafollowed
preparation.
Crude
was directly
inactivated
viaSaliva
TCEP/EDTA
addition
and of95ºC
prior to
ed SARS-COV-2 templates was inactivated as described in (A), then used as template.

RT-LAMP. (B) RT-LAMP followed by COV-ID PCR performed directly on saliva. Saliva with and without

(C)addition
Alignment
sequenced
against SARS-COV-2
genome
from COV-ID
inactivated as
saliva
spiked with
without
ofof1,000
copiesreads
of inactivated
SARS-COV-2
templates
wasofinactivated
described
in (A),
then1,280
used
virions SARS-COV-2 per µL. All SARS-COV-2 reads align exclusively to expected region of the N gene. Open reading frames
as
template.
(C)
Alignment
of
sequenced
reads
against
SARS-COV-2
genome
from
COV-ID
of
inactivated
of viral genome are depicted via gray boxes below alignment. Inset: scale shows reads per 1,000.

spiked
without
1,280 virions
SARS-COV-2
perbyµL.
All SARS-COV-2
reads
alignof exclusively
(D)saliva
Scatter
plot forwith
the ratio
of SARS-CoV-2
/ STATH
reads obtained
COV-ID
(y axis) versus the
number
virions per µLto
expected
region
NThe
gene.
Openwas
reading
frames
of viral
genome
via gray
boxes
below
spiked
in human
salivaof(xthe
axis).
threshold
set above
the highest
values
scoredare
in a depicted
negative control
(dashed
line).
Inset: on
scale
shows
reads
per The
1,000.
(D)plot
Scatter
for the ratio/ STATH
of SARS-CoV-2
/ STATH
(E)alignment.
COV-ID performed
clinical
saliva
samples.
scatter
showsplot
the SARS-CoV-2
read ratio (y axis)
versusreads
the
viral
load in the
estimated
by aversus
clinically
test. The
was set(xbased
on the
obtained
bysample
COV-ID
(y axis)
theapproved,
numberqPCR-based
of virions diagnostic
per µL spiked
in threshold
human saliva
axis).
The
negative controls shown in (D).
threshold was set above the highest values scored in a negative control (dashed line). (E) COV-ID performed
on clinical saliva samples. The scatter plot shows the SARS-CoV-2 / STATH read ratio (y axis) versus the
viral load in the sample estimated by a clinically approved, qPCR-based diagnostic test. The threshold was
set based on the negative controls shown in (D). Experiments and Data generated by R.W-T.

132

4.3.3

Calibration of COV-ID using an artificial spike-in

Existing deep sequencing approaches for massively parallel COVID-19 testing based on RT-PCR
incorporate artificial spike-ins, which serve as an internal calibration controls and allow for better
estimates of viral loads by end-point PCR [8, 9]. At the same time, adding to the reactions an
artificial substrate for amplification helps minimizing spurious signals as it can “scavenge” viral
amplification primers in negative samples. Finally, by providing a baseline amplification even in
empty samples, a properly designed spike-in strategy can reduce variance in total amounts of final
amplified products across samples, which compresses the dynamic-range of sequence coverage for
each patient in a complex pool and, therefore, reduces the risk of inconclusive samples due to low
sequencing coverage [9]. To our knowledge, a spike-in approach for LAMP-based quantification
has not yet been reported, but we reasoned that it would provide similar benefits in the context
of COV-ID. To generate a SARS-CoV-2 spike-in, we synthesized a fragment of the N2 RNA that
retained all primer-binding regions for RT-LAMP and contained a divergent 7-nt stretch of sequence
to distinguish reads originating from the spike-in from those originating from the natural virus
(Figure 4.7 A). After confirming that the spike-in template was efficiently amplified via RT-LAMP
with the N2 primer set (Figure 4.7 B), we performed pooled COV-ID on virus-containing saliva
in the presence of 20 fg of N2 spike-in RNA. As expected [9], addition of a constant amount of
viral spike-in across reactions reduced the variability in total read numbers for individual samples
in the final pool (Figure 4.7 C). As discussed above, a narrower range in sequencing output across
samples in a pool optimizes the utilization of sequencing reads, and ultimately cost per patient.
Because the spike-in provides an internal calibration that is independent of the RNA quality found
in saliva, we found that in several cases normalization against the spike-in resulted in lower apparent
values for negative samples (Figure 4.7 D). This is likely because in cases where very few STATH
reads were obtained, possibly due to degradation of host RNA in the saliva sample, the resulting
small denominator inflated the N2/STATH ratio even for SARS-CoV-2 signal that was low in
absolute terms and likely spurious. Thus, these data show that spike-in strategies are compatible
with the COV-ID workflow and provide a means to stabilize total amplification and read allocation
per sample while also offering an additional calibration control to better estimate the viral load in
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samples where the endogenous STATH mRNA might be below detection due to improper collection
or handling.

4.3.4

Simultaneous detection of SARS-CoV-2 and influenza A by COV-ID

Given the challenge of distinguishing early symptoms of COVID-19 from other respiratory
infections, we evaluated COV-ID for the simultaneous detection of multiple viral pathogens.
Multiple distinct products can be simultaneously amplified by RT-LAMP in the same tube by
providing the appropriate primer sets in multiplex, as we demonstrated above by co-amplifying N2
and STATH in the same COV-ID reaction (see Figure 4.2 ). In fact, simultaneous detection of SARSCoV-2 and influenza virus by RT-LAMP was previously demonstrated, albeit in a fluorescent-based,
low-throughput type of assay [33]. We reasoned that the sequencing-based readout of COV-ID
would allow extending this approach to the simultaneous detection of multiple pathogens as well
as endogenous (host mRNA) and artificial (spike-in) calibration standards, all in a single reaction.
To test the ability of COV-ID to simultaneously detect multiple viral templates, we selected and
validated a generic “flu” RT-LAMP primer set that recognizes several strains, including influenza
A virus (IAV) and influenza B [33, 34], and modified the BIP and FIP sequence to introduce the
COV-ID barcodes and PCR handles individual barcodes (Figure 4.6 E and Table 4.1 ). We added
inactivated SARS-CoV-2 virus (BEI resources) and IAV strain H1N1 RNA (Twist Biosciences) to
saliva according to a 3 x 3 matrix of 10,000 copies, 1,000 copies, or 0 copies (Figure 4.3 A), as well
as the N2 spike-in control. We performed multiplex COV-ID on these samples using primers sets
for STATH, N2 (to detect SARS-CoV-2), and IAV (to detect H1N1) and sequenced to an average
depth of 11,000 reads per sample. Both H1N1 and SARS-CoV-2 were detected above background
and the signal correlated with the amount of the respective template added to saliva (Figure 4.3 B).
Overall, multiplex COV-ID correctly identified samples that contained SARS-CoV-2 (6/6), H1N1
(4/6), or both (6/8) (Figure 4.3 C), indicating the potential and versatility of our sequencing-based
RT-LAMP assay.
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4.3.5

Paper-based saliva sampling for COV-ID

As an additional step toward increasing the throughput of the COV-ID approach, we explored
avenues to simplify collection, lower costs, and expedite processing time. Absorbent paper is
an attractive alternative to sample vials for collection, given its low cost, wide availability, and
smaller environmental footprint. In fact, paper has been used as a means to isolate nucleic acid
from biological samples for direct RT-PCR testing [35] as well as RT-LAMP [36, 37]. We sought to
determine whether the COV-ID workflow would be compatible with saliva collection on absorbent
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paper. First, we immersed a small square of Whatman filter paper into water containing various
dilutions of inactivated SARS-CoV-2. After 2 min, the paper was removed and transferred to PCR
strip tubes followed by heating at 95ºC for 5 minutes to air-dry the sample (Figure 4.4 A). Next,
we added the RT-LAMP mix containing the N2 COV-ID primer set directly to the tubes containing
the paper squares and let the reaction proceed in the usual conditions. COV-ID PCR products of
the correct size were evident in all samples containing viral RNA, with sensitivity of at least 100
virions/µL (Figure 4.4 B) and in none of the controls, demonstrating that the presence of paper
does not interfere with the RT-LAMP reaction and subsequent PCR amplification with Illumina
adapters. To assay direct COV-ID detection from saliva on paper, we saturated Whatman filter
paper squares with saliva containing different amounts of inactivated SARS-CoV-2 virus, which, we
reasoned, would be equivalent to a patient collecting their own saliva by chewing on a small piece
of absorbent paper. Next, we placed the paper squares into reaction tubes containing TCEP/EDTA
inactivation buffer (see Methods) similar to that used for the in-solution samples used in our previous
experiments (see Figure 4.1 A). We dried the paper at 95ºC and performed RT-LAMP followed by
PCR (Figure 4.4 C). This COV-ID workflow resulted in sequencing-compatible PCR products or the
correct size starting from saliva spiked with as few as 50 virions / µL (Figure 4.4 D), suggesting the
paper-based approach has similar sensitivity to the conventional in-solution method. Taken together,
these data show that the RT-LAMP step of COV-ID is compatible with the presence of paper in
the reaction tube and suggest that self-collection of saliva by patients directly on absorbent paper
could provide a simple and cost-effective strategy to collect and test thousands of saliva samples for
multiple pathogens.
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4.4

Discussion

Testing strategies are vital to an effective public health response to the COVID-19 pandemic,
particularly with the spread of the disease by asymptomatic individuals. An ongoing challenge
to COVID-19 testing is the need for massive testing strategies for population-level surveillance that
are needed for efficient contact tracing and isolation. As of December 2020, most FDA-approved
clinical SARS-CoV-2 diagnostic tests are based on time-consuming and expensive protocols that
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include RNA purifications and RT-PCR [31] and must be performed by trained personnel in
well-equipped laboratories. Point-of-care antigen tests provide a much faster turnaround time
and require little manipulation, but there remains limited data on their specificity in real-world
applications [38]. Because of reagent limitations and diagnostic testing bottlenecks, prioritization
of COVID diagnostic testing continues to be for symptomatic individuals and individuals who
are particularly vulnerable for infection after exposure [39]. Private organizations, including
colleges and universities, have circumvented some of these challenges by contracting with private
laboratories to establish asymptomatic surveillance testing protocols; this is a costly option for
population-level surveilling of asymptomatic SARS-CoV-2 infections.
In order to scale testing to the necessary level and frequency, surveillance tests must
possess the following qualities: 1) sensitivity, to identify both asymptomatic and symptomatic
carriers; 2) simplicity in methodology, to be performed in a number of traditional diagnostic
laboratories, without specialized equipment; 3) low cost and easily accessible reagents; 4) ease
of collection method; 5) rapid turnaround time to allow for isolation and contract tracing; and 6)
ability to co-detect multiple respiratory viruses, given the overlap in patient symptoms. To this
end, we have developed COV-ID, an RT-LAMP-based parallel sequencing SARS-CoV-2 detection
method that can provide results from tens of thousands of samples per day at relatively low cost to
simultaneously detect multiple respiratory viruses.
COV-ID features several key innovations that make it well-suited to high-throughput
testing. First, COV-ID uses a two-dimensional barcoding strategy [9], where the same 96 barcodes
are used in each RT-LAMP plate, making it possible to pre-aliquot barcodes in 96-well plates ahead
of time (“print plates”) and store them at -20ºC, simplifying execution of the assay and shortening
turnaround times. Second, since RT-LAMP does not require thermal cycling, tens of thousands of
samples can be run simultaneously in a standard benchtop-sized incubator or hybridization oven
held at 65ºC. Third, individual samples are pooled immediately following RT-LAMP; therefore,
a single thermocycler has the potential to process up to 96 or 384 RT-LAMP plates, generating
9,216 or 36,864 individually barcoded samples, respectively (Figure 4.1 A, 4E). Only 96 unique FIP
barcodes are required for this scaling; here, we show that 28 out of 32 LAMP barcodes tested were
functional for both N2 and STATH. This proof of principle experiment demonstrates the feasibility
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of generating the library of barcodes required to apply COV-ID to a large population. Notably,
COV-ID can generate ready-to-sequence libraries directly from saliva absorbed onto filter paper,
which would allow for major streamlining of the often-challenging logistical process of sample
collection (Figure 4.4). Thus, COV-ID libraries for thousands and tens of thousands of samples
can be generated with relatively minimum effort in biological laboratories with basic equipment
and easily accessible reagents. With the pervasive diffusion of deep sequencing technologies in the
last few years, most departments and institutes have access to abundant sequencing capacity. With
the average throughput of an Illumina NextSeq 500/550, a relatively affordable next-generation
sequencer, up to 9,216 (96 RT-LAMPs x 96 pools) can be sequenced at a depth of 48,000 reads per
sample, and up to 36,864 (96 RT-LAMPs x 384 pools) can be sequenced at a depth of 12,000 reads,
which, we showed, is more than sufficient to obtain information about multiple viral and control
amplicons. Considering that reagents for one NextSeq run cost 1,500 U.S. dollars, the theoretical
sequencing cost per sample could be as low as $0.04 (Figure 4.4 E). While sequencing instruments
are relatively specialized and not ubiquitous, amplified COV-ID DNA libraries could be shipped to
remote facilities for sequencing in a cost-effective manner as previously proposed by the inventors
of LAMP-seq [14]. Finally, because of the limited sequence space against which reads must be
aligned, computational analysis of the resulting data can be performed in a matter of minutes with
optimized pipelines, providing results shortly after the sequencing run has completed.
COV-ID has sensitivity of 5–10 virions of SARS-CoV-2 per µL in contrived saliva samples
(Figure 4.2 D) and at least 300 virions /µL in saliva collected from patients in a clinical setting
(Figure 4.2 E). Given that none of the positive clinical samples that we could test had an estimated
viral load < 300 virions /µL, further testing will be required to determine the actual sensitivity of
COV-ID. On the other hand, a much larger number of clinical saliva specimens will be needed to
determine the extent to which variability in saliva collections and storage might affect sensitivity.
Finally, the sensitivity of COV-ID on saliva collected and dried on paper was as low as 50 virions
/ µL, at least judging by the appearance of a PCR product (Figure 4.4 D). It is possible that
deep sequencing of these products would reveal even higher sensitivity. Given that estimates of
sensitivity required for effective SARS-CoV-2 surveillance testing are approximately 100 virions /
µL [7, 40], COV-ID provides an effective testing platform regardless of the protocol and template
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used. In conclusion, COV-ID is a flexible platform that can be executed at varying levels of scale
with additional flexibility in sample input, making it an attractive platform for surveillance testing.
Population-level monitoring of SARS-CoV-2 infections will be critical while vaccines are being
distributed to the global population, and continued surveillance will likely remain an effective
strategy to protect immune-compromised and unvaccinated members in society and within entities
and organizations where regular monitoring is critical to social isolation strategies. To that end,
effective, low-cost, multiplexed, and readily-implementable strategies for surveillance testing, such
as COV-ID, are important to mitigate the effects of the current and future pandemics.
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4.9
4.9.1

Methods
RT-LAMP primer design

Primers against ACTB were designed using PrimerExplorerV5 (https://primerexplorer.jp/e/) using
default parameters and including loop primers (Table 4.1 ).
For COV-ID, priming sequences for PCR were inserted in FIP and BIP primers between
the target homology regions (F1c and F2, and B1c and B2, respectively, see Figure 4.5 ). After
testing, we determined that 12 nts and 11 nts were most effective for the P5 and P7 binding
regions, respectively, being the shortest insertion that allowed reliable PCR amplification from
LAMP products without impacting LAMP efficiency. In addition a 5 nt barcode sequence was
inserted at the immediate 3’ end of the P5-binding region of the FIP primer.

4.9.2

LAMP barcode design

Starting from the total possible 1,024 unique 5-nt barcodes, we removed those that matched any
sequence within the RT-LAMP primers used in this study (Table 4.1 ) in either sense or anti-sense
orientation. From the remaining pool, we selected 32 barcodes with hamming distance of at least
2 between all candidates. We tested FIPs incorporating candidate barcodes for ACTB, STATH, N2,
and IAV primer sets on saliva RT-LAMP with 1,000 copies of target amplicon. Primers that failed
to show LAMP signal by real time fluorescence monitoring or generate expected PCR product were
discarded. Final usable barcodes are provided in (Table 4.2 ).

4.9.3

Saliva preparation

We prepared 100x TCEP/EDTA buffer (250 mM TCEP, 100 mM EDTA, 1.15 N NaOH) [28].
TCEP/EDTA buffer was added to human saliva at 1:100 volume, then samples were capped,
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vortexed to mix and heated in a thermocycler (95ºC 5 min, 4ºC hold) until ready to use for RTLAMP. When indicated, heat-inactivated SARS-CoV-2 (BEI Resources Cat. NR-52286) or H1N1
genomic RNA (Twist Biosciences Cat. 103001) was added to inactivated saliva prior to RT-LAMP.

4.9.4

N2 spike-in synthesis

To prepare the in vitro transcription template for SARS-CoV-2 N2 spike-in RNA, we performed
RT-PCR using Power SYBR RNA-to-Ct kit (Thermo Cat. 4389986) of heat inactivated SARSCoV-2 (BEI Resources Cat. NR-52286) using the following primers: N2-B3 and N2-spike-T7
S. PCR product was purified and used as a template for in vitro transcription using HiScribe T7
transcription kit (NEB Cat. E2040S). RNA was purified with Trizol (Thermo Cat. 15596026),
quantified via A260 , then aliquoted in BTE buffer (10 mM bis-tris pH 6.7, 1 mM EDTA) and stored
at -80ºC. Primers used and final spike-in sequence are provided in Table 4.1 .

4.9.5

RT-LAMP

All RT-LAMP reactions were set up in clean laminar flow hoods and all steps before and after
LAMP were carried out in separate lab spaces to avoid contamination. RT-LAMP reactions were
set up on ice as follow: for each amplicon 5 or 6 LAMP primers were combined into 10x working
stock at established concentrations: 16 µM FIP, 16 µM BIP, 4 µM LF, 4 µM LB, 2 µM F3, 2 µM
B3. For multiplexed COV-ID reactions 10x working primer mixes for each amplicon were either
added proportionally so that the total primer content remained constant, or mixed so that BIP and
FIP primers were scaled down depending on amplicon number while remaining primers (LF and/or
LB, F3, B3) were kept at same concentration as in single reactions. Each 10 µL RT-LAMP reaction
mix consisted of 1x Warmstart LAMP 2x Master Mix (NEB Cat. E1700S), 0.7 µM dUTP (Promega
Cat. U1191), 1 µM SYTO-9 (Thermo Cat. S34854), 0.1 µL Thermolabile UDG (Enzymatics Cat.
G5020L), 1 µL of saliva template and optionally 20 fg of N2 Spike RNA. Reactions were prepared in
qPCR plates or 8-well strip tubes, sealed, vortexed and centrifuged briefly, then incubated in either
a QuantStudio Flex 7 or StepOnePlus instrument (Thermo) for 65ºC 1 hr. Real-time fluorescence
measurements were recorded every 30 sec to monitor reaction progress but were not used for data
analysis. Following LAMP the reactions were heated at 95ºC 5 min to inactivate LAMP enzymes.
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4.9.6

Library construction by PCR amplification

All post-LAMP steps were carried out on a clean bench separate from LAMP reagents and
workspace. For individual LAMP samples, LAMP amplicons were diluted either 1:100 or 1:1,000 in
water. For pooling of individually barcoded LAMP reactions, equal amounts of all LAMP reactions
were combined and then either diluted 1:1000 or purified via SPRIselect beads (Beckman Coulter
Cat. B23317) using a bead-to-reaction ratio of 0.1x. Purified material was diluted to final 100-fold
dilution relative to LAMP. 1 µL of diluted LAMP material was used as a template for PCR using
OneTaq DNA polymerase (NEB Cat. M0480L) with 100 nM each of custom dual-indexed Illumina
P5 and P7 primers in either 10 or 25 µL reaction (Table 4.1 ). PCR reactions were incubated as
follows: (25 cycles of stage 1 [94ºC x 15 sec, 45ºC x 15 sec, 68ºC x 10 sec], 10 cycles of Stage 2 [
94ºC x 15 sec, 68ºC x 10 sec], 68ºC x 1 min, 4ºC x ∞). Note, for initial pilot COV-ID and clinical
sample experiments (Figure 4.2 D–E, Figure 4.6 C) PCR incubation was performed as above with
modification: [Stage 1 x 10 cycles, Stage 2 x 25 cycles]. PCR products were resolved on 2%
agarose gel to confirm library size, then all were pooled and purified via MinElute PCR purification
kit (Qiagen Cat. 28004) and quantified using either Qubit dsDNA High Sensitivity kit (Thermo Cat.
Q32851) or Kapa Library Quantification Kit for Illumina (Kapa Cat. 07960140001).

4.9.7

Patient samples

Clinical saliva samples were obtained and characterized as part of a separate study at the University
of Pennsylvania [41] and collected under Institutional Review Board (IRB)-approved protocols (IRB
protocol #842613 and #813913). Briefly, salivary samples were collected from possible SARSCoV-2 positive patients at one of three locations: (1) Penn Presbyterian Medical Center Emergency
Department, (2) Hospital of the University of Pennsylvania Emergency Department, and (3) Penn
Medicine COVID-19 ambulatory testing center. Inclusion criteria including any adult (age > 17
years) who underwent SARS-CoV-2 testing via standard nasopharyngeal swab at the same visit.
Patients with known COVID-19 disease who previously tested positive previously were excluded.
After verbal consent was obtained by a trained research coordinator, patients were instructed to selfcollect saliva into a sterile specimen container which was then placed on ice until further processing
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for analysis.

4.9.8

Paper COV-ID

Squares of Whatman no. 1 filter paper (2 mm x 2 mm) were cut using a scalpel on a clean surface
under a laminar flow hood and stored at room temperature until used. Using ethanol-sterilized finenosed tweezers a single square was dipped twice into unprocessed, freshly collected saliva with or
without added SARS-CoV-2 (BEI Resources Cat. NR-52286) until saliva was saturated on paper
by eye. Paper was then transferred to well of 96-well plate containing 10 ul of 1x TCEP/EDTA
buffer (2.5 mM TCEP, 1 mM EDTA, 1.15 NaOH). Plate was placed on heat block inside laminar
flow hood or inside open thermocycler and incubated at 95ºC x 10 min. 10 ul RT-LAMP mixture
was prepared as described above in the absence of the N2 Spike RNA. 10 ul of RT-LAMP reaction
mixture was added to each paper strip, then plate was sealed and incubated 65ºC x 1 hr, 95ºC x
5 min in QuantStudio Flex 7 (ThermoFisher). 1 ul of each reaction was diluted 1:100 and PCR
amplified as described above.

4.9.9

Sequencing

Libraries were sequenced on one of the following Illumina instruments: MiSeq, NextSeq 500,
NextSeq 550, NovaSeq 6000 and sequenced using single end programs with a minimum of 40
cycles on Read 1 and 8 cycles for index 1 (on P7) and index 2 (on P5).

4.9.10

Sequence Analysis

Reads were filtered for optical quality using FASTX-toolkit utility fastq quality filter
(http://hannonlab.cshl.edu/fastx toolkit/), then cutadapt [42] was used to remove adapters and
demultiplex LAMP barcodes. Reads were aligned to a custom index containing SARS-CoV2 genome (NC 045512.2), Influenza H1N1 coding sequences (NC 026431.1, NC 026432.1,
NC 026433.1, NC 026434.1, NC 026435.1, NC 026436.1, NC 026437.1, NC 026438.1), STATH
coding sequence (NM 003154.3), and custom N2 spike sequence (Table 4.1 ) ,target sequences
using bowtie2[43] with options –no-unal and –end-to-end. Alignments with greater than 1 mismatch
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were removed and the number of reads mapping to each target were extracted and output in a table
format for each barcode (sample).

145

4.9.11

Data Availability

4.9.12

Supplemental Tables

Name

Sequence
CI_N2

CI_N2-FIP

TTCCGAAGAACGCTGAAGC CTCTTCCGATCT NNNNN GGAACTGATTACAAACATTGGCC

CI_N2-BIP

CGCATTGGCATGGAAGTCA CATCTCCGAGC CAATTTGATGGCACCTGTGTA

N2-B3

GACTTGATCTTTGAAATTTGGATCT

N2-F3

ACCAGGAACTAATCAGACAAG

N2-LB

CTTCGGGAACGTGGTTGACC

N2-LF

GGGGGCAAATTGTGCAATTTG
CI_Act1

Act1-FIP

TGCCGCCAGACAGCACTGTG CTCTTCCGATCT NNNNN TGAAGTGTGACGTGGACATC

Act1-BIP

TTGCCGACAGGATGCAGAAGG CATCTCCGAGC GCGCTCAGGAGGAGCAAT

Act1-LB

CCTGGCACCCAGCACAATGAAG

Act1-B3

GCCGATCCACACGGAGTAC

Act1-LF

GGCGTACAGGTCTTTGCG

Act1-F3

GGCATCCACGAAACTACCTT

CI_STATH
-FIP
CI_STATH
-BIP
STATH-F3

AGCTCCAATCATGGAAACCATG CTCTTCCGATCT NNNNN AGCCAACTATGAAGTTCCTTG

STATH-LF

GAGCCAAGATGAAGGCAA

STATH-B3

GCCTCAATAATCATGTCCTGCA

CI_IAVFIP
CI_IAVBIP
IAV-LF

TTAGTCAGAGGTGACARRATTG CTCTTCCGATCT NNNNN CAGATCTTGAGGCTCTC

IAV-LB

CMAGTGAGCGAGGACTG

IAV-F3

GACTTGAAGATGTCTTTGC

IAV-F3_2

GACTGGAAAGTGTCTTTGC

IAV-B3

TRTTATTTGGGTCTCCATT

IAV-B3_2

TRTTGTTTGGGTCCCCATT

P5 primer
(index nt =
N)
P7 primer
(index nt =
N)
N2 Spike
T7-S
N2-B3

AATGATACGGCGACCACCGAGATCTACAC NNNNNNNN
ACACTCTTTCCCTACACGACGCTCTTCCGATCT

N2_Spike
IVT
template
sequence

TAATACGACTCACTATAGGGACCAGGAACTAATCAGACAAGGAACTGATTACAAACATTGGCCGCAG
TACATGCAATTTGCCCCCAGCGCTTCAGCGTTCTTCGGAATGTCGCGCATTGGCATGGAAGTCACAC
CTTCGGGAACGTGGTTGACCTACACAGGTGCCATCAAATTGGATGACAAAGATCCAAATTTCAAAGA
TCAAGTC

CI_STATH

AAGATTCGGTTATGGGTATGGC CATCTCCGAGC GTTGTGGGTATAGTGGTTGTTC
GTAGCACATCATCTCTTGAAGCT

CI_IAV

TABLE 4.1

TTGTKTTCACGCTCACCGTG CATCTCCGAGC TTTGGACAAAGCGTCTACG
GTCTTGTCTTTAGCCA

CAAGCAGAAGACGGCATACGAGAT NNNNNNNN GTCTCGTGGGCTCGGAGATG

TAATACGACTCACTATAGGGACCAGGAACTAATCAGACAAGGAACTGATTACAAACATTGGCCGCA
GTACATG CAATTTGCCCCCAGCGC
GACTTGATCTTTGAAATTTGGATCT

Oligonucleotide sequences
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Barcode

Sequence

Statherin
STATH
Effective

Actin Act1

Influenza A IAV

CCTGT

SARS
N2
Effective

Effective

Effective
(N2, STATH)
Yes

Effective (All
4 targets)
No

i01
i02

Failed

GTTAC

Effective

Effective

Effective

i03

GCATC

Effective

Effective

Effective

Effective

Yes

Yes

Failed

Yes

No

i04

TGCGA

Effective

Effective

i05

ATCAT

Effective

Effective

Effective

Effective

Yes

Yes

Effective

Failed

Yes

i06

GCTTG

Effective

No

Effective

Effective

Effective

Yes

i07

CACTG

Yes

Effective

Effective

Effective

Failed

Yes

i08

No

AGTCA

Effective

Failed

Effective

Effective

No

No

i09

CTAGA

Effective

Effective

Effective

Effective

Yes

Yes

i10

TAACG

Effective

Effective

Effective

Effective

Yes

Yes

i11

CTAGT

Effective

Effective

Effective

Effective

Yes

Yes

i12

AGCCT

Effective

Effective

Effective

Failed

Yes

No

i13

AAATG

Failed

Effective

Effective

Effective

No

No

i14

AGCCC

Effective

Effective

Effective

Effective

Yes

Yes

i15

ATATC

Effective

Effective

Effective

Effective

Yes

Yes

i16

CCAAG

Effective

Effective

Failed

Effective

Yes

No

i17

CGAGT

Effective

Effective

Effective

Failed

Yes

No

i18

CGATG

Effective

Effective

Failed

Effective

Yes

No

i19

CGCGG

Effective

Effective

Effective

Effective

Yes

Yes

i20

CGGAT

Effective

Effective

Effective

Effective

Yes

Yes

i21

GCGCC

Effective

Effective

Effective

Effective

Yes

Yes

i22

GGCGA

Effective

Effective

Effective

Effective

Yes

Yes

i23

GGTGT

Effective

Effective

Effective

Effective

Yes

Yes

i24

GTCAA

Effective

Effective

Effective

Effective

Yes

Yes

i25

GTCGC

Effective

Effective

Effective

Effective

Yes

Yes

i26

GTGAT

Effective

Effective

Effective

Effective

Yes

Yes

i27

TAAAC

Failed

Effective

Effective

Effective

No

No

i28

TACTA

Effective

Effective

Effective

Effective

Yes

Yes

i29

TAGAG

Failed

Effective

Effective

Effective

No

No

i30

TCTAG

Effective

Effective

Effective

Effective

Yes

Yes

i31

TGAAT

Effective

Effective

Effective

Effective

Yes

Yes

i32

TTATA

Effective

Effective

Effective

Effective

Yes

Yes

Barcode yield

28/32

20/32

TABLE 4.2

COV-ID barcode validation data
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4.10

Supplementary Data

Key
CTCTTCCGATCT

Target RNA

AGATCGGAAGAG
B1c

B2c

B3c

B2

CGAGCCTCTAC

3’

C

AG

TC
CG

F1

TC

F2

c CA

F3

5’

1. Primer BIP anneals to target RNA
and facilitates cDNA synthesis

GAGAAGGCTAGA

CATCTCCGAGC

Primer BIP

5’

GCTCGGAGATG
NNNNN

B1

XXXXXXXX
B2c

B3c

B2

B3

C

TC

5’

c CT

CT

NN

F2
F2c

F1c

B1

5’

B1c CA
TC
TC

NN

CG A

NN

N

F3
F3c

3’
+
5’

F2

F1

B1c

B2c GCTCGGAGATG B1

F2c

F1c

B1

B2 CGAGCCTCTAC B1c

N F2

3’
5’

B1c

F1

T A GC

5’

T F1c
TC
CT

3’

B1

G

B2 CGAGCCTCTAC B1c

B1c
B1

G

3’

B1

B2

B1c
B2c GC

F1
F1c

G

5’

B2c GC

T F1c
TC
CT

B1

c CA

TC

CG
TC

C
AG

F1

N NNN T C
F1 GAGAAGGCTAGA NNNNN F2c

CG A

B2c GC

B2c GCTCGGAGATG B1

B1

F1c CTCTTCCGATCT NNNNN F2

N

N NNN T C

B1c

F1c

3’
NN

NN

CG A

T A GC

5’

B1c

F1

T F1c
TC
CT

B2c GCTCGGAGATG B1

F1c
F1 GAG
AA
G

5’

3’

F2c

ANN N

N F2

GC T

AG

B1c CA
TC
TC

NN

NN

2F
F1c CTCTTCCGATCT NNNNN F2
F1 GAGAAGGCTAGA NNNNN F2c

F1

B1c

B2c GCTCGGAGATG B1

F1c

B1

B2 CGAGCCTCTAC B1c

3’

F1c
F1 GAG
AA
G

F2c

CT

TT

CC

AG

CT

NT

1F

Cc

ANN N

5’

GC T

AG

3’

GC

A F1
AG
GA

B2

NNNA

+

B1

F1c

NN

T CG

N NNN T C

F2
F2c

GA

N

N

7. Strand displacement leads to fold out of 2nd strand,
creating concatenation of target sequence

N

c CT
CT
TC
CG
AT
CT

CT

3’

F1

N F2

F1

AT

F2c

5’

B1c CA
TC
TC

NN

F3c

TC
CG

F2

6. BIP primer anneals to B2c in open loop and extends

B1

5’

CT

F3

T A GC

F1c

B2

F1
c CT

F3c

5. 3’ end of dumbbell is extended

F2c

GC

TC
CG

AT

Primer F3

5’
3’

P7 primer

CT

3’

4. Primer extension from F3, displacing FIP product
and generating dumb-bell

CAAGCAGAAGACGGCATACGAGATYYYYYYYYGTCTCGTGGGCTCGGAGATG

F1

Primer FIP
5’

F3c

G

3. Primer FIP extension from cDNA

+ 3’

3’

5’

AT

B3

TCGGA

B3c

G

B2c
B2

AT

B1c
B1

TCGGA

F1
F1c

G

F2
F2c

5’

5’

AT

F3
F3c

Primer B3

YYYYYYYY

&

AATGATACGGCGACCACCGAGATCTACACXXXXXXXXACACTCTTTCCCTACACGACGCTCTTCCGATCT

B2

3’

5’

TCGGA

5’

3’

GC

B1c
B1

AG

F1
F1c

TC
CG

F2
F2c

B1
c CA

2. Primer B3 extension from target RNA
displaces BIP generated cDNA

F3
F3c

P5 binding sequence (complement)
P5 binding sequence
P5 binding sequence (reverse)
P7 binding sequence
P7 binding sequence (reverse)
P7 binding sequence (complement)
5 nt sample barcode
8 nt P5 & P7 plate barcodes
P5 primer

F1

c CT

CT

NN

NN

N

F2

N NNN T C

N F2

T A GC

B1c

F1

T F1c
TC
CT

T CG

B2 CGAGCCTCTAC B1c

B1

F1c

A F1
AG
GA

5’

+
F1c

B2c GCTCGGAGATG B1

F2

F1
F1c TCT
TC
C

3’

F2c NNNNN AGATCGGAAGAG F1

c
B1
1c
B CATCTCCGAGC

GA T

B1

B2

F1c

5’

3’
A B C D E F G H I J K L

F2c

C T AG

A B C D E F G H I J K L

1
2
3
4
5
6
7
8

9. 96 barcoded LAMP reactions are pooled
and diluted 1:100 then transferred to
single well of 96 well plate.

F1 AG
AA
GG

NNNN

NNNA

8. LAMP reaction proceeds to rapidly amplify
target sequence

AN

NN

F2c

GA

NNN N

CT

CT

AT

N

TC
CG

1
2
3
4
5
6
7
8

i7

i96
i ...
i2 3
i1

NNNNN

CAAGCAGAAGACGGCATACGAGATYYYYYYYYGTCTCGTGGGCTCGGAGATG

NNNNN

NNNNN

NNNNN

5’

c
B1
1c
B CATCTCCGAGC

B2

B1

F1c

3’

i5
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Steps of COV-ID protocol are depicted, showing RT-LAMP mechanism and the ultimate amplicon that is
sequenced. For clarity, only selected steps of RT-LAMP reaction are shown and loop primer intermediates
are not depicted. For full LAMP mechanism see [21]
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(A) Validation of control human amplicons for RT-LAMP on saliva. RT-LAMP of TCEP/EDTA inactivated saliva was performed
with conventional RT-LAMP primer sets for ACTB and STATH in the presence or absence of RNase A.
(B) Saliva COV-ID sequence validation. Single saliva COV-ID reaction using N2 primers was sequenced by the Sanger method.
(C) Characterization of COV-ID sequencing libraries. Breakdown of reads for sequence data presented in Fig. 2D. Samples
without added template consist of predominantly adapter dimers.
(D) Validation of COV-ID LAMP barcodes. 32 potential barcodes were tested for LAMP primer sets indicated, incompatible
barcodes are marked in red.
(E) Validation of pooled PCR. COV-ID was performed on saliva samples using unique LAMP barcodes. The RT-LAMP reactions
were then amplified either by individual PCR or by first pooling and then performing a single PCR on the pool.
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(A) Validation of control human amplicons for RT-LAMP on saliva. RT-LAMP of TCEP/EDTA inactivated
saliva was performed with conventional RT-LAMP primer sets for ACTB and STATH in the presence
or absence of RNase A. (B) Saliva COV-ID sequence validation. Single saliva COV-ID reaction using
N2 primers was sequenced by the Sanger method. (C) Characterization of COV-ID sequencing libraries.
Breakdown of reads for sequence data presented in Figure 4.2D. Samples without added template consist
of predominantly adapter dimers. (D) Validation of COV-ID LAMP barcodes. 32 potential barcodes were
tested for LAMP primer sets indicated, incompatible barcodes are marked in red. (E) Validation of pooled
PCR. COV-ID was performed on saliva samples using unique LAMP barcodes. The RT-LAMP reactions
were then amplified either by individual PCR or by first pooling and then performing a single PCR on the
pool. Experiments and Data generated by R.W-T.
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5. CONCLUSIONS
5.1

Development of a novel method to identify RNA-protein
interactions

In chapter two I described RBR-ID, a method we developed to identify RNA-binding proteins
and the protein regions involved in RNA-binding across the nuclear proteome.

By using

photosensitive nucleotide analogs and ultraviolet radiation, we induce RNA-protein crosslinks that
affect quantification via bottom-up (peptide-based) mass spectrometry. With the aid of several
replicates to overcome mass spectrometry-associated variability, we can apply RBR-ID to identify
RBPs in an unbiased manner. This method dispenses with the need for enrichment of polyA RNA
and therefore can profile RBPs binding to any species of RNA. Focusing on the nuclear proteome
of mouse embyronic stem cells, we identify 803 RBPs of which 427 were previously unannotated
as binding to RNA. The novel putative RBPs were enriched for gene ontology terms involved in
chromatin binding and regulation, as well as histone-binding domains such as the chromodomain
and bromodomains, and we successfully validated the RNA-binding activity of several novel RBPs
in vivo. The peptide-level resolution afforded by RBR-ID also permits identification of RBRs in
an in vitro context using recombinant proteins and RNA. We confirmed the utility of RBR-ID in
vitro using the well-studied viral RBP MS2CP [1], correctly identifying the known RBR of the
protein and observing the highest RBR-ID signal from a peptide directly abutting the protein-RNA
interface. Our in vivo RBR-ID dataset further revealed RBR regions inside the RBP positive hits,
including many well known RNA-binding domains such as RRM, KH and dsRBD. Overlays of
RBR-ID data onto published RNA-protein structures showed peptide hits clustered around RNAbinding interfaces and further confirmed the utility of the peptide-level resolution of RBR-ID. We
validated 6 RBRs on RBR-ID hits in vivo, demonstrating that the RBR identified by RBR-ID was
the primary contributor to RNA-binding activity. Development of this method has provided an
additional tool to profile protein-RNA interactions in different contexts and revealed more about the
characteristics of chromatin-associated RBPs.
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5.1.1

Recent advances and future directions in RNA-protein interaction research

Since publication of our manuscript in 2016 it has received over 100 citations, and several groups
have validated RBRs that we identified, including BRD4 [2], TET2 [3], and CTCF [4]. In the case
of chromatin architectural protein CTCF, RBR-ID identified two RBRs inside the ZF1 and ZF10
zinc finger domains that are not known to bind DNA. Mutants made removing each of the RBRs
individually led to a significant reduction in CTCF-RNA binding via PAR-CLIP [4]. Expression of
these mutants in mESCs led to loss of CTCF from many sites on chromatin, large scale changes in
gene expression and loss of chromatin looping. Fascinatingly, the set of CTCF binding sites lost
in each RBR mutant showed virtually no overlap with each other, with ZF1 mutants losing binding
primarily inside gene promoters while ZF10 mutant were lost from intronic and intergenic regions
[4]. Another study using a similar mutant in the ZF10 domain found loss of CTCF from roughly half
of its binding sites [5]. Assuming that these effects are due to changes in RNA-mediated chromatin
interactions, it would indicate the modular function of RBRs in binding to specific RNA ligands
with perhaps distinct purposes. Investigating this exciting hypothesis could provide a significant
step forward in our understanding of how RNA interactions help regulate chromatin structure.
RBR-ID identified an RBR in the catalytic domain of TET2, suggesting that this important
regulator involved in active DNA demethylation might also modify RNA, supported by evidence
that TET proteins can modify RNA in Drosophila [6]. Follow-up studies confirmed that RNA is
modified by TET2 in mammalian cells to generate 5-hydroxymethylcytosine (5-hmC) to destabilize
RNAs in different contexts [3, 7]. In addition, work by Chongsheng He and others in our lab have
demonstrated that in mESCs, TET2 binds and modifies tRNAs to facilitate generation of tRNA
fragments [8]. These findings demonstrate how RBR-ID has helped expand our understanding of
several important chromatin regulatory enzymes.
We have also since applied in vitro RBR-ID to map other chromatin regulatory proteins.
The chromatin remodeler ATRX is required for proper X inactivation and binds RNA–including
the lncRNA Xist–but the function of these interactions is unclear [9]. We carried out RBR-ID
on recombinant ATRX with an Xist RNA fragment and identified several peptides within aa 400750 that we classified as an RBR. This region was necessary and sufficient to bind Xist in vitro
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[10]. Nuclear fractionation in the presence of RNase lead to loss of WT ATRX from the chromatin
fraction, similar to behavior of PRC2 subunits in response to RNase treatment [11] and implicating
RNA in regulating ATRX chromatin localization. However, ΔRBR ATRX showed no sensitivity
to RNase treatment, providing strong evidence that this region interacts with RNA in vivo and is
necessary for proper chromatin localization [10]. This example demonstrates the practical utility of
our screening approach in identifying RNA-protein interactions and providing tools to address the
function of these interactions in chromatin regulation.

’Click’ assisted RNA interactome capture
Interest in RNA-protein interactions has risen steadily in the last few years, concomitant with a rapid
succession of new methods to probe RNA-protein interactions. Since our manuscript was published
there have been exciting developments in methodology to identify RBPs and their associated RBRs.
Updated interactome capture methods have been developed that incorporate 5-ethynyluridine (5EU)
into RNA (RICK [12]; CARIC [13]). Following UV crosslinking of proteins and RNA (with or
without 4sU), the 5EU can be modified with ’click’ chemistry to add a biotin handle for streptavidin
purification. Precipitated RBPs are then analyzed by high resolution mass spectrometry [12,
13]. CARIC identified 597 RBPs, including 167 that were not identified previously by mRNA
interactome studies in human cells. Additionally, 186/597 RBPs were also identified in our RBRID dataset, suggesting that both methods are able to profile non-polyA RNA-protein interactions
[13]. The RICK method identified 720 high-confidence RBPs, of which 295 were unique to the
method. To enrich for non polyA RNA binding proteins, the authors depleted polyA RNAs from
their extracts before precipitating the crosslinked RNA-protein complexes, identifying 205 RBPs
that overlapped with their 295 RICK-unique RBP hits (69.2%). These 205 RBPs therefore are
highly likely to bind to non-polyA RNA, and intriguingly when the authors examined what GO
terms were enriched in this stringent subset the strongest hit was chromosome organization (p =
4.18×10−45 , 74 out of 205), supporting our finding that many chromatin-related proteins exhibit
RNA-binding behavior.
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Phase-separation assisted identification of RBPs
Novel methods have also emerged to identify RBRs using the physicochemical properties of RNA
crosslinked to peptides. Three recent methods take advantage of the the enrichment of RNA-peptide
adducts at the interphase of a guanidinium thiocynate /phenol/chloroform (Trizol) mixture [14–16].
In these methods, SILAC-labeled cells are grown prior to UV-crosslinking of one isotope label
(heavy or light), then samples are combined and purified via Trizol interface enrichment. These
methods allow for purification of crosslinked RNA-protein hybrids and subsequent processing to
examine both the RNA and protein components in parallel, such as one group who combined PARCLIP with interphase enrichment to greatly simplify the often frustrating method [16]. One of
the interphase enrichment methods, protein-crosslinking and RNA extraction (XRNAX), combined
interphase purification with silica-column cleanup to further enrich RNA-protein adducts prior to
LC-MS/MS, identifying over 1200 RBPs, including 565 that were not identified in previous polyA
interactome studies. By comparing the characteristics of the RBPs identified in non polyA versus
polyA associated RBPs, the authors noted a strong bias in RRM-containing proteins towards the
polyA cohort, while the histone-binding bromodomain was most enriched domain in the non-polyA,
consistent with our previous RBR-ID data. Potentially more significant, the authors also found
enrichment in the non polyA RBP set for several tripeptide motifs (e.g. GRG, GGG, GSG) found
in intrinsically disordered proteins (IDPs) that are linked to liquid-liquid phase separation [15, 17].
These findings highlight the distinct characteristics of non-poly-A RBPs and again reinforce the link
between RNA, chromatin regulation and nuclear condensates. Future research should seek to further
uncover the properties and function of nuclear RBPs in chromatin regulation. Another similar
method, orthogonal organic phase separation (OOPS), sequenced the RNA present in in the Trizol
interface of UV-crosslinked extracts, finding consistent loss of read coverage inside 3’ UTRs and
established RBP binding sites when compared to un-crosslinked samples, suggesting this method
provides a way to profile RBP-binding sites across the transcriptome [14]. Additionally, the use of
SILAC labeling enables exploration of changes in RNA-protein interactions in response to different
biological conditions. The authors take advantage of this to examine changes in RBP behavior
upon cell cycle arrest, finding increased abundance of metabolic enzymes in the interphase fraction,
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showing that RBP activity of these proteins increases in response to stress. These approaches can
now be used to examine changes in RBP behavior in response to other variables, such as cell
differentiation state or viral infection.

Precise identification of RNA-binding sites
Recent progress has also improved the resolution of mapping RNA-protein interactions. Prior
attempts to directly identify crosslinked peptide-RNA adducts using mass spectrometry have
performed poorly, due to the considerable challenge of matching nucleotides of many varying
masses to a peptide spectra [15, 18].

One promising recent method addresses this issue

by substituting inconsistent RNase digestion of UV-crosslinked extracts with hydrofluoric acid
treatment to efficiently digest oligonucleotides down to a consistent and minimal moiety to facilitate
identification by mass spectrometry [19]. This treatment enabled the use of only a single variable
uridine modification in the LC-MS/MS database search, greatly simplifying the analysis and
increasing identification efficacy. This approach, called RBS-ID, identified 1970 RNA-binding
sites that fell within 642 proteins, a remarkable improvement over previous attempts, which found
a maximum of 281 RNA-binding residues [19]. Combining the RBS-ID approach with targeted
analyses of chromatin-related complexes could reveal functional residues involved in RNA binding.
The current outlook for research studying RNA-protein interactions is positive, as methods to study
them are rapidly maturing alongside an emerging understanding of the large scope of RNA function
in chromatin biology.

5.1.2

Identification of an RNA regulatory site on PRC2

In chapter 3, I present data detailing our efforts to understand RNA-binding activity of the PRC2
complex. Building on the method we developed in chapter 2, I modified the approach with
by incorporating SILAC for improved quantification and used an immunoprecipitation step to
enrich for PRC2 to improve coverage relative to our previous proteome-wide dataset. Using this
targeted variant of RBR-ID we identified RBRs across all PRC2 subunits identified, demonstrating
that RNA-binding is a property shared by all PRC2 variants. Several PRC2 RBRs identified in
previously annotated RNA-binding regions [20–22], while others were previously unknown. One
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RBR in particular was located on EED directly adjacent to the stimulatory recognition motif (SRM)
of PRC2 [23], raising the possibility of cross-talk between peptide-mediated stimulation of PRC2
and RNA inhibition [24]. RBDmap [25] of recombinant PRC2 provided confirmation of the SRMadjacent RBR on EED. We showed that addition of the H3K27me3 stimulatory peptide could relieve
RNA inhibition of PRC2 KMT activity on both histone and non-histone substrates. This showed
that RNA inhibition of PRC2 could occur through a mechanism separate from competition of DNA
or nucleosome binding [26]. We further showed that addition of a JARID2 stimulatory peptide–
that binds the SRM–competed with G-quadruplex (G34) RNA for PRC2 binding, demonstrating
that the regulatory center of PRC2 binds RNA in the absence of stimulatory peptides. Based
on the antagonistic relationship between RNA and PRC2 binding to chromatin, our findings
help understand how PRC2 can overcome inhibition from nascent RNA through stimulation from
H3K27me3 or JARID2 K116me3 peptides.

5.1.3

Developments in understanding PRC2-RNA interactions and future directions

Recent evidence has emerged further dissecting the role of RNA in PRC2 regulation. Beltran
et al. recently focused on the relationship between nascent RNA and PRC2 occupancy, having
previously shown loss of RNA leads to PRC2 accumulation on chromatin [11, 27]. iCLIP [28]
analysis of SUZ12 showed a strong enrichment for G-rich RNA sequences, consistent with previous
findings showing PRC2 binding to G-rich sequences [29–31]. The authors then identified RNA
sequences predicted to form G4 structures and found a surprising enrichment of these sequences
near the first intron-exon junction of coding transcripts. When they compared these predicted G4
motifs with their iCLIP data they observed a strong overlap with SUZ12 iCLIP peaks, providing
in vivo evidence to support the in vitro observations of PRC2 binding to G-quadruplex structures
[27]. Recruitment of G4-containing sgRNAs using dCas9 to Polycomb target genes led to loss of
PRC2 and H3K27me3 levels at the locus, demonstrating that G4 RNA can evict PRC2 from genes.
These findings demonstrate how PRC2 responds to transcriptional activity by leaving chromatin and
binding to G4 structures on nascent RNA, remaining poised for future silencing. In the presence
of methylated JARID2, PRC2 is able to overcome G4 inhibition and place H3K27me3 de novo.
While previous work has shown that PRC2 responds to transcriptional status [32], this is one of the
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first studies to examine the timing of PRC2 regulation. Given that bulk population measurements of
various PRC2 subunits show them having largely overlapping occupancy on chromatin [33], timeresolved studies of specific polycomb target loci may help reveal the functions of different PRC2
subunits. Another recent study found that a diminished RNA-binding EZH2 mutant led to aberrant
cardiomyocyte differentiation in induced human pluripotent stem cells, suggesting that RNA-PRC2
interactions are involved in cell differentation [34]. Future work should help us understand how
PRC2-RNA interactions regulate PRC2 activity and localization in pluripotent and differentiated
cell types.
Our targeted RBR-ID analysis of PRC2 identified multiple regions of the complex in
binding RNA, including several that were not captured by our in vitro RBDmap analysis of PRC2
crosslinked with G4-RNA ligands. This discrepancy points either to technical differences between
the two methods, or to the possibility that there are other non-G4 RNA ligands that bind specific sites
on PRC2 in vivo. Most notably, targeted RBR-ID identified an RBR on EZH2 that was originally
described by Kaneko et al. (EZH2 aa 342-368) [20]. Removal of this region does not affect PRC2
affinity for G4 RNA in vitro [22], yet I have found that EZH2 mutants lacking aa 342-368 show the
greatest loss of RNA binding as measured by PAR-CLIP (Figure 5.1 A). This supports the notion
that PRC2 binds other RNAs in addition to G4-containing transcripts, and may indicate multiple
modes of PRC2-RNA regulation. Systematic analysis of different PRC2 mutants could determine
if the various RBRs on PRC2 have distinct RNA ligands, and if so, could determine if the multiple
RBRs have distinct functions that might explain the contradictory observations related to RNAmediated PRC2 recruitment [35].
In addition to EZH2 I was also able to validate an RBR on the PRC2.2 subunit AEBP2.
This subunit is known to stimulate PRC2 activity [36] and mediate PRC2 binding to H2AK119Ub
[37]. Targeted RBR-ID revealed an RBR inside the 3 tandem zinc finger (ZF) domains of AEBP2
that corresponded closely to one identified in our proteome data (Figure 5.1). RNA pull-down
experiments using recombinant protein fragments precipitated a fragment spanning the RBR (Figure
5.1 C), and deletion of the AEBP2 RBR led to a reduction of RNA-binding activity as measured
via PAR-CLIP, further validating this region as being involved in binding RNA in vivo. To better
understand the role of the various AEBP2 ZFs in RNA-binding and PRC2 regulation, I generated
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AEBP2 KO mESCs and then attempted rescue experiments with various mutants lacking one or
more ZF domains (Figure 5.1 E,F). RNA-seq of the rescue samples showed that while the wildtype AEBP2 was able to partially recapitulate wild-type expression patterns, all the various ZF
mutants showed much weaker correlation with wild-type cells. While this indicates the AEBP2
zinc fingers are important functionally for maintaining polycomb function, it does not directly
indicate RNA involvement, as recently published work from Eva Nogales has shown the AEBP2
directly binds to H2AK119Ub nucleosomes via its zinc fingers [37]. In order to specifically
examine the role of RNA in AEBP2 function more refined separation-of-function mutants would
be necessary, potentially using updated approaches as RBS-ID to make pinpointed mutations (see
above) [19]. Intriguingly, recent work cataloguing the protein interactors of the FIRRE lncRNA
identified PRC2 subunits AEBP2 and JARID2, supporting the possibility that PRC2 may recognize
specific RNAs through RBRs distinct from those involved in G4-RNA recognition [38]. Systematic
high-throughput CLIP-based sequencing of core and various accessory subunits of PRC2 can test
this hypothesis, identifying whether any RNAs interact specifically with accessory subunits.
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Figure 2. Validation of RBRs in AEBP2 and EZH2. (A) Localization of proteome-wide (red) and targeted
(blue) RBR-ID hits on the domains of EZH2. PAR-CLIP of EZH2 mutants with deletions spanning the targeted
RBR-ID hits. The “RBR” mutant is the 342–368 (B) Domains of AEBP2 displayed with RBR-ID hits shown as
in (A). Recombinant fragments used in (C) are indicated.
162(C) In vitro crosslink and RNA-mediated pull-down
of N-terminal and C-terminal fragments. (D) PAR-CLIP in HEK293 overexpressing HA-tagged WT AEBP2 or
a mutant lacking the second zinc finger (∆). RNA signal (top) and protein loading control (bottom) are shown.
(E) Overview of AEBP2 short isoform, showing mutants generated deleting indicated regions. (F) AEBP2
Mutants shown in (E) were transfected into AEBP2 KO mESCs alongside GFP control. RNA was collected for
RNA-seq analysis. Correlation heatmap is shown for 822 differentially expressed genes identified in AEBP2
KO cells

(A) Localization of proteome-wide (red) and targeted (blue) RBR-ID hits on the domains of EZH2. PARCLIP of EZH2 mutants in HEK293 cells with deletions spanning the targeted RBR-ID hits. The “RBR”
mutant deletion spans 342–368 [20] (B) Domains of AEBP2 displayed with RBR-ID hits shown as in (A).
Recombinant fragments used in (C) are indicated. (C) In vitro crosslink and RNA-mediated pull-down of
N-terminal and C-terminal fragments. (D) PAR-CLIP in HEK293 overexpressing HA-tagged WT AEBP2
or a mutant lacking the second zinc finger (Δ). RNA signal (top) and protein loading control (bottom) are
shown. (E) Overview of AEBP2 mutants generated deleting indicated zinc finger domain(s). (F) AEBP2
Mutants shown in (E) were transfected into AEBP2 KO mESCs alongside GFP control. RNA was collected
for RNA-seq analysis and analysed. Correlation heatmap is shown for 822 differentially expressed genes
identified in AEBP2 KO cells.

5.1.4

A novel SARS-CoV-2 testing method

In Chapter 4, I present a set of experiments detailing the development of a novel testing method
for SARS-CoV-2, based on a combination of barcoded RT-LAMP and deep sequencing. This
method, referred to as COV-ID has been developed specifically to support large-scale testing. The
method is inexpensive and uses unpurified saliva, a validated diagnostic analyte [39] that does not
require invasive collection methods and minimizes sample processing steps and reagent demands.
Our preliminary evaluation of the properties of this method revealed a limit of detection of 5–10
virions of SARS-CoV-2 per µL in contrived saliva samples and at least 300 virions /µL in saliva
collected from patients in a clinical setting. The latter concentration was the lowest retrieved in the
available clinical samples. It is therefore possible that the limit of detection for COV-ID in clinical
samples may be lower than such threshold. The sensitivity demonstrated here exceeds the standard
recommended for screening and surveillance tests of approximately 100 virions/µL [40, 41].
While most COV-ID data presented was performed using unpurified saliva samples, we
also present some preliminary proof-of principle experiments that show that this method can be
applied to dried saliva samples collected on filter paper. The possibility of detecting SARS-CoV2 in dried saliva samples on a paper substrate could dramatically simplify sample collection and
remove another barrier to testing. In our preliminary experiments we showed that COV-ID using
paper substrates has a sensitivity of at least 50 virions /µL, demonstrating the viability of this testing
approach.
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5.1.5

Outlook for future SARS-CoV-2 testing initiatives

In the development of COV-ID we have had challenges managing the acute sensitivity of the RTLAMP method and preventing contamination. This is a constant risk to any diagnostic laboratory
but especially for those using RT-LAMP, since contaminating amplicons can self-amplify at room
temperature without primers and proceed much more rapidly than PCR. Efforts to mitigate the
risk of contamination would strengthen COV-ID and make it a more robust testing solution. For
example, preparing all reagents in separate aliquots in an entirely different lab, and then storing them
separately from any reaction products. Another outstanding question is how to multiplex RT-LAMP
effectively. We were able to multiplex 3 targets in a single reaction, SARS-CoV-2, STATH, and
influenza, but we observed inconsistent amplification for influenza. Other attempts at multiplexing
RT-LAMP have faced similar issues, suggesting that competing amplification reactions can inhibit
each other or expend all available nucleotides or enzyme [42]. To mitigate this issue we tried
reducing the concentrations of BIP/FIP primers in multiplexed reactions, but further optimization
may yield more consistent data. Also given the rapid emergence of several new mutant strains of
SARS-CoV-2 [43], effective tests should be able to detect multiple variants to avoid false negative
results. While sequencing can identify variants that occur within the amplicon, variants that impair
LAMP primer binding sites may not be amplified efficiently. Therefore if additional amplicons
can be multiplexed efficiently, then inclusion of other viral amplicons would be an effective way to
simultaneously detect all viral variants in circulation as they emerge..
Regularly performed population-level screening tests are recognized as important
elements of a pandemic response plan. Such population surveillance has a remarkable impact
not only for clinical care, as it will allow the early identification of suspected cases and improve
individual care, but also for public health. This strategy in fact can facilitate the identification of
high-risk population pockets that may require specific public health measures. Furthermore, because
vaccination campaigns have recently started [44], ongoing testing will help monitor the vaccination
efficacy and guide further vaccine development.
The implementation of large-scale testing presents technical and economic challenges. As
a result, although the number of tests performed in The United states has markedly increased since
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the first outbreak, the relative ratio of positive to total tests performed has only slightly increased.
Although such numbers may be affected by the reporting method used (multiple testing of same
individuals, retrospective reports, lack of follow-up data) and may not reflect a real-time assessment
of the cases, they overall indicate that a large fraction of the supposedly asymptomatic population
may still not have access to testing.

5.1.6

Final Remarks

In conclusion, in the above chapters I show how methods to profile RNA-binding proteins can
enable more effective interrogation of chromatin regulation, and use these methods to reveal a new
mode of regulation of the epigenetic regulator PRC2. Following that work I switched focus to
development of a SARS-CoV-2 diagnostic method due to the unprecedented challenge that the
COVID-19 pandemic has presented in terms of meeting sufficient testing capacity, without which
public health measures are much less effective.
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